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Abstract 
Maternal metabolism undergoes dramatic changes in pregnancy in order to 
sustain and nourish the developing fetus. During healthy pregnancy the mother 
goes from an anabolic state in early pregnancy to a state of catabolism in late 
pregnancy with increased lipolysis together with a significant reduction in insulin 
sensitivity. Pre-eclampsia (PE) characterised by hypertension and proteinuria is a 
major cause of maternal and perinatal morbidity. There is acute ‘atherosis’ in 
PE placenta, and lipid accumulation within glomerular cells and liver.  PE women 
have an early, excessive triglyceride and free fatty acid (FFA) rise and greater 
cardiovascular disease (CVD) risk in later life. The cause of these lipid 
abnormalities in PE is unknown but disordered adipocyte function including 
exaggerated lipolysis and aberrant release of adipokines (such as IL-6 and TNF 
alpha) is a major candidate pathway.  Elevations in FFAs, and pro-inflammatory 
adipokines could underpin the oxidative stress, endothelial dysfunction, 
inflammation, and insulin resistance - characteristic features of PE.  
The aims of this thesis were to acquire a better understanding of lipid 
metabolism and function in normal pregnancy, to determine if adipocyte 
function was altered in PE and, if so, to establish mechanisms. In addition I 
planned to corroborate epidemiological evidence of increased future CVD risk 
and to establish which risk factors accounted for this increased risk. 
I collected subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) 
biopsies in non-labouring pregnant healthy (n=31) and PE (n=14) women who 
underwent caesarean section. Maternal blood was collected prior to delivery and 
phenotyping of the mother was performed including plasma assay for 
cholesterol, triglyceride, HDL-cholesterol, IL-6, TNF-α, leptin, adiponectin, high 
sensitivity CRP, glucose and insulin concentrations. Maternal BMI at booking, 
standardised blood pressure measurements and birth weight centile were also 
recorded.  I determined ex vivo lipolytic activity (basal, isoprotenerol stimulated 
and insulin suppression of lipolysis) and adipokine production in response to 
lipopolysaccharide (LPS) stimulation from these biopsies. The gene expression of 
relevant target genes and macrophage densities in each adipose depot by 
immunocytochemistry (ICC) was also performed.  In addition I performed carotid 
ultrasound assessment of women with a previous history of PE (n=31) and 
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matched controls (n=29). Ethical approval was obtained from Glasgow Royal 
Infirmary LREC and all patients gave their informed consent.  
I found that in normal pregnancy, adipocyte lipolytic function is independent of 
maternal BMI. Adipocyte lipolytic function of SAT and VAT are also independent 
of each other. Adipose tissue is very metabolically flexible and the rate of whole 
body lipolysis is still insulin sensitive in late gestation. VAT is more closely 
related to markers of maternal insulin resistance (IR) and is more sensitive to 
catecholamine stimulation and less sensitive to insulin suppression of lipolysis 
than SAT, the basis of the “portal paradigm”.  Increasing BMI is associated with 
an increase in VAT cell size, with increased lipolysis and an increase in pro-
inflammatory adipokines, a potential mechanism through which increasing 
obesity could predispose to metabolic complications of pregnancy.  In contrast 
SAT cell size is not closely related to BMI and this may reflect the adaptation of 
this depot to increasing fat mass through both hypertrophy and hyperplasia, a 
metabolically advantageous response. TNF alpha is an important correlate of 
basal lipolysis in SAT. 
In PE there is decreased insulin sensitivity of both SAT and VAT compared to 
controls as calculated by the fat cell insulin sensitivity index (or responsiveness 
to insulin once the tissue is stimulated by isoproterenol). This would potentially 
make a significant impact on total circulating FFA as almost 60% of circulating 
FFA are from these adipose depots. The rise in FFA in PE occurs early in 
pregnancy and contributes significantly to IR. Therefore the IR of adipose tissue 
could lead to a vicious cycle of increased lipolysis, increased FFA and further 
exacerbation of IR. In contrast to controls, SAT cell size is intimately related to 
BMI suggesting that adaptation to increasing fat mass is mainly through 
adipocyte hypertrophy which could lead to increased endoplasmic reticulum 
stress, increased IR and increased release of inflammatory adipokines. I have 
shown that SAT cell size does relate to adipokine release in PE, with increased 
release of leptin, CRP and PAI-1 and paradoxical increase in the anti-
inflammatory IL-10. I had hypothesised that in addition to an inherent defect in 
adipocyte function there was an additional factor present in maternal serum of 
women with PE released from the placenta which excessively stimulated 
lipolysis. I failed to demonstrate any effect of maternal serum on adipocyte 
lipolysis in either controls or PE.  
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I also found that after stimulation with LPS, there was increased release of TNF 
alpha and IL-6 in VAT in PE but not in controls, with higher gene expression of 
these adipokines. TNF alpha release also correlated negatively with the fat cell 
insulin sensitivity index (FCISI) of VAT implicating a paracrine effect in this 
tissue. I also demonstrated an increase in gene expression of cfms (activated 
macrophages) relative to control gene, and increased density of cfms+ 
macrophages/adipocytes in the VAT of PE women implicating activated adipose 
tissue macrophages as a potential source of the increased release of 
inflammatory adipokines.  
Lastly I attempted to corroborate epidemiological evidence for the increase 
future risk of CVD women with a history of PE by assessing two surrogate 
markers for atherosclerosis - carotid IMT and carotid plaque scores. Both were 
found to be increased, with plaque scores significantly so. Classic risk factors 
such as age, lipids, BP and smoking did not attenuate this effect and BMI only 
marginally attenuated it, therefore only partially explaining this increased risk.   
In summary the data presented in this thesis provides further evidence that PE is 
a “metabolic syndrome of pregnancy” with disordered adipocyte function and 
metabolism, with an increased future risk of CVD in later life. Further studies on 
adipose accumulation, function and composition in normal and complicated 
human pregnancy are warranted. 
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1.1 Introduction 
Human pregnancy is characterised by striking changes in maternal metabolism 
and body composition in order to provide sufficient energy and nutrients to the 
developing fetus and later for lactation. In this review, I will describe the 
physiology of lipolysis in human adipose tissue as a prelude to the examination 
lipoprotein metabolism during normal pregnancy and in the presence of 
additional maternal metabolic stresses such as obesity and other risk factors for 
diabetes. The evidence regarding the contribution of lipids to the pathogenesis 
of pre-eclampsia will be assessed, and the relationship of pregnancy with 
cardiovascular disease in later life explored.  Finally the potential areas in this 
field necessitating further research will be considered.   
1.2 Physiology of lipolysis in human adipose tissue 
The major area of storage of triglycerides (TG) is white adipose tissue (WAT) and 
it allows surplus fuel to be stored in times of calorific excess and expended 
during times of need such as fasting or prolonged exercise. Lipolysis is the 
catabolic process through which TG are broken down into glycerol and non-
esterified fatty acids (NEFA). Three main organs produce and export fatty acids 
(FA): white adipose tissue (WAT), the intestine and liver. In humans, the main 
source for adipocyte TG is from chylomicrons and very low density lipoproteins 
(VLDL). Lipoprotein lipase produced in the adipocyte and transported to the 
endothelial surface of capillaries. TG in the lipoprotein particles are hydrolyzed 
by LPL releasing NEFA for uptake and storage by adipocytes. In WAT, LPL activity 
is cyclical, being highest after meals and lowest after fasting. 1 2In normal 
subjects there is fine-tuning of TG synthesis and lipolysis in response to 
hormonal and neural influences and is innervated by the autonomic system 
(parasympathetic and sympathetic nervous system). Lipolysis leads to release of 
NEFA which are not only energy substrates but are also highly toxic to cells and 
have been implicated in most of the pathological processes involved in obesity 
and insulin resistance.3 4  
The mobilization of fat stored in AT is mediated through both hormone sensitive 
lipase (HSL) and the more recently characterised adipose triglyceride lipase 
(ATGL).5 HSL was considered the key enzyme catalysing the rate-limiting step of 
AT lipolysis but this concept has recently been challenged with the finding that 
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ATGL is the predominant lipase in AT and an important regulator of TG 
degradation in skeletal muscle. ATGL was independently reported by three 
groups  and is also subject to a recent review.6 It is thought to be important in 
both basal and catecholamine-stimulated lipolysis. ATGL knockout mice show 
blunted fat cell lipolysis and as a consequence become obese with deposition of 
TAGs in multiple sites, particularly the heart.7 The sequential hydrolysis of TAG 
is regulated by the lipases and results in the liberation of FA at each step with 
the generation of DAG (diacylglycerol), MAG (monoacylglycerol), and glycerol. 
The current view is that ATGL and HSL work in a serial manner- ATGL initiates 
lipolysis by acting on TAG to produce DAG, which is then hydrolysed by HSL to 
MAG, which are finally converted to FA and glycerol by monacylglycerol lipase 
(MGL) 8(Figure 1) 
 
Figure 1 Sequential hydrolysis of triacylglycerides 
ATGL initiates lipolysis by acting on TAG to produce DAG, which is then hydrolysed by HSL 
to MAG, which are finally converted to FA and glycerol by MGL.  
Catecholamines, insulin and natriuretic peptides are considered to represent the 
major regulators of lipolysis in humans (Figure 2). Several novel lipolytic and 
anti-lypolytic agents have been discovered but their function in vivo are still to 
be clarified. Catecholamines are the most important stimulator of lipolysis and 
act via the symphathetic nervous system through ß1, ß2 and ß3 adrenoreceptors 
(AR) in the human fat cell. They initiate activation of lipolysis by stimulation of 
cAMP production via Gs–proteins and activation of protein kinase A (PKA).
9 The 
two main targets for PKA phosphorylation are HSL and the perilipins 10, and this 
results in a dramatic increase in lipolysis. Perilipins are a family of proteins 
which regulate coordination of lipid storage and utilization in various cell 
types.11 Perilipin A is the predominant form which covers the lipid droplets in 
mature adipocytes. Perilipin phosphorylation results in important physiological 
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alteration of the droplet surface that facilitates the action of HSL and ATGL.11  
Coexisting on the human fat cell are α2-adrenoceptors which when stimulated 
inhibit cAMP production and lipolysis through GI-inhibitory proteins
12. Thus in 
humans, the balance of beta and alpha adrenoreceptors mediates the net effect 
of catecholamines on lipolysis. The relative importance of β and α-adrenergic 
effects in human fat depots varies with age, adipose mass, WAT location and 
sex. 
Insulin is a potent mediator of fat metabolism and promotes glucose uptake by 
adipocytes and re-esterification of NEFA. Insulin is the main inhibitor of lipolysis 
and acts by it ability to lower cAMP levels via activation of phosphodiesterase 3B 
and therefore reducing PKA activity. 13 
Natriuretic Peptides (NP) are known to have a key role in the regulation of salt 
and water homeostasis and the control of blood pressure. They have also been 
found to exert a powerful lipolytic response in human AT via activation of a 
cGMP dependent pathway in contrast to cAMP seen with catecholamines.14 
Expression of atrial natriuretic peptides (ANP) receptor mRNA and binding 
studies have confirmed the presence of types A and C ANP-receptors (NPR-A and 
NPR-C).15  Not surprisingly it appears that insulin (as it acts via PD 3B to lower 
cAMP) has no effect on ANP stimulated lipolysis in contrast to its potent 
inhibition of catecholamine induced lipolysis.16 Real-time PCR has shown that 
large adipocytes express higher mRNA levels of NPR-A than small adipocytes on 
their cell membrane.17   NP appears to contribute to the physiological response 
of increased lipolysis during exercise 18 and this is particularly relevant in 
subjects receiving ß AR blockade.19 20  
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Figure 2 Major pathways involved in the stimulation of human fat cell lipolysis. Adapted 
from 21 
Signal transduction pathways for catecholamines via adrenergic receptors, metabolite-
driven inhibitory receptors and atrial natriuretic peptides via type A receptor (NPR-A). 
Protein kinases (PKA and PKG (cGK-I)) are involved in target protein phosphorylation. HSL 
phosphorylation promotes its translocation from the cytosol to the surface of the lipid 
droplet. Perilipin phosphorylation induces an important physical alteration of the droplet 
surface that facilitates the action of HSL. ATGL acts to initiate lipolysis by acting on TAG to 
produce DAG, which is then hydrolysed by HSL to MAG.  Docking of adipocyte lipid-binding 
protein (FABP4) to HSL favours the outflow from the cell of NEFAs released by the 
hydrolysis of triacylglycerols. Insulin, via stimulation of fat cell insulin receptors and 
phosphodiesterase-3B stimulation promotes cAMP degradation and antilipolytic effects 
while it is not active on cGMP-dependent pathways (not shown in the diagram). ATGL, 
adipose triglyceride lipase; FABP4, adipocyte fatty acid binding protein 4; GC, guanylyl 
cyclase; Gi, inhibitory GTP-binding protein; Gs, stimulatory GTP-binding protein; HSL, 
hormone-sensitive lipase; MGL, monoacylglycerol lipase; NEFA, nonesterified fatty acid; 
NPR-A, type A natriuretic peptide receptor.  
1.3 Lipid Metabolism in Normal Pregnancy  
1.3.1 Early Pregnancy 
Maternal metabolism during pregnancy adapts to benefit the growth and 
development of the fetus and can be divided into two phases.  During the initial 
two thirds of gestation, when fetal energy demands are limited, maternal fat 
stores increase.22 This is attributable in part to maternal behavioural change 
including hyperphagia 23 and to increased adipose tissue lipogenesis.24 In early 
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pregnancy insulin sensitivity is normal or even slightly improved with normal 
peripheral sensitivity to insulin and hepatic basal glucose production.25 This 
metabolic environment together with pregnancy related endocrine changes 
including increasing levels of oestrogen, progesterone and cortisol favours 
lipogenesis and fat accumulation. 26 
 
1.3.2 Late Pregnancy  
During the latter stages of pregnancy this anabolic state switches to a state of 
catabolism with a marked increase in lipolysis rates and a corresponding rise in 
maternal free fatty acids (FFA) and glycerol.27 28(Figure 3) This change is 
enhanced by an increase in hormone-sensitive lipase (HSL) activity and mRNA 
expression and a decrease in lipoprotein lipase (LPL) activity.29 Exaggerated 
catecholamine release in response to even modest maternal hypoglycaemia and 
the insulin resistant state of late pregnancy contribute to this switch.30 31 Insulin 
effects on lipolysis (adipose tissue) and fat oxidation (in liver and muscle) are 
significantly impaired during the 3rd trimester compared to earlier in pregnancy 
and also post partum.31 Reduced expression of PPARγ and its target genes may 
also contribute to accelerated fat metabolism in late pregnancy.32 This catabolic 
state corresponds to the time of maximum fetal growth and by increasing FFA 
use in the mother, increases availability of glucose and amino acids for the 
fetus.33 Increased lipolysis and therefore maternal glycerol production supports 
gluconeogenesis as glycerol is preferentially used as a substrate for glucose 
which easily transfers to the fetus.27 34 During times of fasting or starvation in 
late pregnancy there is increased ketogenesis from FFA in the  maternal liver.35 
Ketone bodies are readily transferred to the fetus and can be utilized for energy 
or for fetal lipogenesis.36 37 There is an excellent review by Herrera et al 
exploring lipid metabolism in normal pregnancy in further detail.38 
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Figure 3 Lipoprotein metabolism in late pregnancy 
This diagram summarises the main changes in lipoprotein metabolism which occur in 
advancing gestation. Due to increasing insulin resistance there is an increase in hormone-
sensitive lipase (HPL) activity and a decrease in lipoprotein lipase (LPL) activity. This 
results in a marked increase in lipolysis rates and corresponding increase in free fatty acids 
(FFA), delivered to the liver. These are channeled into hepatic triglyceride synthesis and 
increased secretion of VLDL. Oestrogen (E2) is the primary determinant of increased 
hepatic VLDL production. E2 also acts to promote Apo A1 production and reduce hepatic 
lipase (HL) activity with a resultant increase in HDL production. The reduced LPL activity 
contributes to the increase in plasma VLDL levels by reducing the peripheral catabolism of 
this lipoprotein. 
 
1.4 Body Composition 
All women increase maternal fat stores in early pregnancy irrespective of pre-
pregnancy adiposity to meet the feto-placental and maternal demands of late 
gestation and lactation. Women of normal weight gain around 3.8 kg of fat 39 
during pregnancy although there is substantial variation. 40-42 Total fat appears 
to increase to a peak toward the end of the second trimester before diminishing 
which corresponds to the period of increased lipolytic activity.43 44  In women of 
normal weight the majority of fat is accumulated centrally in the subcutaneous 
compartment of the trunk and upper thigh.45 46 In later stages of pregnancy there 
is an increase in both the thickness of pre-peritoneal fat (visceral) and the ratio 
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of  pre-peritoneal to subcutaneous fat as measured by ultrasound.47 This pattern 
may be relevant to increasing insulin resistance and lipid changes that occur as 
pregnancy progresses. Indeed accumulation of hepatic fat has been shown to be 
an important mediator of insulin resistance during pregnancy in the rat model.48 
Regionality of fat accumulation may be important due to regional variations in 
metabolic function as highlighted previously. Obese women, who will have more 
saturated subcutaneous fat stores, tend to accumulate fat more centrally than 
lean women, at least as estimated by using the skin-fold thickness technique, an 
observation which may reflect their more insulin-resistant state.46 Visceral 
adiposity appears correlated more strongly to adverse metabolic outcomes in 
pregnancy including gestational diabetes mellitus, gestational hypertension and 
pre-eclampsia.49-51 Furthermore visceral adiposity in early pregnancy appears to 
correlate better than subcutaneous fat or body mass index (BMI) with metabolic 
risk factors such as blood pressure, insulin resistance and lipids.52 Lean subjects 
have a greater increase in percent of body fat in pregnancy compared with 
obese subjects but there is no difference in actual total fat mass.46  
A large population-based Swedish study of 151 025 women highlighted the 
relevance of inter-pregnancy weight gain.53 It demonstrated that an increase of 
BMI of 3kg/m2 between two consecutive pregnancies resulted in an increased 
risk of pre-eclampsia, gestational diabetes, gestational hypertension, caesarean 
delivery, still birth and large for gestation age births even if a women has a 
healthy BMI for both pregnancies. This study re-inforces the evidence for 
causality between being overweight and obese and adverse pregnancy outcome    
 
1.5 Changes in Lipoprotein Profile during Pregnancy 
Pregnancy is characterized by marked increases in plasma lipid concentrations as 
gestation advances. Plasma cholesterol and triglyceride concentrations rise by 
25-50% and 200-400% respectively. The increase in triglyceride is mainly due to 
VLDL triglyceride which shows a three fold increase from 14 weeks’ gestation to 
late pregnancy.54 VLDL comprises two fractions, VLDL1 which is secreted by the 
liver to supply tissues with triglyceride fatty acids in the post-absorptive state 
and VLDL2 which is the major precursor of the major cholesterol transporting 
particles IDL and LDL. VLDL1 and VLDL2 increase in parallel by an average of 4-
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fold as plasma triglyceride increases with advancing gestation.55  These changes 
are due to increased adipose tissue lipolysis resulting in increased delivery of 
FFA and glycerol to the liver where they are re-esterified for the synthesis of 
triglycerides and incorporated into VLDL. The insulin resistant condition of 
pregnancy may contribute to the increased VLDL production but the effect of 
oestrogen is more likely the primary determinant of increased VLDL production 
by the liver.55 56 In addition to increased VLDL production there appears to be a 
decrease in maternal VLDL catabolism which may be due to a reduction in LPL 
activity in the third trimester.56 Oestradiol concentration rises steadily 
throughout pregnancy which suppresses postheparin hepatic lipase activity which 
in turn results in reduced triglyceride hydrolysis in IDL and LDL particles. 
Moreover there is an increase in cholesteryl ester transfer protein activity in mid 
trimester of pregnancy which would, in the presence of high plasma TG, 
contribute to enrichment of lipoprotein fractions with triglyceride.55 56 
 
Despite a rise in TG in normal pregnancy, HDL-cholesterol levels are elevated by 
the 14th week and rise by a maximum of around 40% at 28 weeks’ gestation 
mainly due to an increase in the HDL2 subfraction with a proportional fall in 
HDL3a and HDL3b. 54 56 The mean concentration of HDL-cholesterol is around 2 
mmol/L compared to around 1.5 mmol/L in the non-pregnant.55 This increase in 
HDL is driven by rising oestrogen concentration which acts on the liver to 
promote apo AI production and a simultaneous fall in hepatic lipase activity 
(which is responsible for hydrolysis of HDL2 to smaller HDL3 which is more 
rapidly removed from the circulation).55 56 
  
During normal pregnancy there is a rise in LDL of around 70%. 55.   Although this 
increase is less marked than TG there are some important qualitative changes in 
the LDL composition favouring a more “atherogenic” profile with a proportional 
increase in small dense LDL (LDLIII) in late pregnancy.57 55 In keeping with the 
non-pregnant population, this is driven by higher plasma triglycerides where a 
“threshold” effect may be seen.55 
 
1.6 Placental Transfer of Lipids 
Fatty acids are required by the developing fetus as they are important 
constituents of cell membranes.58 The fetus can produce some of the FFA from 
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fetal lipogenesis but the majority is acquired via the maternal circulation via the 
placenta. All of the essential fatty acids must be acquired from the mother from 
which the long chain polyunsaturated fatty acids (LCPUFA) are derived.59 These 
are of particular importance as they form membranes within the brain and 
nervous system. FFA can be released from circulating maternal TG-rich 
lipoproteins by placental lipoprotein lipase. Fatty acids cross the placenta by 
simple diffusion and more importantly through fatty acid binding proteins 
located in placental membranes and cytoplasm.60 The maternal LCPUFA status is 
a key determinant of FA status in the fetus although the placenta is able to 
selectively transfer important PUFA.59 Maternal supplementation with LCPUFA 
such as docosahexanoic acid (DHA) found in oily fish can also influence 
preferential uptake from mother to fetus.61  
 
Cholesterol, essential for fetal growth, is also transported from mother to fetus 
although it has been shown in animal models that fetal synthesis can provide a 
significant proportion required for fetal growth.62  Cholesterol is transported 
across the placenta from maternal LDL and HDL via LDL receptors and scavenger 
receptor B1 respectively. Cholesterol is transferred to fetal HDL probably via 
membrane localized efflux cholesterol transporter proteins ACBG1 and ABCA1.63 
Maternal hypercholesterolaemia can result in the presence of fatty steaks in the 
fetal aorta and may have implications for future disease in the offspring, 
although this remains to be definitely proven64  
1.7 Lipid Metabolism Obese vs Lean Pregnancy 
Maternal obesity is a well established and potentially modifiable risk factor for 
adverse pregnancy outcome including hypertensive disorders of pregnancy, fetal 
macrosomia and gestational diabetes mellitus (GDM).65 Rates of obesity are 
rising within the obstetric population with evidence of a 2-fold increase in 
women attending for antenatal care in the last decade.66 Therefore an 
understanding of metabolic differences between lean and obese women during 
pregnancy is useful.  Lean subjects have a greater increase in percent of body 
fat in pregnancy compared with obese subjects but there is no difference in 
actual total fat mass.46 Obese women tend to accumulate fat more centrally 
than lean women, at least as estimated by using the skin-fold thickness 
technique, an observation which may reflect their more insulin-resistant state.46 
In lean women there is an inverse relationship between changes in fat mass and 
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changes in insulin sensitivity in early pregnancy.28 In contrast in obese women 
there was no such relationship in early gestation but one does materialise over 
the longer gestation period from pre-pregnancy to late gestation.42 This suggests 
a slower metabolic responsiveness of obese women during pregnancy. Indeed in 
obese women there was an initial increase in insulin sensitivity from pre-
pregnancy to early pregnancy.42  
 
Interestingly obese women do not show any alteration in either basal 
carbohydrate oxidation or non-oxidisable carbohydrate metabolism from early to 
late pregnancy in contrast to a 50-80% increase in basal fat oxidation.42 This 
corresponds to the period of fat accumulation and reduced insulin sensitivity. In 
addition women with a high BMI have the largest increase in their basal 
metabolic rate (BMR) compared to women with normal or low BMI. 67 68 These 
differences lend support to the hypothesis that there is an adaptive process in 
obese individuals who are insulin resistant to prevent additional weight gain.69  
 
Maternal obesity results in alteration of the plasma lipid profile with higher 
serum triglyceride and VLDL cholesterol concentrations than those observed in 
lean women.70 71 This is seen together with lower HDL-cholesterol although LDL-
cholesterol and total cholesterol concentrations remain similar.71. This pattern 
of dyslipidaemia is similar to that of the metabolic syndrome in the non-
pregnant population.72  
1.8 Lipid Metabolism GDM vs NGT 
 
Gestational diabetes mellitus (GDM) is defined as a glucose intolerance at the 
upper end of the population distribution that is first detected during 
pregnancy.73 It is present in around 4-9% of all pregnancies depending on the 
population studied. 74 75 Its clinical importance reflects an increased perinatal 
morbidity related to fetal macrosomia, increased maternal risk of type 2 DM in 
later life and long term risk to offspring including obesity, sustained glucose 
intolerance and impaired intellectual ability.76 77 A detailed discussion of 
carbohydrate metabolism in pregnancy is beyond the scope of this review. In 
summary, normal pregnancy is characterized by a progressive increase in insulin 
secretion by 3-3.5 fold in late pregnancy coupled with increasing insulin 
resistance to levels around 50-70% less than that of non pregnant women.25 78 In 
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addition there is an increase in basal hepatic glucose production in spite of 
increased fasting insulin concentration.78 In GDM there is a similar increase in 
first-phase insulin response but the increase is attenuated compared to normal 
controls.79 However obese women with GDM have an exaggerated second-phase 
response compared to obese controls.80 As expected, insulin resistance is also 
greater in GDM than controls as measured by insulin suppression of glucose 
production.79 80 Thus, women who develop GDM begin pregnancy far closer to the 
metabolic thresholds beyond which they would develop glucose intolerance; 
pregnancy simply pushes these women beyond this threshold. 
 
In GDM there is dyslipidaemia consistent with insulin resistance. Plasma TG 
levels are significantly higher than in normal pregnancy and there is enrichment 
of lipoprotein fractions with TG within VLDL and HDL particles.81 There is also 
evidence that GDM increases LDL susceptibility to oxidation.82 As previously 
described post-prandial free fatty acids (FFA) are increased in late pregnancy 
due to insulin resistance and this effect is more pronounced in GDM.83 Women 
with GDM were found to have lower levels of insulin receptor substrate 1 (IRS-1) 
which may contribute to reduced suppression of lipolysis.32  
 
Lean women with impaired glucose tolerance prior to pregnancy had a smaller 
increase in fat mass compared to lean women with NGT.28 In obese women there 
was no apparent difference between women with NGT and GDM in the amount of 
or distribution of accumulated fat.42 46  
1.9 Lipid Metabolism in Pre-eclampsia 
 
Pre-eclampsia (PE) occurs in 2-4% of pregnancies and is a leading cause of 
maternal and neonatal morbidity and mortality in the developed world. It is a 
multi-system disorder resulting in the classic manifestations of hypertension due 
to vasoconstriction, proteinuria due to glomerular damage and oedema due to 
increased vascular permeability.84 Placental damage associated with the 
condition can result in intrauterine growth restriction. Delivery is the only known 
cure - thus, PE is a frequent cause of premature delivery and low birth weight.  
As yet the underlying pathogenesis of the disorder had not been completely 
understood. The clinical signs of PE are relatively simple manifestations of a 
complex underlying pathological process with activation of the coagulation 
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system, platelets and leukocytes and disturbances in metabolism which combine 
to provoke widespread endothelial damage and dysfunction. This in turn 
augments further activation of leukocytes and coagulation resulting in a vicious 
cycle of vascular injury. The disorder is likely to be a result of heterogeneous 
causes resulting from the interaction of placental and maternal factors.85 In the 
presence of a placental trigger the maternal response will depend on the 
maternal genotype and phenotype resulting in the clinical syndrome of PE.86  
 
1.9.1 Excess fat accumulation in several tissues 
The classic pathological lesion seen in the placental bed in PE is ‘acute 
atherosis’ resulting from the accumulation of lipid-laden macrophages 
surrounded by areas of fibrinoid necrosis in the spiral arteries – features 
comparable  to atherogenesis in non-pregnant women.84 Similarly, the 
characteristic lesion in the glomerulus – endotheliosis - involves the 
accumulation of lipids within glomerular endothelial cells while the liver also 
accumulates excess fat.84 This process is even more marked in HELLP syndrome 
and acute fatty liver of pregnancy, which are severe complications related to 
PE. Lipid accumulation at sites of endothelial damage emphasise the potential 
role of lipid disturbance in the vascular injury of PE. Therefore, whatever the 
precise nature of the ‘triggering’ placental factor in PE, it almost certainly 
provokes a disturbance in lipid metabolism which contributes to vascular damage 
 
1.9.2 Dyslipidaemia of pre-eclampsia 
In PE the hyperlipidaemia of normal pregnancy is exaggerated further via greater 
synthesis and potentially via lower peripheral catabolism (see Figure 2 for 
summary). Although direct evidence for impairment of peripheral catabolism is 
lacking there is a suggestion of the over representation of common mutations in 
the LPL gene in women with PE.87 These mutations are associated with a 
reduction in LPL activity and dyslipidaemia in the non-pregnant.  It has long been 
recognised that maternal hypertriglyceridaemia is significantly higher among 
pre-eclamptic women than normal matched controls.88-91 Importantly this rise 
occurs well in advance of manifestations of the disease.92 93 Furthermore there 
are some important qualitative changes in lipid composition as a consequence of 
high plasma TG. There is an almost three fold higher VLDL1 and an almost two 
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fold higher VLDL2 concentration than in control healthy pregnancy.89  Total LDL 
concentrations are similar but the exaggerated rise in TG drives increased 
production of small dense LDL in PE pregnancy to almost three times that seen 
in normal pregnancy with a reduction in large, buoyant LDL subfractions.89 94-96 It 
has been established in cardiovascular disease that hyperlipidaemia results in 
endothelial damage via oxidative stress and parallels exist between the 
atherogenic lipid profile seen in PE. Small, dense LDL exhibit enhanced oxidative 
potential and once oxidised these particles are believed to be highly atherogenic 
promoting foam cell formation and endothelial dysfunction.97 Soluble vascular 
cell adhesion molecule-1 (VCAM-1), a marker of vascular dysfunction, is elevated 
in PE and correlates with LDL cholesterol in pregnancy.98  Plasma triglycerides 
also correlate with the lipid peroxidation metabolite malondialdehyde.99 
Oxidised LDL but not native LDL inhibits trophoblastic cell invasion in a 
concentration dependent manner and this may be a further mechanism by which 
dyslipidaemia leads to impaired placentation and PE.100 Furthermore there is a 
reduction in endothelial protective HDL cholesterol.89 94 101  
 
1.9.3 Elevated Fatty Acids and their effects 
Together with an early rise of plasma triglycerides in women who go on to 
develop PE, a rise in FFA is also observed independent of maternal adiposity 
suggesting early exaggerated adipocyte lipolysis.92 Elevated FFA can be 
detrimental in several ways. Exposure of the liver to elevated FFA leads to 
reduced hepatic insulin extraction leading to systemic hyperinsulinaemia and 
accelerated gluconeogenesis.102 There is also increased esterification of FFA and 
reduced hepatic degradation of apolipoprotein B which leads to an increased 
synthesis and secretion of small VLDL particles and triglycerides. In addition to 
the effects on the liver, increases in FFA promote peripheral insulin resistance 
by reduction of insulin mediated glucose uptake (primarily in skeletal muscle).103  
Elevation of FFA has also been shown to impair endothelial function, via several 
potential mediatory mechanisms, through blunting of nitric oxide dependent 
tone via increases in the formation of reactive oxygen species in endothelial and 
vascular smooth muscle cells.104 105   
 
These adverse effects have also been confirmed in pregnancy and PE women. 
Increased FFA are an important mediator of insulin resistance in pregnancy.106 
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The high ratio of FFA to albumin in serum of PE women compared to normal 
controls resulted in increased uptake of FFA  by cultured endothelial cells which 
are further esterified into TG.107 In addition serum of PE women induces VCAM-1 
expression in endothelial cells an effect mimicked by the addition of FFA to 
serum of normal pregnancy.108  
 
FFA are also implicated in inflammation and have been shown to be an 
important mediator of inflammation in macrophages and are associated with 
increased CRP levels in obese women.109 110 Thus the combination of insulin 
resistance, dyslipidaemia, oxidative stress, endothelial dysfunction and 
inflammation apparent in PE could be in part be attributable to this early 
elevation in FFA. There is preliminary evidence that the trigger for this increase 
in FFA and adipocyte lipolysis is present in serum of women with PE.107  
 
1.10 Factors influencing adipocyte function  
1.10.1 Anatomical Location 
There are important differences between visceral or intra-abdominal and 
subcutaneous WAT depots. At the same BMI, women on average have greater 
subcutaneous fat mass and higher plasma levels of FFA than men. Visceral 
adiposity is more closely related to adverse metabolic outcomes including insulin 
resistance, hyperinsulinaemia, dyslipidaemia, hypertension and the metabolic 
syndrome.111 In visceral fat there is a higher turnover of lipids due to its greater 
sensitivity to catecholamine-induced lipolysis and decreased sensitivity to 
insulin.112 Visceral fat is in direct contact with the liver via the portal venous 
system. The liver is therefore exposed to chronic elevation of NEFA which as 
outlined above produces alteration in liver metabolism and promotes hepatic 
insulin resistance - the basis for the ‘portal paradigm’. In addition, visceral fat 
may further influence increased insulin resistance through a variety of 
inflammatory pathways.113 The differences are enhanced in obesity and 
polycystic ovarian syndrome. Alternatively, rather than visceral fat being 
directly or fully responsible for metabolic dysregulation of obesity, its rising 
volume may also simply signal saturation of ‘good’ fat storage capacity.  Drolet 
et al have proposed a model whereby subcutaneous fat acts as the primary fat 
depot and when the storage capacity of this depot is reached “overspill” into 
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secondary fat depots including, amongst other tissues, visceral fat, occurs.114 
Excess subcutaneous fat appears to be metabolically favourable.115 The much 
higher subcutaneous storage capacity of women compared to men and therefore 
less propensity to accumulate fat in the visceral compartment likely explains the 
lower prevalence of metabolic disturbances, and diabetes in middle-age, in 
women compared to men. This theory may also in part explain why certain racial 
groups such as South Asians are at increased susceptibility to central obesity and 
its metabolic consequences. 116 Similarly, in certain chronic illnesses, e.g. HIV, a 
loss of subcutaneous fat storage capacity may ‘push’ fat more centrally into key 
metabolic organs and instigate greater insulin resistance.117  Interestingly, fat 
from ‘ectopic sites’ such as visceral fat is preferentially lost with modest weight 
loss and may explain how modest weight loss appears to provide significant 
metabolic and clinical benefits.118 
1.10.2 Fat cell size and function. 
The adipocyte is the only cell type whose size may vary considerably in 
physiological conditions. Regional growth of AT is determined by the capacity of 
the mature adipocyte to accumulate and mobilize TG. Sex differences in body 
fat distribution and adipocyte metabolism suggest that the storage capacity and 
propensity of fat cells to enlarge (fat cell hypertrophy) or to differentiate (fat 
cell hyperplasia) may be regulated in a depot specific fashion. In women 
adipocytes from subcutaneous depot are larger than visceral fat, with marked 
regional differences in AT metabolic function in these two depots.114 Pre-
adipocytes produce two functionally distinct forms of adipocytes which 
characteristically predominate at different sites.119 Differentiation of these pre-
adipocytes into lipid-storing, mature adipocytes are dependent on the 
expression of numerous transcription factors including CEBPα, PPARγ and 
SREBPIc which are differentially expressed in subcutaneous and visceral AT.114  
As adipocytes increase in size both lipogenesis and lipolysis become increasingly 
active with increasing fatty acid flux across their cell membranes. Key enzymes 
utilized in AT metabolism have increased activity and mRNA levels in  larger 
adipocytes compared to smaller adipocytes such as fatty acid synthase, HSL, LPL 
and GLUT4, with upregulation of genes required for lipid metabolism as 
determined in microarray analysis.  
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Adipocyte size in fat is also related to adverse metabolic complications. 
Individuals with type II diabetes and dyslipidaemia had larger subcutaneous 
adipocytes, and adipocyte size in femoral fat is related to fasting plasma insulin, 
TGs and HDL- cholesterol ratios in men and women. Increasing adipocyte size is 
associated in a shift toward dominance of pro-inflammatory adipokines including 
TNF alpha and IL-6. This may be a result of dysregulated release of adipokines in 
hypertrophic larger adipocytes.120 Adipocyte hypertrophy is also thought to 
result in endoplasmic reticulum (ER) stress which results in activation of 
metabolic factors that trigger insulin resistance, with release of inflammatory 
cytokines and increased macrophage recruitment.121  
1.11 Adipokines and Pregnancy 
 
The view that adipose tissue is simply a storage organ of excess triglycerides has 
changed dramatically over recent years. It has been shown to secrete a diverse 
range of cytokines, proteins and signals which have both paracrine and 
endocrine actions and a wide-ranging influence on the metabolic and 
physiological function of other organs.122 In particular fat cells secrete factors 
involved in inflammation (TNFα, IL-6), haemostasis (PAI-1), insulin sensitivity 
(adiponectin) and energy balance and control of appetite (leptin). Adipokines 
including adiponectin, leptin, TNF alpha and IL-6 are increasingly implicated as 
important mediators of maternal metabolism particularly in relation to insulin 
resistance (IR) and lipid metabolism.  
1.11.1 Adiponectin 
Adiponectin is the most abundant adipokine in circulation and is synthesized 
exclusively in adipocytes and in contrast to other adipokines it is negatively 
correlated with adiposity.123 In humans, low plasma adiponectin concentrations 
are highly correlated with insulin resistance in obesity and type 2 diabetes.124  
Adiponectin is an insulin-sensitizing agent and mediates its effects through 
activation of adensosine monophosphate (AMP) protein kinase leading to 
increased uptake of glucose by myocytes and reduction in hepatic 
gluconeogenesis125 and by  increasing fatty acid oxidation in skeletal muscle by 
the sequential activation of AMP activated protein kinase, p38 mitogen-activated 
protein kinase and PAR alpha phosphorylation. Human adiponectin circulates in 3 
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isoforms- high molecular weight (HMW), middle MW and low MW. Although the 
total adiponectin level correlates well with insulin sensitivity, it has been found 
that the HMW isoform is an even better correlate.126 Maternal HMW adiponectin 
is the most prevalent adiponectin isoform regardless of gestational age or BMI 
status.127. The relevance of adiponectin in lipid and glucose metabolism in 
pregnancy is still to be elucidated. Catalano et al have demonstrated that total 
adiponectin secretion and adiponectin mRNA levels in WAT decline with 
advancing gestation in lean women, associated with a 25% increase in fat mass 
128. Adiponectin is negatively correlated with HOMA in late pregnancy in healthy 
women without GDM.129 Similar to subjects with obesity or type 2 diabetes, 
studies have shown that adiponectin is reduced in women who have had GDM130 
and in women with GDM during pregnancy compared to controls matched for 
BMI. In human and animal studies, maternal adiponectin levels were found to 
decreased or unchanged during normal pregnancy.131 132 Reduced adiponectin 
concentration may be consistent with increasing IR of pregnancy, whereas a lack 
of association may represent an independent role of adiponectin in pregnancy. 
As PE is a state of IR it was assumed that adiponectin levels would be lower, 
however Ramsay et al were the first to show that maternal adiponectin levels 
were marked elevated by nearly 50% in PE.133 However since then although 
several studies supported this finding, others showed the converse and no 
change in adiponectin levels.131 132 The lack of correlation between adiponectin 
levels and markers of IR in PE may suggests an atypical role of adiponectin in 
this syndrome. Interestingly adiponectin mRNA expression in adipose tissue of PE 
women was found to be similar to healthy controls.134  
1.11.2 Leptin 
Leptin is mainly synthesized and secreted by adipose tissue and is involved in 
involved in control of food intake and energy balance. Without functional leptin 
severe obesity occurs as in the ob/ob mouse.135 Adipocytes secrete leptin in 
direct proportion to adipose tissue mass as well as nutritional status. Plasma 
leptin concentrations positively correlate with subcutaneous fat due to its mass 
effect and higher secretion rate as compared to visceral fat.136 Insulin is a 
potent activator of leptin mRNA expression and protein secretion and is the 
major mediator of increased postprandial leptin concentrations.137 Obese 
individuals have higher leptin mRNA and protein levels than lean individuals.138 
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Serum leptin levels are elevated throughout normal human pregnancy and 
concentrations increase with advancing gestational age.139 140 Although the origin  
of leptin is still to be established, the placenta is thought to be a major 
contributor of maternal hyperleptinaemia 141. Leptin has wide ranging effects in 
reproduction including maternal physiology, implantation, paracrine effects in 
the placenta and fetal development and growth.142 Leptin has some important 
effects on lipid metabolism acting peripherally to prevent TG accumulation in 
peripheral tissues, but also regulates fuel partitioning by promoting lipid 
oxidation and protein synthesis and by curtailing lipogenesis, resulting in a 
selective loss of adiposity while preserving lean body mass.143 144 It mediates its 
liporegulatory actions both centrally and directly on the liver and WAT indicated 
by reduced expression of key enzymes involved in fatty acid synthesis in these 
tissues 145 146.Therefore one potential role of hyperleptinaemia in pregnancy may 
be to enhance mobilization of maternal fat stores to provide energy substrates 
for the developing fetus. 
The majority of studies suggest that maternal leptin concentrations and 
placental leptin synthesis are increased in pregnancies complicated by PE, with 
levels correlating with the severity of disease even before its clinical onset.147-149 
The role of leptin in the pathogenesis of PE is still to be elucidated but increased 
leptin could be considered to be a compensatory response aiming to increase 
nutrient delivery to an underperfused, hypoxic placenta. Leptin does correlated 
with other inflammatory markers including TNF alpha and IL-6 in normal and PE 
pregnancy, and may therefore be involved in the inflammatory and metabolic 
processes of both.150 
1.11.3 TNF alpha 
The inflammatory cytokine TNF alpha is associated with obesity and insulin 
resistance151 and is an independent predictor of CHD and CVD events and total 
mortality among men.152 Absolute levels and expression of TNF alpha in obese 
individuals compared to lean are higher. In addition TNF alpha correlates with 
insulin levels and decreased insulin sensitivity in IR individuals.153 154 It can lead 
directly to insulin resistance by inhibiting insulin signaling through several 
mechanisms including inducing serine phosphorylation of the insulin receptor 
IRS1.155 TNF alpha can also induce IR by stimulation of adipocyte lipolysis, and 
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through modulation of other adipokines including adiponectin and leptin. TNF 
alpha contributes to endothelial dysfunction via inhibition of endothelium 
dependent vasodilatation156 and triggers pro-coagulant activity and fibrin 
deposition.157 It is produced widely in immune cells, placenta and adipose tissue. 
TNF alpha is a potent regulator of lipid metabolism and induces lipolysis through 
multiple signaling pathways.158 TNF alpha rises during normal pregnancy 
primarily thought to be due to placental production, and is an important 
independent predictor of insulin sensitivity in late pregnancy.159 Maternal TNF-
alpha levels are higher in PE compared to normal pregnancy and could 
contribute to the pathogenesis of the condition through its effects on IR and 
endothelial dysfunction. Despite higher levels in PE, placental expression of TNF-
alpha does not appear to be higher therefore suggestive of an alternative source 
for the increased plasma levels.160 
1.11.4 IL-6 
IL-6, another proinflammatory cytokine implicated in IR, is secreted in 
significant amounts by SAT, in addition to a wide range of other cells  and 
correlates with BMI in non-pregnant.161  In vivo, administration of IL-6 stimulates 
whole body lipolysis and exerts anti-insulin effects.162 163 TNF alpha induces Il-6 
gene transcription and protein secretion in differentiated adipocytes.164 Similar 
to TNF alpha,  IL-6 is produced by the placenta, immume cells and AT and serum 
levels increases during pregnancy.165 IL-6 is increased in obese compared to lean 
women in pregnancy 166. IL-6 has also been related to pregnancy-associated 
insulin resistance.167 
1.11.5 CRP 
The best characterized biomarker of inflammation is C-reactive protein (CRP) 
produced predominantly by the liver. CRP is an acute-phase reactant synthesized 
mainly in the liver and is regulated by circulating levels of IL-6, although IL-1 and 
TNF alpha can also induce hepatic CRP mRNA expression.168 The liver was 
believed to be the major source of CRP, with its synthesis mainly under 
transcriptional control by IL-6 and, to a lesser extent, by other cytokines. 
However, now adipose tissue-derived IL-6 appears to be a major regulator of 
hepatic CRP production. CRP is also produced by adipose tissue, but it is unclear 
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to what extent AT contributes to circulating CRP levels. Elevated CRP is a strong 
independent predictor of the metabolic syndrome, cardiovascular disease and 
diabetes 169 170. CRP is positively correlated with plasma FFA in non-pregnant 
women.110CRP levels in normal pregnancy fluctuate widely but median values are 
consistently elevated throughout pregnancy.171 In addition, CRP is elevated in 
metabolic complications of pregnancy including PE and GDM, although this may 
be in part secondary to increased adiposity 172 173.  
1.11.6 Plasminogen Activator Inhibitor-1 
PAI-1 is a regulatory serine-protease inhibitor that decreases fibrinolysis and 
correlates well with visceral adiposity, hyperinsulinaemia and the expression of 
which is increased in the VAT of obese individuals.174 175 The link between PAI-1 
and the metabolic syndrome is now well established, with the more severe the 
syndrome the higher the plasma level of PAI-1.176. The mechanisms of PAI-1 over 
expression in obesity are complex and it is likely that a variety of inducers at a 
variety of sites are involved, including ectopic fat in the liver and visceral fat.177 
178 PAI-1 is also implicated in adipose tissue differentiation and in the control of 
insulin signalling in adipocytes.179 180 In normal pregnancy in order to prepare the 
body for the haemostatic challenge of delivery fibrinolytic capacity is 
diminished, mainly due to markedly increased levels of PAI-1 from endothelial 
cells (a marker of endothelial dysfunction) and PAI-2 from the placenta. The 
ratio of PAI-1/PAI-2 is elevated in women with PE and in particular early onset 
disease and obese relative to lean pregnant women.181 182  
1.11.7 Pregnancy, pre-eclampsia and cardiovascular disease 
 
There is increasing epidemiological evidence to suggest that adverse pregnancy 
outcomes such as PE, preterm delivery and low birth weight are associated with 
increased risk in later life of cardiovascular disease (CVD) in the mother. 183-186 
Jonsdottier et al, in a population based study investigated the association 
between hypertensive complications in pregnancy and death rates from ischemic 
heart disease (IHD). They found that the relative risk (RR) of dying from IHD was 
significantly higher among eclamptic women (RR=2.61; 1.11-6.123) and those 
with PE (RR=1.90; 1.02-3.52) than those with hypertension alone.184 In a 
retrospective cohort study in Scotland using discharge data of almost 130,000 
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women, PE was associated with a two-fold increased risk of subsequent IHD 
(RR2.0;1.5-2.5).185 More alarmingly if a woman had a combination of PE, preterm 
delivery and a baby of low birth weight she had a risk of IHD admission or death 
seven times that of controls (95% CI 3.3-14.5). A recent meta-analysis combining 
eight studies (2 346 997 women) with a mean follow up of 11.7 years 
demonstrated a relative risk of 2.16 (1.86-2.52) of IHD in women with pre-
eclampsia substantiating previous evidence.187 This doubling of risk remains 
robust even after adjusting for pre-pregnancy hypertension, diabetes mellitus, 
obesity, dyslipidaemia, the metabolic syndrome and smoking.186  
 
Gestation of onset also appears to influence the risk - if PE occurred prior to 37 
weeks’ gestation the risk of IHD was almost eight-fold (7.71,4.4-13.5).187 Indeed 
parity itself is associated with increased risk of CVD with prospective studies 
finding a positive association.188 189  A study by Lawlor and colleagues found a “J” 
shaped association between number of children and CHD, with the lowest 
prevalence among those with two children and a linear increase with subsequent 
children.190  Although the association was attenuated by adjustment for obesity 
and metabolic risk factors it was not completely obliterated. The authors 
suggest that normal pregnancy is a state of insulin resistance and dyslipidaemia 
and repeated pregnancies may have adverse long-term effects. These 
epidemiological links are biologically plausible as PE and CVD share many 
features including dyslipidaemia, insulin resistance, endothelial dysfunction, 
inflammation and oxidative stress common risk factors, either genotypic or 
phenotypic, might underlie both PE and CHD. Greer and Sattar proposed a model 
whereby pregnancy with its concomitant digression into a metabolic syndrome is 
a “stress test” of maternal metabolic response (Figure 4).191 Women who 
develop adverse pregnancy outcomes such as PE make greater excursions into 
metabolic disturbances during pregnancy and are predisposed to metabolic and 
vascular disease in later life. 
 
   
Shahzya S Huda, 2010 Chapter 1 44 
 
Figure 4 Risk factors for vascular disease are identifiable during excursions into the 
metabolic syndrome of pregnancy.  
Adapted from 191. 
1.11.8 Summary of aims and objectives: 
There are several directions in which further research would be beneficial and 
will be explored in this thesis and are summarized as follows: 
• To investigate the lipolytic function and properties of adipocytes in 
normal human pregnancy including its relationship to BMI, differences in 
function depending on regionality of the adipose tissue, and relationship 
to maternal markers of inflammation and insulin resistance. 
• To compare adipocyte lipolytic function between PE and normal 
pregnancy and to determine whether the basal or stimulated adipocyte 
release of FFA is exaggerated in women with PE. 
• To determine if plasma from women with PE excessively stimulates 
adipocytes suggesting the presence of a stimulatory lipolytic factor in PE 
plasma. 
• To determine if adipocyte release of adipokines is exaggerated under 
either basal or stressed conditions in women with PE compared to 
controls. 
• To determine if macrophage infiltration of adipose tissue, as a marker of 
tissue inflammation, is increased in women with PE compared to controls 
   
Shahzya S Huda, 2010 Chapter 1 45 
• To corroborate epidemiological evidence that women with PE have an 
increased cardiovascular risk in later life using carotid ultrasound 
surrogate markers for atherosclerosis and to determine which risk factors 
can account for any observed difference. 
 
 
 
 
    
2 Materials and Methods 
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2.1 Subjects 
Ethical approval was obtained from the Glasgow Royal Infirmary Local Research 
Ethics Committee 1 (REC reference no 06/S0704/14).  All subjects were given an 
information leaflet (case or control appropriate) and gave written informed 
consent to participate.   
2.1.1 Cases 
We recruited non-labouring pregnant women with pre-eclampsia (PE) undergoing 
caesarean section. PE was defined according to the International Society for the 
Study of Hypertension in Pregnancy (ISSHP)192 criteria i.e. DBP greater than 
110mm Hg on one reading or > 90mm Hg on repeated readings with proteinuria 
(≥0.3g of protein per 24 hours or ≥2+ protein on dipstick testing, in the absence 
of infection or renal disease). All gestations were included however gestation 
matched controls less than 32 weeks were difficult to find. In total 14 cases 
were recruited. 
2.1.2 Controls 
Healthy non-labouring pregnant women undergoing elective CS, either at term 
(>37 completed weeks of gestation) or pre-term but without hypertension or 
intra-uterine growth restriction (IUGR) being delivered for other obstetric 
indications were recruited as controls. IUGR was defined as an estimated fetal 
weight less than the 5th centile or less than the 10th centile plus either 
oligohydramnios or abnormal umbilical artery doppler. In the preterm group this 
was for problems such as placenta praevia or antepartum haemorrhage. Control 
women were matched to PE cases for smoking habit, age (+/- 5 years) and 
booking BMI (+/- 2 kg/m2). In total 36 healthy pregnant women were recruited. A 
subgroup of matched controls were used for comparison in Chapters 4,5,and 6.  
2.2 Buffers 
The following physiological buffers using distilled water were prepared using 
chemicals from Sigma Ltd, Poole Dorset unless otherwise stated. 
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2.2.1 KRH Buffer 
KRH buffer (NaCl 118mM, NaHCO3  5mM, KCL 4.7 mM, KH2PO4 1.2mM, MgS04 
1.2mM, HEPES 25mM, pH adjusted to 7.4) was prepared in advance, autoclaved 
and stored at 4°C. Wash, collection and digestion buffers were prepared on the 
day of tissue collection. 
2.2.2 Wash Buffer 
The wash buffer was derived form the KRH buffer and contained in addition 2.5 
mM CaCl2 and 151 mM bovine serum albumin (Sigma Ltd, Poole, Dorset, UK) with 
pH adjusted to 7.4. 
2.2.3 Collection Buffer 
Wash buffer with addition of glucose to obtain concentration of 3mM.  
2.2.4 Digestion Buffer 
For each gram of fat tissue 4ml of collection buffer with 2mg/ml collagenase 
(Collagenase, Worthington Type 1, Lorne Laboratories, Twyford, Essex, UK) was 
added.  
2.3 Tissue collection 
Maternal blood (20ml) was obtained prior to caesarean section into a selection 
of blood bottles with varying additives including K2EDTA, lithium heparin, clot 
activator, buffered sodium citrate and potassium oxalate. They were transferred 
to the laboratory to be immediately centrifuged at 3000rpm for 15 minutes and 
the resulting plasma and serum pipetted into aliquots (colour-coded to 
appropriate additive) and stored at -70°C. Tissue collection buffer was prepared 
fresh on day of collection and pre-warmed to 37°C. The surgeon was briefed to 
obtain a sample of subcutaneous adipose tissue (SAT) around the size of a 50 
pence coin (around 6-8g) on entry into abdominal cavity and this was placed in 
the collection buffer. Immediately after delivery of the cord and placenta, a 
sample of cord blood was obtained and transferred into pre-prepared blood 
bottles. A sample of visceral adipose tissue (VAT) was obtained from the 
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omentum after closure of the uterus and haemostasis secured. This was again 
the size of a 50 pence coin and was also placed in collection buffer.  Both 
samples were transferred to the laboratory where processing of fat was 
immediately commenced. A research technician was available on return to the 
laboratory to process the cord blood and other tissue. Cord blood was 
centrifuged and the resulting serum/plasma was divided into aliquots to be 
stored at -70°C. Two samples of cord around 2cm in length, four samples of full 
thickness placenta, paired samples of SAT and VAT when excess tissue was 
available were “flash-frozen” in liquid nitrogen and then placed in pre-cooled 
metal containers to be stored at -70°C.  A further 2 samples of placenta were 
fixed in 10% buffered paraffin prior to being embedded in paraffin, cut into 
sections and mounted on slides for later use. 
2.4 Processing the fat sample 
The fat sample was placed in a petri dish with warm wash buffer and any large 
blood vessels, fibrous tissue or skin was removed before weighing the sample. 
Two sections of both SAT and VAT of around 1g were flash frozen and placed in 
pre-cooled metal containters and stored at -70°C for later total RNA extraction. 
Adipocyte cell suspensions were prepared in accordance with the method 
described by Rodbell.193 In brief the fat sample was added to the appropriate 
volume of digestion buffer and cut into smaller pieces with scissors before 
agitating in a 37°C water bath (Grant, OPS-200) for 30 minutes. At the end of 
the 30 minutes the digestate was passed through a metal tea strainer (pore size 
600uM). The filtrate comprised a layer of adipocytes floating on top of the 
digestion buffer.  
Using a needle and syringe, the digestion buffer was replaced with warm wash 
buffer 5 times prior to aspirating as much buffer as possible below the adipocyte 
layer to leave adipocytes suspended at approximately 90% cytocrit.  
Adipocyte cell suspension (100ul) was added to 900ul of warm wash buffer in a 
15ml Falcon centrifuge tube. All assays were carried out in duplicate. All 
reagents were added to the relevant tubes and the timing of the assay was 
commenced. The tubes were placed in a 37°C shaking water bath at 91 cycles 
per minute and incubated for 120 minutes.  
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The remaining adipocyte suspension was divided into 150ul aliquots and frozen 
at -70°C for later quantification of DNA.  
2.5 Lipolysis Assay - Conditions and reagents 
2.5.1 Basal lipolysis 
No reagent was added to adipocyte cell suspension and warm wash buffer 
2.5.2  Insulin 
Insulin (Human Actrapid® Novo Nordisk)(10ul) was added to 590µl of KRH buffer 
to produce the insulin STOCK (10µM).This was diluted by a factor of 10 to a 
concentration of 1µM. 10ul of 1µM solution was added to the adipocyte cell 
suspension ( total volume 1ml) to give a final concentration of 10nM.   
2.5.3  Isoproterenol 
Isoproterenol is a non-specific beta adrenergic agonist which stimulates lipolysis 
in the adipocyte. Isoproterenol (49.5mg) was added to 100ml of KRH buffer to 
obtain a STOCK of 2mM.  This was diluted by a factor of 100. 10ul of this solution 
was added to the adipocyte cell suspension to give a final concentration of 
200nM. 
2.5.4  Isoproterenol and insulin 
Insulin and isoproterenol was prepared as above and 10 ul of each solution was 
added to give a final concentration of 10nM and 200nM respectively. 
2.5.5  Lipopolysaccharide 
Sterile balanced salt solution (1 ml of autoclaved KRH buffer) was added to a 
vial of 1mg LPS powder.  Concentration of LPS STOCK: 1mg / ml. This was 
diluted by a factor of 10 in KRH buffer and 10ul of this solution was added to the 
final adipocyte cell suspension to give a concentration of 1µM.  
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2.5.6 Determining concentrations and time lines 
A time course of lipolysis and dose response curves for isoproterenol and insulin 
were determined by Dr EK Tan who had worked on refining the methods for 
submission as a thesis for a degree of Master of Science. 
2.5.6.1 Time course 
Using adipose tissue of normal healthy pregnant women at term a time course of 
lipolysis was determined by measuring NEFA release with isoproterenol 
stimulation. Maximum isoproterenol stimulated release was at 180 minutes and 
then plateaued. A time point of 120 minutes which was within the linear phase 
of stimulation was chosen as the sampling time point 
2.5.6.2 Isoproterenol and Insulin dose-response 
Increasing concentrations of isoproterenol resulted in increasing release of NEFA 
as calculated as percentage stimulation above basal release to a maximum at 
2uM, with a plateau after that. A concentration of 200nM which was within the 
linear phase of the dose- response curve was used in the lipolysis assay. Similarly 
the concentration of insulin was chosen based on a dose response curve 
determining percentage suppression below basal release.  
2.5.6.3 Lipopolysaccharide 
Lipopolysaccharide (LPS) is an endotoxin and constitutes the lipid portion of the 
outer leaflet of Gram-negative bacteria. It acts on toll-like receptor (TLR) 4 on 
adipocytes. It was shown to neither stimulate nor suppress lipolysis (Dr EK Tan).  
A time-course and dose–response curve was performed to determine the 
concentration of LPS to use in the final lipolysis assay by measuring the cytokine 
IL-6 by ELISA (R&D Systems, Abindgdon, UK)  
An initial experiment was performed using increasing concentrations of LPS 
(0,1nM,10nM,100nM,1000nM,10000nM) added to adipocyte suspensions prepared 
as before. Samples of the supernatant were taken at time points 0, 30 mins, 60 
mins, 120 mins and 18 hours for analysis of IL-6 concentrations. This showed that 
IL-6 did not appear to be released from the adipocytes until at least 2 hours 
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incubation. Time points 120 mins and 18 hours were chosen for practicality of 
sampling. At 18 hours all concentrations were greater than 400 pg/ml. Dilutions 
were not performed. (Figure 5) 
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Figure 5 Release of IL-6 from adipocytes  
IL-6 release did not appear to occur until at least 120 minutes incubation. The maximum 
sensitivity of the ELISA was 400 pg/ml. Time points 120 mins and 18 hours were chosen for 
practicality of sampling. At 18 hours all concentrations were greater than 400 pg/ml. 
Dilutions were not performed.  
A time course was performed (n=3) with sampling taken at 2, 4, 6, and 18 hours 
(Figure 6) 
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Figure 6 Time course of IL-6 release with increasing concentrations of LPS 
 
From a practical point of view the best sampling time of the supernatant during 
the lipolysis experiments would either be at 2 hours or 18 hours (overnight). The 
2 hours time point was chosen as it was in the linear portion of the graph. 
A dose-response curve was also performed (n=4)(Figure 7). 
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Figure 7 Effect of increasing concentration of LPS on IL-6 release sampled at 2 hours 
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We therefore determined that a concentration of 10-6 M LPS to be used in the 
final methodology.  At levels of 10-5 M of LPS concentrations of IL-6 paradoxically 
fell implying a possible toxic effect of very high concentrations of LPS on the 
adipocyte. 
 
2.5.7 Measuring Fatty Acid Concentration 
At the end of the assay (time = 120mins) aliquots (5ul) obtained from the buffer 
layer below the cellular suspension were obtained for estimation of non-
esterified fatty acid concentration (NEFA) using a Wako NEFA-C Assay kits (Alpha 
laboratories, Eastleigh, Hampshire, UK). The Wako enzymatic method relies 
upon the acylation of coenzyme A(CoA) by the fatty acids in the presence of 
added acyl-CoA synthetase (ACS). The acyl-CoA produced is oxidized by added 
acyl-CoA oxidase (ACOD) with the generation of hydrogen peroxide. Hydrogen 
peroxide, in the presence of peroxidase (POD) permits the oxidative 
condensation of 3-methyl-N-ethyl-N-(b-hydroxyethyl)-aniline (MEHA) with 4-
aminoantipyrine to form a purple colour. This was measured by a microplate 
spectrophotometer (Multiscan EX, Thermo Electron Corporation) at 550nm. The 
within-run precision of the assay is 2.7%CV, 1.1%CV and 1.1%CV for mean 
concentrations of 0.33mmol/L, 0.62mmol/L and 0.99mmol/L, respectively 
(manufacturer). The linear range of the assay is 0-2.0mmol/L.  
2.5.8 Measuring Glycerol Concentration 
At the end of the assay (time = 120 minutes) aliquots (10ul) obtained from the 
buffer layer below the cellular suspension were obtained for estimation of 
glycerol concentration using a colorimetric glycerol assay kit (Randox 
Laboratories Ltd, Co Antrim, UK). This utilizes a quinoneimine chromagen system 
in the presence of glycerol kinase, peroxidise and glycerol phosphate oxidase 
which results in the formation from glycerol of n-(4-antipyryl)-3-chloro-5-
sulphonate-p-benzoquinoneimine to produce an orange colour. The optical 
density was measured at 520nm using a microplate spectrophotometer. 
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2.6 Fat cell sizing 
An unfixed fresh cellular suspension of adipocytes (10ul with 10ul KRH buffer) 
was prepared on a glass slide. An Olympus BX50 microscope using a x10 lens 
connected to 3-CCD colour camera (JVC) was used for digital image capture. 
Computer visualisation of the images were achieved with the image analysis 
program Image-Pro Plus 4.0 (Figure 8) and later analysed with Adobe Photoshop 
Version 7.0. An image of a stage micrometer with 100um markings was taken to 
convert pixels as measured by Adobe Photoshop to microns.(Figure 9)  
Diameter of adipocyte in um = y/x*100 when y= cell diameter in pixels and x= 
number of pixels between markings in stage micrometer ie 100um 
At least 100 adipocytes on the digital images were manually measured to derive 
the mean diameter of each adipocyte preparation. 
 
Figure 8 Image of cellular suspension of adipocytes (x100 magnification) 
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Figure 9 Image of stage micrometer with 100um markings (x100 magnification) 
2.7 Determining Fat Cell Numbers 
Fat cell number is important to determine as cellular density will influence the 
rate of lipolysis as measured by fatty acid and glycerol concentration in aliquots 
of the supernatant. Fat cell number was measured indirectly by quantifying the 
DNA content in a known volume of adipcotye suspension. The number of 
adipocytes would be directly proportional to the amount of adipocyte DNA 
content and lipolysis rates are expressed per ug of DNA. The DNA was isolated 
from a known quantity of adipocyte suspension that was previously frozen at -
70°C and thawed at room temperature using the Blood Prep DNA Purification 
protocol on the ABI PrismTM  6100 Nucleic Acid PrepStation (Applied 
Biosystems)(Figure 10). 
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Figure 10 Protocol for DNA isolation using the ABI PrismTM  6100 Nucleic Acid PrepStation 
Purification solution was added to adipocyte suspensions (2 x 150 ul of 
adipocytes for each specimen ie total of 300ul of cells) in eppendorf tubes. This 
was spun at 13,000 rpm for 2 minutes to separate lipid and water phase. Using 
fine-tip pastettes the water phase was carefully pipetted into the relevant well 
leaving the lipid phase behind in order to minimise clogging.  The standard 
BloodPrepTM protocol was adapted below (Table 1). 
   
Shahzya S Huda, 2010  Chapter 2 58 
 
Step Description Volume Position Incubation Vacuum Time(sec) 
1 Load 1st 
sample 
650ul Waste 0 80 300 
Repeat 
Step 1 a  
Load 2nd 
sample  
650ul Waste 0 80 300 
2 Add 
purification 
solution 
650ul Waste 0 80 400 
Repeat 
Step 2 a 
      
3 Add Wash 
solution 
650ul Waste 0 80 60 
Repeat 
Step 3 b 
      
4 Add Wash 
solution 
600ul Waste 0 80 60 
5  Add Wash 
Solution 
300ul Waste 0 80 60 
6 Preelution 
Vacuum 
- Waste 0 100 120 
7(ensure 
collection 
tray in 
place) 
Touch off 
(rock 
gently) 
 Waste    
8 Elution 
solution 1 
100ul Collection 180 0 - 
9 Collection  Collection 0 60 120 
10 Elution 
solution 2 
100ul Collection 0 60 120 
a 300ul of adipocyte cell suspension was used to improve DNA yield above the 
limit of Nanodrop sensitivity (ie 5ng/ul). A max of 150ul of sample can be 
added at Step 1 
b An additional wash step was added to minimise contamination with 
guanidine HCL present in purification solution 
Table 1  Adapted BloodPrepTM protocol to isolate DNA from adipocytes. 
The concentration of DNA was quantified using Nanodrop® ND 100 which is a 
cuvette free spectrophotometer which can accurately measure nucleic acid 
concentrations in small volumes (from 1ul). Absorbance readings are performed 
at 260nm where DNA absorbs light most strongly, and the number generated 
allows one to estimate the concentration of the solution. A “blank” 
measurement with a 50:50 mixture of elution buffer I and II was performed to 
minimise high absorbance at 230nm due to salts in the elution buffers. Measuring 
the intensity of absorbance of the DNA solution at wavelengths 260 nm and 
280nm is used as a measure of DNA purity. DNA absorbs UV light at 260 and 280 
nm, and aromatic proteins absorbs UV light at 280 nm; a pure sample of DNA has 
the 260/280 ratio at 1.8 and is relatively free from protein contamination. A DNA 
   
Shahzya S Huda, 2010  Chapter 2 59 
preparation that is contaminated with protein will have a 260/280 ratio lower 
than 1.8. 
The results were deemed acceptable if the concentration of DNA was > 5ng/ul 
and absorbance ratio at 260/280 was between 1.60 -2.00 (Figure 11). If not, the 
graphs were individually assessed to determine if there was an identifiable peak 
at absorbance 260nm, and if so the result was accepted. (Figure 12). If not, the 
process was repeated again using stored 150ul aliquots of adipocyte suspensions.      
 
 
Figure 11 Concentration of DNA of adipocyte preparation as measured on nanodrop 
The concentration of DNA was >5ng/ul and the absorbance ration at 260/280 was between 
1.60-2.00 (1.88). 
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Figure 12 Concentration of DNA of adipocyte preparation as measured on nanodrop 
The concentration of DNA was >5ng/ul. The absorbance at 260/280 was greater than 2.00 
(2.05) but there was an identifiable peak at absorbance 260nm. Therefore the result was 
deemed acceptable. 
2.8 Bioplex 
At time=120min paired 120ul aliquots of the buffer layer below the adipocyte 
layer was frozen at -80°C for later analysis of cytokines. Cytokine quantification 
was carried out with Bio-Plex (BIO-RAD®) system and suspension array 
technology. This is a multiplexed, particle based, flow cytometric assay which 
utilises anti-cytokine monocloncal antibodies linked to microspheres 
incorporating distinct proportion of two fluorescent dyes. Each of the 100 
spectrally addressed bead sets can contain a captive antibody specific for a 
unique target protein. Fluorescent intensity of the bead identifies the reaction. 
Analyte-specific antibodies are pre-coated onto colour-coded microparticles. 
Microparticles, standards and samples are pipetted into wells and the 
immobilised antibodies bind the analytes of interest. After washing away any 
unbound substances, a biotinylated antibody cocktail specific to the analytes of 
interest is added to each well. Following a wash to remove any unbound 
biotinylated antibody, streptavidin-phycoerythrin conjugate (Streptavidin-PE), 
which binds to the captured biotinylated antibody, is added to each well. A final 
wash removes unbound Streptavidin-PE and the microparticles are resuspended 
in buffer and read using the Luminex analyzer. One laser is microparticle-
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specific and determines which analyte is being detected. The other laser 
determines the magnitude of the phycoerythrin-derived signal, which is in direct 
proportion to the amount of analyte bound. Our assay was customised to detect 
and measure multiple adipokines (Table 2) using the R + D Systems Obesity Base 
Kit (cat no LOB000). 
 
 
Adipokine Cat No: 
Serpin E1/PAI-1 LOB1786 
CCL2/MCP-1 LUH279 
IL-6 LUH206 
Leptin LUB398 
TNF alpha LUH210 
Adiponectin LOB1065 
IL-10 LUH217 
Table 2 Adipokine antibodies and catalogue numbers 
 
The previously frozen samples were thawed at room temperature and spun at 
10,000rpm for 1 min then diluted in Calibrator diluent RD5K in a ratio of 1:20. 
All standards, buffers and reagents were prepared as per the manufacturers 
protocol. The desired number of wells of 96 well filter plate was prewet with 
100ul wash buffer and then removed by vacuum filtration. The bottom of the 
filter plate was dried thoroughly with a clean paper towel (lint free). The 
diluted microparticle mixture was resuspended and 50ul pipetted into each well.  
Standard or sample (50ul) was added into each well. The plate was covered with 
foil and shaken at 500rpm for 3 hours at room temperature. Buffer was removed  
by vacuum filtration and washed 3 times with 100ul Bio-Plex wash buffer 
blotting the bottom of filter plate with clean paper towel after every wash to 
prevent cross-contamination. Diluted biotin antibody cocktail (50ul) was added 
to each well and then covered with foil and shaken at 500rpm for 1 hour at room 
temperature.  The buffer was removed by vacuum filtration and a further 3 
washes were performed. Diluted streptavidin-PE (50ul) was added to each well, 
covered with foil and shaken at 500rpm for 30 mins at room temperature. At the 
end of the incubation the buffer was removed and a further 3 washes 
performed. The microparticles were then resuspended in each well with 100ul 
wash buffer and the plate covered with sealing tape and shaken at 500rpm for 
2mins. The plate was read on Biorad Bioplex analyser Luminex 100 within 90 
minutes. All results were in pg/ml.  
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2.9 Isolation of Total RNA  
RNA was isolated using the Tissue RNA Isolation protocol from Applied 
Biosystems for ABI PRISM 6100 Nucleic Acid Prepstation.  Keeping the tissue 
frozen using dry ice and liquid nitrogen 50mg tissue was weighed into a pre-
cooled universal and the exact weight was noted. Nucleic acid purification lysis  
(2.5ml) (1:1 PBS) was added. This was homogenised for 30 secs and left on wet 
ice for 30 mins (placenta) or 1 hour (adipose tissue). The homogenized lysate 
was stored at -20oC until purification. The lysate underwent prefiltration 
according to the manufacturer’s protocol in order to increase the yield of total 
RNA and reduce clogging in the purification tray. In this technique the 
homogenised lysate was passed across the tissue pre-filter tray and collected. 
Purification of the filtered tissue lysate was achieved by passing the lysate 
through a purification tray containing an application-specific membrane. Wash 
solutions (AbsoluteRNA Wash solution) were applied to the membrane and the 
purified RNA was eluted into a 96-well PCR plate. This process was performed 
using the manufacturer’s semi-automated protocol.  
2.10 Quantitative real time PCR 
RNA was reverse transcribed to cDNA using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Warrington , UK) according to the 
manufacturer’s instructions. A No RT control was also performed (Table 3). 
Preparation Sample mix with RT(ul) No RT control (ul) 
10 x RT buffer 1 1 
25 x dNTPs 0.4 0.4 
10 x random primers 1 1 
Multiscribe reverse 
transcriptase 
0.5 0 
Superasein (1U/ul) 0.5 0.5 
Nuclease free water 1.6 2.1 
Total volume per 
reaction  
5 5 
 + 5ul RNA + 5ul RNA 
Total voume 10 ul 10ul 
Table 3 Constituents of assay. 
cDNA was quantitated using TaqMan® technology on an ABI Prism 7900HT 
(Applied Biosystems).The target assays were purchased from Applied Biosystems 
and listed in Table 4. Briefly 1.25ul of 20 x target assay or control assay mix was 
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added to 12.5ul of 2 x Mastermix (Applied Biosystems), 10.25ul deionised 
distilled water and 1ul cDNA. The thermal cycler conditions were 50oC 2min, 
95oC for 10 min then 40 x 95oC for 15 secs and 60oC for 1min. Data was analysed 
using the Sequence Detection software, which calculated the threshold cycle 
(CT) values. The expression of the target assays were normalized by subtracting 
the CT value of the endogenous control (18s and PPIA) from the CT value of the 
relevant target assay. The fold increase relative to the control was obtained by 
using the formula 2-∆CT. 
Gene 
symbol 
TaqMan® gene expression assay Assay ID Source 
CD68  CD68 molecule Hs00154355-
m1 
Applied 
Biosystems 
PP1A peptidylprolyl isomerase A 
(cyclophilin A) 
Hs99999904-
m1 
Applied 
Biosystems 
18S Endogenous control 4310893E 
 
Applied 
Biosystems 
IL-6 Interleukin-6 Hs00174131-
m1 
Applied 
Biosystems 
TNF-α Tumour necrosis factor- alpha Hs00174128-
m1 
 
 
c-fms colony stimulating factor 1 
receptor 
Hs99999197-
m1 
Applied 
Biosystems 
Table 4 Taqman gene expression assays 
 
2.11 Immunocytochemistry 
2.11.1 Processing of biopsies 
Biopsies of SAT and VAT which had previously been flash frozen in liquid nitrogen 
and stored at -70◦C were defrosted at room temperature. Approximately 1cm3 
section was fixed in 30 ml of zinc formalin (Cellpath Acetic Zinc Formalin) for 24 
hours. It was then processed on a Leica ASP overnight and taken through the 
following solutions: zinc formalin for 1 hour 15 minutes, 70% methylated spirit 
for 1 hour, 90% methylated spirit for 1 hour, methylated spirit phenol for 1 hour, 
industrial alcohol for 3 x 1 hour, xylene for 45 minutes, then 2 x 1 hours and 3 
wax treatments for 1 hour, 1 hour 30 minutes, and 1 hour 30 minutes. The 
paraffin blocks were subsequently used in immunocytochemistry (ICC). Sections 
7 um thick were cut from the paraffin embedded tissue on a microtome (Leica 
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RM 2135) and mounted on electrostatic superfrost slides, heated to 60◦C 
overnight and stored in slide boxes until used. Placental tissue as was fixed in 
10% buffered formalin prior to being embedded in paraffin, cut into 5um 
sections and mounted on slides for later use. 
 
2.11.2 ABC method 
The antibodies used in ICC were polyclonal anti human cFMS (Chemicon cat 
no.CBL776) and monoclonal anti-human macrophage CD68 (Dako-CD68, PG-M1 
code no. M876) which represent activated and total macrophages respectively.  
The sections were heated to 60◦C for 35 min, depariffinized in xylene, and 
rehydrated in a graded alcohol series. Endogenous peroxidise activity was 
quenched using 0.5% hydrogen peroxide in methanol. Sections were washed in 
PBS. In sections to be incubated with anti-cfms, antigen was retrieved by 
microwaving in a pressure cooker (Lakeland Plastics Ltd., Cumbria, UK) at full 
power for 5 min in citrate buffer (10 mM, pH 6.0). The sections were washed in 
H20 then blocked with 20% goat/20% human serum. Section to be incubated with 
anti CD68, antigen was retrieved by pre-treatment with 0.1% trypsin in TRIS 
buffer containing 0.1% calcium chloride for 15 minutes and then washed in PBS. 
They were blocked by adding 20% horse/20% human serum. Sections were then 
incubated overnight for 16 hours at 4◦C with the primary antibody diluted either 
in 2% goat serum at a dilution of 1:25 (cfms) or in 2% horse serum at a dilution of 
1:50(CD68). Slides were washed in PBS and were incubated for 30 minutes with 
2◦Ab biotinylated anti-rabbit IgG (Vector laboratories)  diluted 1:200 in 2% goat 
serum (cfms) or biotinylated horse anti-mouse (Vector) diluted 1:200 in 2% horse 
serum both with 5% human serum added. Sections were washed in PBS and then 
incubated with avidin DH/biotinylated horseradish peroxidase H reagent (Vector) 
in PBS for 30 min before final washing. The antigen was localized using 1 mg/ml 
diaminobenzidine tetrahydrochloride (Sigma-Aldrich), 0.2% hydrogen peroxide in 
50 mM Tris HCl, pH 7.6, and appeared as a brown end product. Sections were 
counterstained with Harris hematoxylin (Sigma-Aldrich).  In sections using anti –
CD68 negative controls included slides incubated without the primary antibody 
and sections incubated with a mouse monoclonal antibody against IgG1 (Dako-
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X931), an enzyme that is neither present nor inducible in mammalian tissue. 
Tonsillar tissue was used as a positive control for all primary antibodies used. 
2.12 Quantification of macrophage cell density  
Macrophages were identified using histological analysis in ten randomly selected 
high powered fields (x 400 objective magnification) and were counted by two 
independent observers who were blinded to the specimen details. The area for 
each high-powered filed was 0.23mm2. Macrophages within the blood vessels 
were not included in the counts. Tissue macrophage densities were expressed as 
cell count per field (placenta) and cell count per adipocyte.   
2.13 Maternal and Cord Blood Phenotyping 
Maternal blood (20ml) was obtained prior to caesarean section into a selection 
of blood bottles with varying additives including K2EDTA, lithium heparin, clot 
activator, buffered sodium citrate and potassium oxalate. They were transferred 
to the laboratory to be immediately centrifuged at 3000rpm for 15 minutes and 
the resulting plasma and serum pipetted into aliquots (colour-coded to 
appropriate additive) and stored at -70°C. Cord blood was obtained from the 
cord with a needle and syringe after delivery of the placenta. The sample was 
also centrifuged and stored as aliquots at -70°C. 
Cholesterol and triglyceride were determined by enzymatic colorimetric assays 
on a Roche 917 analyser (Roche Diagnostics Ltd., Burgess Hill, United Kingdom). 
LDL and HDL were measured after ultracentrifugation at 105,000g at 4 oC for 16 
hours, followed by precipitation of the LDL fraction using a solution of heparin 
and manganous chloride. Glucose was measured by hexokinase/glucose-6-
phosphate dehydrogenase assay on an Abbott c8000 analyser (Abbott 
Diagnostics, Maidenhead, United Kingdom). High sensitivity C-reactive protein 
(CRP) was measured by an immunoturbidimetric assay (Roche Diagnostics Ltd., 
Burgess Hill, United Kingdom). Insulin was measured by a direct sandwich 
Enzyme-Linked Immunosorbent Assay (ELISA) (Mercodia AB, Uppsala, Sweden). 
IL-6 (Cat No:HS600B), TNF-alpha (Cat No: HSTA00D), leptin (Cat No: DLPOO) and 
adiponectin (Cat No:DRP300) were all by the quantitative sandwich ELISA (R&D 
systems, Abingdon, UK). NEFA in serum was measured using a Wako NEFA-C 
Assay kits (Alpha Laboratories, Eastleigh, Hampshire, UK) and read on a 
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microplate spectrophotometer (Multiscan EX, Thermo Electron Corporation) at 
550nm.   
2.14 Statistics 
Data was assessed for normal distribution using a Ryan-Joiner test and 
transformed to achieve a normal distribution where necessary. Comparisons 
between groups was made by two sample t-test (control vs PE) or paired t test 
(SAT vs VAT), and expressed as means with standard error for the mean (SEM). 
For non-parametric data comparisons were made using Mann-Whitney U test and 
data expressed as median and inter-quartile range.  Pearson’s correlation 
coefficients were calculated to assess associations between variables, and 
results were expressed as r value, R2 and p-value.  A p-value of <0.05 was 
considered significant. The data was adjusted for potential cofounders using the 
General Linear Model. All statistical analysis was carried out in Minitab (version 
15). 
 
    
3 Adipocyte Lipolytic Function in Normal 
Pregnancy  
   
Shahzya S Huda, 2010  Chapter 3 68 
3.1 Introduction 
Obesity, which is characterized by an increase in adipose tissue, is increasing in 
the western world to epidemic proportions. It is widely shown that increasing 
adiposity is linked to a broad range of metabolic abnormalities including insulin 
resistance hypertension, dyslipidaemia and increase risk of cardiovascular 
disease. Obesity or adiposity affects almost all aspect of female reproductive 
life including the metabolic complications of gestational diabetes and pre-
eclampsia. Adipose tissue itself has increasingly been found to have far reaching 
metabolic and endocrine effects and alterations in adipose tissue function with 
increasing adiposity may provide, at least in part, the link between adiposity and 
metabolic complications of pregnancy. It is therefore important that we have a 
better understanding of its function in both normal and abnormal states. 
I have investigated the lipolytic properties of adipocytes taken at elective 
caesarean section (CS) from women with healthy pregnancies of varying BMI. 
Much of the work on adipocyte function in pregnancy from AT explants has been 
on animal models and the following investigations represent the first detailed 
examination of adipocyte characteristics in normal human pregnancy in over 30 
years194. This will provide the basis for future comparisons with complications of 
human pregnancy involving adipocyte metabolism and function including pre-
eclampsia, IUGR and GDM. 
3.2 Specific Research Questions 
1. Do adipocytes respond to catecholamines and insulin in a similar manner 
to those of the non-pregnant ie isoproterenol stimulates lipolysis and 
insulin suppresses lipolysis? 
2. Are direct measures of adipocyte lipolytic function related to maternal 
BMI? 
3. Are direct measures of adipoyte lipolytic function related to plasma 
measures of insulin resistance? 
4. What are the relationships between maternal adipokine and inflammatory 
markers and direct measures of adipocyte lipolytic function? 
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5. What is the relationship of adipocyte cell size and measures of adipocyte 
function?  
6. Are there functional differences in AT metabolism in pregnancy depending 
on their anatomical locations and does this pattern reflect other insulin 
resistant states. 
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3.3 Results 
3.3.1 Subjects 
Thirty six non-labouring women were recruited as described in methods section 
2.1.2. The characteristics are described in Table 5. 
Characteristics Cohort (n=36) 
Age, y 31.2(5.3) 
BMI, kg/m2 28.2(5.4) 
Lean <30kg/ m2 (%) 72.2 
Smokers (%) 8.3 
DEPCAT* 4(4-6) 
Gestation at delivery, wk      38.9(1.2) 
Parity (0,1,2) 7,22,7 
Systolic pressure, mmHg 114.6(13.4) 
Diastolic pressure, mmHg 69.9(8.2) 
Birthweight, g 3466.8(532) 
Birthweight centile 57.7(28.4) 
Table 5 Characteristics of control women.  
All values expressed as mean and standard deviation (*median and interquartile range) 
 
Lipolysis assays were undertaken as set out in methods section 2.5, 2.6 and 2.7. 
Maternal biochemical markers were determined as detailed in methods section 
2.12. 
 
3.3.2 Action of Isoproterenol and Insulin on Lipolysis 
In SAT when lipolysis rates are expressed as the release of NEFA isoproterenol 
stimulates lipolysis (0.36[0.05] vs 0.76[0.07] mmol/L/ugDNA, p<0.001) and 
insulin suppresses basal lipolysis (0.36[0.05] vs 0.24[0.02] mmol/L/ugDNA, 
p=0.001). Insulin also attenuates the effect of catecholamine stimulation of 
lipolysis (0.76[0.07] vs 0.56[0.06] mmol/L/ugDNA, p <0.001)(Figure 13).  
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Figure 13 Comparison of NEFA release in subcutaneous fat in healthy pregnancy.  
Isoproterenol stimulates release over basal (p<0.001), insulin suppresses release (p=0.001), 
and insulin attenuates isoproterenol stimulation (p<0.001) (n=36). SBA =basal liploysis in 
SAT, SISO=lipolysis in presence of isoproterenol in SAT, SINS=lipolysis in the presence of 
insulin in SAT, SINS=lipolysis in the presence of isoproterenol and insulin in SAT. Values 
displayed as mean and SEM. Comparisons made using paired t-test to basal release unless 
otherwise indicated. *=p≤0.05, **=p≤0.01, ***=p≤0.001. 
A similar effect in subcutaneous fat of healthy controls is seen if lipolysis rates 
are calculated from glycerol release. Isoproterenol stimulates lipolysis 
(114.6[14.6] vs 270.1[19.4] umol/L/ugDNA, p<0.001), no effect is seen with 
insulin on basal release (114.6[14.6] vs 127[18.2] umol/L/ugDNA, p=0.5) but 
insulin does attenuate catecholamine stimulation of lipoloysis (270.1[19.4] vs 
242.4[25.4] umol/L/ugDNA, p=0.034).(Figure 14) 
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Figure 14 Comparison of glycerol release in subcutaneous fat in healthy pregnancy 
Isoproterenol stimulates release (p<0.001) and insulin attenuates isoproterenol stimulation 
(p=0.034)(n=36). SBA =basal liploysis in SAT, SISO=lipolysis in presence of isoproterenol in 
SAT, SINS=lipolysis in the presence of insulin in SAT, SINS=lipolysis in the presence of 
isoproterenol and insulin in SAT. Values displayed as mean and SEM. Comparisons made 
using paired t-test to basal release unless otherwise indicated.  *=p≤0.05, **=p≤0.01, 
***=p≤0.001. 
 
Similarly in visceral fat of control women isoproterenol stimulates lipolysis when 
calculated from NEFA release (0.25[0.05] vs 0.61[0.11] mmol/L/ugDNA, 
p<0.001), insulin suppresses basal release (0.25[0.05] vs 0.20[0.04] 
mmol/L/ugDNA, p=0.034) and insulin attenuates the effect of isoproterenol 
(0.61[0.11] vs 0.51[0.09] mmol/L/ugDNA, p<0.001) (Figure 15) 
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Figure 15 Comparison of NEFA release in visceral fat in healthy pregnancy.  
Isoproterenol stimulates release (p<0.001), insulin suppresses release (p=0.034) and insulin 
attenuates isoproterenol stimulated release (p<0.001)(n=36). VBA =basal liploysis in VAT, 
VISO=lipolysis in presence of isoproterenol in VAT, VINS=lipolysis in the presence of 
insulin in VAT, VINS=lipolysis in the presence of isoproterenol and insulin in VAT. Values 
displayed as mean and SEM. Comparisons made using paired t-test to basal release unless 
otherwise indicated. *=p≤0.05, **=p≤0.01, ***=p≤0.001. 
When lipolysis rates are expressed as glycerol release isoproterenol stimulates 
release (80[13.3] vs 189.5[17.5] umol/L/ugDNA, p<0.001), insulin has no effect 
on basal release (80[13.3] vs 80.6[11.9] umol/L/ugDNA p=0.95) and insulin 
appears to attenuate isoproterenol stimulated release (189.5[17.5] vs 172.3[19] 
umol/L/ugDNA, p=0.111)(Figure 16). 
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Figure 16 Comparison of glycerol release in visceral fat in healthy pregnancy. 
Isoproterenol stimulates release (p<0.001) and there is a trend for insulin to attenuate the 
effect of isoproterenol (p=0.111)(n=36). VBA =basal liploysis in VAT, VISO=lipolysis in 
presence of isoproterenol in VAT, VINS=lipolysis in the presence of insulin in VAT, 
VINS=lipolysis in the presence of isoproterenol and insulin in VAT. Values displayed as 
mean and SEM. Comparisons made using paired t-test to basal release unless otherwise 
indicated. *=p≤0.05, **=p≤0.01, ***=p≤0.001. 
 
 
The degree of stimulation by isoproterenol was calculated as a percentage of 
basal release of NEFA ie percentage stimulation = (SISO-SBA)/SBA)*100 and the 
degree of suppression by insulin was calculated as a proportion of basal release 
ie :(SBA-SINS/SBA)*100.  Visceral fat is more responsive to stimulation by 
isoproterenol compared to subcutaneous fat (239[32] vs 159 [20]%, p=0.04) 
(Figure 17) and this trend was also apparent when lipolysis was expressed by 
glycerol release (337[83] vs 236[34]%, p=0.265).(Figure 18). There was a trend 
for basal suppression of lipolysis to be lower in VAT although this did not reach 
significance (8.8[7.6] vs 22.7[4.6]%, p=0.123). 
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Figure 17 Percentage stimulation and inhibition of NEFA release in SAT and VAT in healthy 
pregnancy. 
Visceral fat is more responsive to stimulation by isoproterenol (p=0.04)(n=36). SISO% -
percentage stimulation of lipolysis by isoproterenol in SAT, SINS%-percentage inhibition of 
lipolysis by insulin in SAT, VISO% -percentage stimulation of lipolysis by isoproterenol in 
VAT, VINS%- percentage inhibition of lipolysis by insulin in VAT. Values displayed as mean 
and SEM. *=p≤0.05, **=p≤0.01, ***=p≤0.001. 
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Figure 18 Percentage stimulation and inhibition of glycerol release of SAT and VAT in 
healthy pregnancy.  
There was a non significant trend for VAT to be more sensitive to isoproterenol stimulation 
than SAT when expressed as glycerol release. SISO% -percentage stimulation of lipolysis 
by isoproterenol in SAT, SINS%-percentage inhibition of lipolysis by insulin in SAT, VISO% -
percentage stimulation of lipolysis by isoproterenol in VAT, VINS%- percentage inhibition of 
lipolysis by insulin in VAT. Values displayed as mean and SEM. 
3.3.3 Relationship of stimulated, inhibited and basal lipolysis 
In SAT, the metabolic flexibility (ie its responsiveness to stimulation and 
inhibition) of the adipocytes is related to the basal lipolysis of the cell. The 
lower the basal lipolysis of the AT the increased susceptibility it is to stimulation 
by isoproterenol (r=-0.056, R2 31.8%, p<0.001) (Figure 19). 
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Figure 19 Basal Lipolysis versus percentage stimulation in SAT in healthy pregnancy. 
The higher the basal lipolysis the lower the percentage stimulation by isoproterenol 
(p<0.001)(n=36). 
In addition in SAT basal lipolysis is related to sensitivity of the fat to suppression 
by insulin. As basal lipolysis increases so does the degree of suppression by 
insulin (r=0.58, R2 = 33.5%, p<0.001) (Figure 20). 
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Figure 20 Basal lipolysis versus percentage inhibition in SAT in healthy pregnancy. 
The higher the basal lipolysis the higher the percentage inhibition by insulin (p<0.001) 
(n=36). 
A similar effect is apparent in VAT – increasing basal lipolysis is related to 
reduced susceptibility to stimulation by isoproterenol. (r=-0.45, R2 = 20.5%, 
p=0.009)(Figure 21). 
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Figure 21 Basal lipolysis versus percentage stimulation in VAT in healthy pregnancy.   
As basal lipolysis increases the less responsive VAT is to stimulation by isoproterenol 
(p=0.009)(n=36). 
However there is no apparent relationship between basal lipolysis and sensitivity 
to suppression with insulin in contrast to that seen in subcutaneous fat (Figure 
22). 
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Figure 22 Basal lipolysis versus percentage inhibition in VAT in healthy pregnancy.   
There is no apparent relationship (p=0.219)(n=36). 
There is also an inverse relationship between the sensitivity of SAT and VAT to 
stimulation by catecholamines and inhibition by insulin. (r=-0.46,R2 = 20.7%, 
p=0.005 and r=-0.74, R2 = 54.5%, p<0.000 respectively) (Figure 23 & Figure 24).  
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Figure 23 Percentage stimulation of lipolysis by isoproterenol vs percentage inhibition by 
insulin in SAT.  
There is an inverse relationship (p=0.005) (n=36). 
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Figure 24 Percentage stimulation of lipolysis by isoproterenol versus percentage inhibition 
by insulin in VAT.  
There is an inverse relationship (p<0.000)(n=36). Relationship remains robust when re-
tested without apparent outlier (r=-0.75, p=0.000). 
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3.3.4 Relationship of lipolytic function between VAT and SAT. 
There is no relationship between basal lipolysis in SAT and VAT when expressed 
as either release of NEFA or glycerol. The lipolytic function of SAT and VAT 
appear to be independent. The only apparent correlation is between that of 
isoproternol stimulation of lipolysis when expressed as NEFA release/ugDNA – the 
sensitivity of catecholamine stimulation of SAT is positively associated with that 
in VAT (r=0.46, R2=21.5, p=0.008)(Figure 25). 
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Figure 25 Percentage stimulation of lipolysis versus percentage stimulation  in SAT. 
There is positive correlation between percentage stimulation of lipolysis in VAT and SAT 
(p=0.008)(n=36). 
3.3.5 Relationship between lipolytic function of AT and maternal 
and fetal characteristics. 
There was no correlation between any measure of lipolytic function (ie absolute 
levels of basal, insulin suppressed or isoproterenol stimulated lipolysis or 
percentage stimulation or inhibition of lipolysis) and maternal BMI, age, parity, 
systolic BP ,diastolic BP, gestational age at delivery, birth weight and birth 
weight centile. 
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Maternal plasma levels of NEFA were positively correlated with gestational age 
at delivery (r=0.37, R2=14.0%, p=0.025) (Figure 26). 
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Figure 26 Relationship between gestational age at delivery and maternal NEFA. 
There is a positive correlation between gestational age at delivery and maternal NEFA 
(p=0.025)(n=36). 
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3.3.6 Fat Cell Insulin Sensitivity  
A direct measure of insulin sensitivity of the fat cell was calculated from the 
percentage inhibition of catecholamine stimulated lipolysis by insulin measured 
from the release of NEFA. This was derived from the following calculation 
(Figure 27): 
(SISO-SISO+INS)/(SISO-SBA)*100 
FCISI
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Figure 27 Fat cell insulin sensitivity index. 
The fat cell insulin sensitivity index (FCISI) is calculated from the percentage inhibition of 
catecholamine stimulated lipolysis by insulin ie (SISO-SISO+INS)/(SISO-SBA)*100. 
This was called the fat cell insulin sensitivity index (FCISI). 
Using this measure, visceral fat was less insulin sensitive than subcutaneous fat 
(11%[27] vs 82%[21] p=0.04) in the normal pregnant woman.(Figure 28) 
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Figure 28 Comparison of FCISI between VAT and SAT. 
Visceral fat is less insulin sensitive as measured by the FCISI (11%vs82% p=0.04)(n=36). 
Values displayed as mean and 95% confidence interval. 
There was no correlation between FCISI in SAT and VAT (r=-0.05, p=0.79). 
Maternal plasma glucose, insulin and subsequent HOMA (Homeostatis Model 
Assessment) did not correlate with absolute values for basal lipolysis, stimulated 
lipolysis or insulin attenuated catecholamine stimulated lipolysis in either SAT or 
VAT. HOMA is a measure of whole body insulin resistance and is calculated by 
the product of the fasting concentrations of glucose and insulin divided by a 
constant (22.5)195.  FCISI in visceral fat was negatively correlated with maternal 
glucose (r=-0.46, R2 = 21.5%, p=0.008) which remained robust after adjustment 
for age, BMI and parity (p=0.016).(Figure 29) FCISI in visceral fat was also 
negatively correlated with HOMA (r=-0.32), R2=10.3%, p=0.073) and this 
association became more robust after adjusting for age, BMI and parity 
(p=0.05).(Figure 30) Interestingly the converse was true for subcutaneous fat. 
There was a positive correlation between FCISI in SAT and maternal glucose (ie 
the more insulin sensitive the SAT the higher the maternal glucose) (r=0.49, 
R2=23.6, p=0.003), which persisted after adjustment for age, BMI and parity 
(p=0.005).(Figure 31) In addition there was also a positive correlation with SAT 
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FCISI and HOMA (r=0.34, R2=11.2%, p=0.046) which again remained robust after 
adjustment (p=0.047).(Figure 32) 
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Figure 29 Relationship between FCISI in VAT and maternal glucose. 
FCIS in VAT is negatively correlated with maternal glucose r=-0,464, p=0.016 adjusted for 
age, BMI and parity (n=36). 
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Figure 30 Relationship between FCIS in VAT and maternal HOMA. 
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FCISI in VAT is negatively correlated with maternal HOMA, r=-0.32, p=0.05 after adjustment 
for age, BMI and parity (n=36).  
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Figure 31 Relationship between FCISI in SAT and maternal glucose. 
FCISI in SAT is positively correlated with maternal glucose r=0.49, p=0.005 adjusted for age, 
BMI and parity (n=36). 
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Figure 32 Relationsip between FCISI in SAT and maternal HOMA. 
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FCISI in SAT is positively correlated with maternal HOMA r=0.34,p=0.047 adjusted for age 
BMI and parity (n=36). 
 
Absolute values of basal lipolsis, isoproterenol stimulated lipolysis and insulin 
suppressed lipolysis in ether SAT or VAT did not correlate with plasma markers of 
maternal glucose, insulin or HOMA.  
3.3.7 Relationship of serum lipids and lipolytic activity 
 Maternal serum TGs increase as visceral fat cell insulin sensitivity decreases (r=- 
0.5, R2=24.8%, p=0.004, which is independent of BMI (p<0.001) (Figure 33). 
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Figure 33 Relationship between maternal TG and FCISI in VAT.  
Visceral fat cell insulin sensitivity is negatively correlated with maternal plasmaTG 
(p=0.004)(n=36). 
 
3.3.8 Relationship of Maternal NEFA and Maternal Glucose, 
Insulin and HOMA 
Maternal fasting levels of NEFA are inversely related to maternal glucose levels 
(r=-0.47, R2 = 21.9%, p=0.004)(Figure 34) and maternal insulin levels (r=-
0.59,R2=34.5%, p<0.001)(Figure 35), and therefore not surprisingly with HOMA 
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(r=-0.59,R2=35.2%,p<0.001)(Figure 36). All relationships remained robust after 
adjustment for age, BMI and parity (p=0.002;p<0.001;p<0.001 respectively). In 
addition, as expected, maternal glucose was positively correlated with maternal 
insulin levels (r=0.7, R2=49.1% p<0.001)(Figure 37). 
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Figure 34 Relationship between maternal NEFA and maternal glucose.  
Maternal fasting NEFA is negatively correlated with maternal fasting glucose 
(p=0.004)(n=36). 
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Figure 35 Relationship between maternal NEFA and maternal insulin. 
Maternal fasting NEFA are negatively correlated with maternal fasting insulin 
(p<0.001)(n=36). 
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Figure 36 Relationship between maternal NEFA and maternal HOMA. 
Maternal fasting NEFA are negatively correlated with maternal HOMA (p<0.001)(n=36). 
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Figure 37 Relationship between maternal insulin and maternal glucose. 
Maternal fasting insulin is positively related to maternal fasting glucose (p<0.001) (n=36). 
3.3.9 Relationship of adipokines and lipolysis 
3.3.9.1 Adiponectin 
In this cohort, although there was a trend for a negative association with BMI 
this did not reach significance (p=0.07). There was no correlation with other 
maternal and fetal characteristics ie age, parity, BP, gestational age at delivery, 
birth weight and birth weight centile. 
There was no correlation between adiponectin and any measure of lipolytic 
function in either SAT or VAT (ie absolute levels of basal, insulin suppressed or 
isoproterenol stimulated lipolysis or percentage stimulation or inhibition of 
lipolysis). 
A positive correlation was seen with progesterone (r=0.44, R2=19.2%, p=0.007) 
but not with either oestradiol or hPL (human placental lactogen). This 
relationship remained robust after adjustment for age, parity, BMI, smoking and 
gestation at delivery (p=0.026)(Figure 38). 
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Figure 38 Relationship between maternal plasma adiponectin and maternal progesterone. 
Adiponectin is positively correlated with maternal progesterone (p=0.026) after adjustment 
for age, parity, smoking and gestation at delivery (n=36).  
There was no correlation between adiponectin with markers of insulin resistance 
including maternal glucose, insulin or HOMA in this cohort of normal pregnant 
women at term.  
There was no correlation between adiponectin with maternal NEFA, total 
cholesterol (TC), triglceride(TG), nor high density lipoprotein cholesterol (HDL). 
Adiponectin was negatively correlated with log CRP (r=-0.33, R2=11% p=0.048) 
but this relationship was attenuated when adjusted for maternal BMI (p=0.151). 
No association was found between adiponectin and TNF alpha, IL-6 or leptin.  
3.3.9.2 Leptin 
There is a positive association between leptin and BMI (r=0.5, R2=24.5%, 
p=0.002)(Figure 39). There was no association between leptin and maternal age, 
parity, systolic and diastolic BP, gestation at sampling, birthweight and 
birthweight centile.  
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Figure 39 Relationship between plasma leptin and maternal BMI. 
Leptin is positively correlated with BMI (r=0.5, p=0.002) in normal pregnant women (n=36). 
Leptin correlates with measures of lipolytic function in VAT but not SAT. There is 
a positive correlation between maternal leptin and absolute values of lipolysis in 
the presence of isoproterenol expressed as NEFA release (r=0.36, 
R2=12.6%,p=0.046)(Figure 40) and the presence of isoproterenol and insulin 
expressed as NEFA release (r=0.38, R2 =14.%, p=0.034.(Figure 41) These 
associations remain after adjustment for age, parity, BMI and smoking (p=0.04 
and p= 0.05 respectively). 
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Figure 40 Relationship between maternal leptin and stimulated NEFA release in VAT. 
Leptin is positively correlated with NEFA release in the presence of isoproterenol in VAT 
(r=0.36, p=0.040) adjusted for age, parity, BMI and smoking (n=36). 
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Figure 41 Relationship between maternal leptin and NEFA release in presence of 
isoproterenol and insulin in VAT. 
Leptin is positively correlated with NEFA release in the presence of isoproterenol and 
insulin in VAT (r=0.38, p=0.05) adjusted for age, parity, BMI and smoking (n=36). 
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Figure 42 Relationship between maternal leptin and glycerol release in VAT. 
Leptin is positively correlated with glycerol release in the presence of isoproterenol and 
insulin in VAT (r=0.35, p=0.05) (n=36). 
There is no correlation between leptin and maternal progesterone, oestradiol 
and hPL. 
Leptin is positively correlated with markers of plasma insulin resistance: 
maternal insulin (r=0.45, R2=20.4%, p=0.006) and maternal HOMA (r=0.42, 
R2=17.9%, p=0.01) and remains after adjustment for age, BMI, parity and smoking 
(p=0.01 and p=0.015).  
There is a strong positive association of leptin with log CRP (r=0.59, R2=33.4%, 
p<0.001) but no association was seen with IL-6 and TNFα (Figure 43). This 
relationship remains after adjustment for age, parity, BMI and smoking 
(p=0.006). 
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Figure 43 Relationship between plasma leptin and plasma CRP in healthy pregnancy. 
Leptin is positively associated with log CRP (r=0.59, p=0.006) after adjustment for age, 
parity, BMI and smoking (n=36). 
There was no relationship between leptin and maternal NEFA and lipids in this 
cohort.  
For a summary of the correlations between maternal plasma adipokines and 
inflammatory markers with fetal and maternal characteristics, and markers of 
lipid and glucose metabolism see Table 6 and Table 7. 
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Plasma 
Marker 
Age BMI Systolic BP Diastolic BP Gestational 
Age 
Birthweight      Birthweight 
centile 
Adiponectin NS r=-0.30 
p=0.07 
NS NS r=0.32     
p=0.058 
NS NS 
Leptin NS r=0.5 
p=0.002 
NS NS NS NS NS 
Il-6 NS r=-0.35 
p=0.037 
NS NS NS r=-0.39     
p=0.02 
r=-0.38    
p=0.026 
TNF-α NS r=-0.34 
p=0.04 
NS NS NS NS NS 
CRP NS r=0.37 
p=0.027 
NS NS NS NS NS 
Table 6 Summary of correlations between maternal plasma adipokines and inflammatory 
markers with maternal and fetal characterisitics (n=36). 
Plasma Marker SAT 
Lipolytic 
Measures  
 
VAT 
Lipolytic 
Measures 
 
Glucose Insulin HOMA SAT 
FCISI 
VAT 
FCISI 
NEFA TG TC HDL 
Adiponectin NS NS NS NS NS NS NS NS NS NS NS 
Leptin NS ISO:r=0.36 
p=0.046 
ISO+INS: 
r=0.38   
p=0.034 
NS r=0.45 
p=0.006 
r=0.42 
p=0.01 
NS NS NS NS NS NS 
Il-6 NS NS r=0.35 
p=0.03 
NS NS NS NS NS NS NS NS 
TNFapha Basal: 
r=0.44 
p=0.008 
ISO%: 
r=-0.35 
p=0.036 
INS%: 
r=0.4 
p=0.015 
NS NS NS NS NS NS NS NS NS NS 
CRP NS ISO: r=0.35 
p=0.05   
ISO+INS: 
r=0.45 
p=0.01 
NS NS NS NS NS NS NS NS NS 
Table 7 Summary of correlations between maternal plasma markers of inflammation and 
adipokines with measures of lipid and glucose metabolism (n=36). 
All lipolytic measures are expressed as NEFA release/ugDNA. ISO-in presence of 
isoproterenol; ISO+INS- in presence of isoproterenol and insulin; ISO% -percentage 
stimulation by isoproterenol; INS%-percentage inhibition by insulin.
98 
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3.3.10 Regional differences in the relationship between 
adipose lipolytic function and plasma markers of 
inflammation 
3.3.10.1 C-reactive protein 
CRP is positively correlated with BMI (r=0.37, R2=13.6%, p=0.027) (Figure 44). 
There is no association between CRP and parity, smoking, DEPCAT and 
gestational age of sampling in this cohort. As previously described CRP is 
positively correlated with leptin.  
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Figure 44 Relationship between BMI and maternal CRP. 
BMI is positively correlated with log CRP (p=0.027) (n=36).  
In addition, maternal log CRP is related to VAT function but not SAT function. 
There is a positive correlation between log CRP and NEFA release in the 
presence of isoproterenol (r=0.35, R2=12.2%,p=0.05) ( Figure 45) and this 
association becomes more robust when adjusted for age, BMI and parity 
(p=0.024). In addition it is also positively associated with NEFA release in the 
presence of isoproterenol and insulin (r=0.45, R2=19.9%, p=0.010) and this 
remains robust after adjustment for age, parity and BMI (P=0.008)(Figure 46). 
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Figure 45 Relationship between maternal CRP and stimulated lipolysis in VAT. 
Maternal log CRP is positively associated with NEFA release in the presence of 
isoproterenol in VAT (p=0.024 adjusted for age, BMI and parity) (n=36). 
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Figure 46 Relationship between maternal CRP and lipolysis in presence of isoproterenol 
and insulin. 
Maternal log CRP is positively associated with NEFA release in the presence of 
isoproterenol and insulin in VAT (p=0.008 adjusted for age, BMI and parity) (n=36). 
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These correlations are also apparent between log CRP and glycerol release in 
presence of isoprtoerenol and isoproterenol and insulin in VAT (p=0.024 and 
p=0.005 respectively). 
3.3.10.2 TNF-alpha 
TNF alpha strongly correlates with SAT basal lipolysis when expressed as NEFA 
release mmol/l/ugDNA.(r=0.44, R2=18.9%, p=0.008) This is more robust when 
adjusted for age, BMI and parity (p<0.001).(Figure 47)  This relationship is also 
apparent when basal lipolysis is expressed as glycerol release/ug DNA (p=0.04). 
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Figure 47 Relationship between maternal TNF alpha and basal lipolysis in SAT. 
Maternal log TNF alpha is positively correlated with basal release of NEFA in SAT (r=0.44, 
p<0.001 adjusted for age, BMI and parity) (n=36). 
In addition, TNF alpha is also correlated with other measures of lipolytic 
function in SAT including percentage stimulation of NEFA release by 
isoproterenol (r=-0.35, p=0.036) and percentage suppression of NEFA release by 
insulin (r=0.4, p=0.015). Similarly an association is seen with percentage 
stimulation of glycerol release by isoproterenol (r=-0.33, p=0.05).  
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There are no associations between plasma TNF alpha and measures of lipolytic 
adipocyte function in VAT. 
In addition there is no relationships between maternal plasma TNF alpha and 
plasma markers of insulin resistance in this cohort.  
3.3.10.3 IL-6 
 
Maternal plasma IL-6 correlates with the birth weight centile of infants born to 
women with healthy pregnancies (r=0.37, R2=13.5%, p=0.03) which remains 
robust after adjustment for age, BMI and parity (p=0.01). 
Maternal IL-6 is positively correlated with maternal TNF alpha (r=0.45, R2=19.8%, 
p=0.006). 
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Figure 48 Relationship between maternal plasma IL-6 and TNF alpha. 
Maternal IL-6 is positively correlated with maternal log TNF alpha (r=0.45, p=0.006) (n=36). 
Maternal IL-6 is not correlated with any measures of lipolytic function.  
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3.3.11 Relationship of fat cell size with maternal and fetal 
characterstics 
Subcutaneous fat cells are larger than visceral fat cells (109.1[1.8] vs 85.6[2.4] 
um, p=0.000) (Figure 49) 
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Figure 49 Comparison of size of adipocytes in SAT and VAT. 
Subcutaneous fat cells are larger than visceral fat cells (mean 109.1 vs 85.6 um p=0.000) 
(n=36). Values displayed as mean and SEM. 
Visceral fat cell size is strongly correlated with maternal BMI (r=0.50, R2=24.8%, 
p=0.003) which remains robust after adjustment for age and parity (p=0.008) 
(Figure 50). This relationship is lacking in subcutaneous fat (p=0.085). There is 
no correlation of either VAT or SAT cell size and maternal BP, DEPCAT, gestation 
at delivery and birth-weight. Subcutaneous and visceral fat size are closely 
related (r=0.71, R2=50.6%, p<0.001) independent of BMI (p<0.001) (Figure 51). 
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Figure 50 Relationship of BMI with VAT cell size. 
Visceral fat cell size is positively correlated with BMI independent of age and parity (r=0.50, 
p=0.008) (n=36). 
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Figure 51 Relationship of VAT and SAT cell size. 
Subcutaneous and visceral fat cell size are positively correlated (r=0.71, p<0.001) (n=36). 
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There is no correlation between fat cell size in SAT and VAT and plasma 
measures of insulin resistance.  
3.3.12 Relationship of fat cell size with plasma inflammatory 
markers and adipokines 
Matenal plasma leptin is positively correlated with SAT (r=0.35, R2=12.2%, 
p=0.037) and VAT cell size (r=0.44, R2=19.6%, p=0.01), but this relationship is not 
independent of BMI (p=0.15 and p=0.11 respectively when adjusted for BMI). 
Similarly maternal plasma adiponectin is negatively correlated with VAT cell size 
r=-0.36, R2=12.9%, p=0.04), but this relationship is attenuated when adjusted for 
BMI (p=0.19). Maternal plasma IL-6 (1/1L-6) is also negatively correlated with 
SAT r=-0.4, R2=15.7%, p=0.017) and VAT cell size (r=-0.41, R2=17.0, p=0.017) but 
this relationship is not independent of BMI (p=0.054 and p=0.097 respectively). 
Maternal plasma log CRP is positively correlated with VAT cell size but not SAT 
(r=0.44, R2=19.4%, p=0.01). This is again attenuated when adjusted for BMI 
(p=0.07). There is no correlation between maternal TNF alpha and VAT or SAT 
cell size. 
 
3.3.13 Relationship of fat cell size with measures of adipocyte 
lipolytic function 
SAT cell size is negatively correlated with the FCISI of SAT (r=-0.41, R2=16.5%, 
p=0.014) independent of age, parity and BMI (p=0.031) (Figure 52). 
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Figure 52 Relationship between fat cell size and fat cell insulin sensitivity in SAT. 
Subcutaneous fat cell size is negatively correlated with SAT fat cell insulin sensitivity index 
(r=-0.41, p=0.031 adjusted for age, BMI and parity) (n=36). 
There is no relationship between SAT cell size and absolute levels of basal 
lipolysis, isoproterenol stimulated lipolysis and insulin suppressed lipolysis. VAT 
cell size is positively correlated with basal lipolysis in VAT(r=0.39, R2= 18.8, 
p=0.013)(Figure 53), lipolysis in the presence of isoproterenol (r=0.43, R2= 26.7, 
p=0.002), lipolysis in the presence of insulin (r=0.45, R2= 24.5, p=0.004) and 
lipolysis in the presence of isoproterenol and insulin( r=0.47, R2= 27.1%, p=0.002) 
(Figure 54). There is no relationship between VAT cell size and VAT FCISI. 
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Figure 53 Relationship between VAT cell size and basal lipolysis. 
Basal lipolysis when expressed as NEFA release in VAT is positively correlated with VAT 
cell size (p=0.013) (n=36). 
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Figure 54 Relationship between VAT cell size and lipolysis in presence of isoproterenol and 
insulin. 
VAT cell size is positively correlated with VAT lipolysis in presence of isoproterenol and 
insulin (p=0.002) (n=36). 
107 
 
Shahzya S Huda, 2010  Chapter 3 107 
3.4 Discussion 
This is the first detailed examination of adipocyte lipolytic function from 
primary adipocytes in normal human pregnancy for over 30 years.  
3.4.1 Metabolic Flexibility 
We have confirmed that isoproterenol, a synthetic catecholamine that 
stimulates both beta1 and beta2 adrenergic receptors (with no alpha receptor 
capabilities) stimulated lipolysis in both subcutaneous and visceral AT.  Insulin 
not only suppresses basal lipolysis in these two fat depots but also attenuates 
the effect of catecholamine stimulation. In our cohort the release of NEFA 
appears to be a more sensitive measure of adipocyte lipolysis than glycerol 
release, particularly when assessing insulin suppression of basal lipolysis. This is 
possibly secondary to differential effects of insulin on HSL and ATGL, with HSL 
being of greater importance in stimulated lipolysis and ATGL having greater 
emphasis in basal lipolysis8. In addition glycerol is the end product of lipolysis 
after three separate consecutive steps, whereas NEFA is released after each 
consecutive step (Figure 1). Our data suggests that the lower the basal lipolysis 
of the adipocyte in SAT the increased susceptibility to stimulation by 
catecholamines and reduced sensitivity to suppression by insulin. This suggests 
an inherent metabolic flexibility of the tissue ie those with low basal lipolysis 
are more readily stimulated by catecholamines and respond more effectively to 
‘stressful’ stimuli and correspondingly as basal rates of lipolysis are already low 
they are less readily suppressed further by insulin. This would be metabolically 
advantageous in pregnancy in the third trimester to facilitate energy supply to 
the fetus. A similar effect is seen in VAT in that the adipocytes are more 
responsive to catecholamine stimulation if basal lipolysis is low, and there is an 
inverse relationship between the sensitivity of VAT to stimulation by 
catecholamines and inhibition by insulin.   
3.4.2 Insulin and catecholamine sensitivity 
We have found some important regional differences in adipocyte function in 
pregnancy. It appears that VAT and SAT function independently of each other. In 
our cohort, VAT is more sensitive to stimulation with isoproterenol than SAT. We 
have also demonstrated that VAT is less insulin sensitive than SAT. This is similar 
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to that seen in the non-pregnant and forms the basis of the portal paradigm. 
Visceral fat is more sensitive to the lipolytic action of catecholamines and less 
responsive to the anti-lipolytic effects of insulin thereby leading to increased 
NEFA release. Visceral fat is drained by the portal vein and increased NEFA have 
direct effects on hepatic function including hyperinsulinaemia, hyperglycaemia 
and dyslipidaemia.  The FCISI in VAT (our measure for insulin sensitivity of the 
fat depot) is also related to maternal plasma markers of insulin resistance with 
an inverse relationship with plasma glucose and HOMA. Interestingly the 
converse was true for SAT. This suggests that visceral fat insulin sensitivity may 
be a better marker for maternal metabolic parameters than subcutaneous fat. 
This is supported by a study by Bartha et al which demonstrated that measures 
of visceral fat thickness by ultrasound correlated better with diastolic BP, 
glycaemia, insulinaemia, HOMA, triglycerides and HDL cholesterol than BMI as 
measure in early pregnancy.52 Similarly we have also demonstrated that visceral 
fat insulin sensitivity is inversely correlated with maternal plasma triglycerides. 
NEFA supply to the liver is a major determinant of VLDL TG production196, 
therefore if VAT is insulin resistant, this would result in increased delivery of 
NEFA from this depot thereby contributing to hyper-triglyceridamia. Indeed, 
splanchnic fat (a combination of VAT and liver fat) contributes to a greater 
degree to VLDL TG in insulin resistant men and women in the post-prandial 
state.197  
3.4.3 Lipid metabolism in late pregnancy 
Circulating NEFA arises from lipolysis in adipose tissue and therefore maternal 
plasma levels of NEFA provides a relatively crude measure of whole body 
lipolysis. During the latter stages of pregnancy there is a marked increase in 
lipolysis rates and a corresponding rise in maternal free fatty acids (FFA) and 
glycerol.27 28 This change is enhanced by an increase in hormone-sensitive lipase 
(HSL) activity and mRNA expression and a decrease in lipoprotein lipase (LPL) 
activity.29 Reduced expression of PPARγ and its target genes may also contribute 
to accelerated fat metabolism in late pregnancy.32 Exaggerated catecholamine 
release in response to even modest maternal hypoglycaemia and the insulin 
resistant state of late pregnancy contribute to this switch.30 31 Insulin effects on 
lipolysis (adipose tissue) and fat oxidation (in liver and muscle) are significantly 
impaired during the 3rd trimester compared to earlier in pregnancy and also post 
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partum.31 In keeping with this, in our cohort lipolysis rates appear to increase as 
pregnancy advances which is reflected by the positive correlation seen between 
gestational age and maternal NEFA. Interestingly we also found a strong negative 
correlation with fasting levels of maternal NEFA and maternal levels of insulin, 
HOMA and glucose. This suggests that even in the late 3rd trimester of women 
with healthy pregnancies, AT is still sensitive to the anti-lipolytic effects of 
insulin in the fasting state. Similarly Frayn et al have shown that NEFA release 
from subcutaneous abdominal AT in IR men is still suppressed by high insulin 
concentrations in the fasting state.198  
3.4.4 Adipokines, lipid metabolism and normal pregnancy 
Adipokines including adiponectin, leptin, TNF alpha and IL-6 are increasingly 
implicated as important mediators of maternal metabolism particularly in 
relation to insulin resistance (IR) and lipid metabolism as detailed previously. In 
our cohort we have found no correlation between adiponectin and any measure 
of lipolytic function in either SAT or VAT in late pregnancy nor maternal NEFA 
and lipids. Furthermore our data are suggestive of a negative association of 
adiponectin with BMI (p=0.07). Similarly Catalano et al also showed no 
relationship with measures of lipid metabolism including maternal plasma NEFA 
under conditions of hyperinsulinaemia and the rate of lipid oxidation in basal 
and insulin-stimulated conditions. Despite in-vitro data of adiponectin 
influencing lipid oxidation, its action is impaired in obese subjects.199 200 This 
disparity could be related to the action of other pro-inflammatory adipokines 
such as IL-6 or TNF alpha, which are increased in normal pregnancy. We also 
found no relationship between maternal markers of glucose metabolism and 
adiponectin. Adiponectin as previously detailed has insulin –sensitizing 
properties and levels are lower in insulin resistant states including type II DM and 
obesity. Its role in pregnancy however is still to be defined. Several studies have 
already suggested lack of correlation between adiponectin levels and markers of 
insulin resistance, particularly in complications of pregnancy including PE and 
IUGR.133 201 202  In our study adiponectin is positively associated with 
progesterone, a pregnancy specific hormone, suggesting a possible pregnancy 
specific function for this adipokine. It is hypothesised that adiponectin may act 
in a compensatory fashion in an effort to counteract the effect of inflammation 
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and insulin resistance particularly when these conditions are exaggerated such as 
complicated human pregnancy. 
As expected, there was a strong positive correlation between leptin and BMI in 
this cohort of normal pregnant women, consistent with increasing body fat mass. 
Interestingly maternal serum levels of leptin correlated with measures of VAT 
lipolytic function in normal pregnancy and not SAT. This suggests that in 
pregnancy, leptin may exert its liporegulatory effects more predominantly in 
VAT compared to SAT which may be due either to increased expression and 
secretion from this adipose depot or increased sensitivity to its effects. This may 
also be relevant in complicated human pregnancy - expression of leptin was 
upregulated in VAT but not in SAT in women with GDM. 203 Similarly despite 
hyperleptinaemia in pregnancies complicated by PE, there was no increased 
mRNA expression of leptin in SAT, suggesting either placenta or VAT as the 
source of excess leptin134. As yet no studies have examined expression of leptin 
in visceral fat of normal or complicated human pregnancy. Leptin appears to be 
a significant correlate for markers of insulin resistance in pregnancy including 
maternal insulin and maternal HOMA. Our data are consistent with previous 
studies that demonstrated correlation between measure of insulin sensitivity in 
pregnancy and leptin. 129 204Although this relationship is apparent, it is still 
unclear whether leptin directly influences insulin resistance in pregnancy.  
In our cohort, CRP is associated with increasing BMI.  As in the non –pregnant, we 
have shown that CRP is independently associated with leptin and negatively 
correlated with adiponectin (although not independent of BMI), which 
underscores the potential role of interactions between adipokines.205 Our data 
suggests that CRP is more closely related to visceral adiposity (and in particular 
lipolytic function), a feature already demonstrated in both healthy and IR states 
in the non-pregnant.206-208 The direct anatomical relationship of VAT and the 
liver, the major source of CRP, may underlie this apparent association.  
Our data again highlights regional differences in AT functionality in normal 
pregnancy. TNF alpha is strongly correlated with basal lipolysis in SAT and other 
measures of lipolytic function in this fat depot such as percentage stimulation of 
lipolysis by catecholamines and percentage suppression by insulin. There are no 
apparent correlations with measures of VAT lipolytic function. Regional 
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differences in TNF alpha and its effects on lipolysis have not been well 
characterized in the non-pregnant, although our data suggest a more dominant 
role for TNF alpha in SAT lipid metabolism in late pregnancy. Kirwan et al found 
that TNF –alpha was correlated with insulin sensitivity in late pregnancy and was 
the most important predictor of insulin sensitivity when compared to the 
reproductive hormones, leptin and cortisol. In contrast we found no correlation 
between TNF alpha and plasma markers of insulin resistance including glucose, 
insulin and HOMA.  
We have shown that IL-6 is positively correlated with the birth weight centile of 
women with normal healthy pregnancies. IL-6 has been implicated in fetal 
growth although the studies examining this relationship are few and 
contradictory.209 210 Recently Catalano et al have shown that IL-6 is higher in 
both maternal and cord blood of women who are obese compared to lean, with 
obese women having bigger babies.211 Increased Il-6 may reflect increased 
insulin resistance rather than increasing fat mass per se with a corresponding 
increase in fetal insulin and size. 
3.4.5  Adipocyte cell size 
Fat cell size and relation to adipocyte function in pregnancy also demonstrates 
important variations according to AT location. We have demonstrated that 
booking BMI does not seem to be an important determinant of adipocyte lipolytic 
function unlike fat cell size. As in the non-pregnant woman, visceral adipocytes 
are smaller than subcutaneous adipocytes, and more closely related to BMI than 
subcutaneous fat. This may in part be explained by the finding in non-pregnant: 
women with higher subcutaneous fat mass exhibit both adipocyte hypertrophy 
and hyperplasia, whereas increased omental fat was primarily due to 
hypertrophy.114 Visceral fat cell size appear to be more closely related to direct 
measures of lipolytic function including basal lipolysis and absolute levels of 
stimulated, suppressed and insulin attenuated stimulated lipolysis, than 
subcutaneous fat cell size. In contrast subcutaneous fat cell size is related to the 
FCISI of the tissue with larger fat cells being less insulin sensitive than their 
smaller counterparts. This is consistent to previous studies which have shown 
that enlarged subcutaneous adipocytes independently predict insulin sensitivity 
and type 2 DM.212 213 Our data demonstrate correlations between adipokines and 
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fat cell size in both visceral and subcutaneous fat although not independent of 
BMI. Increasing cell size is predominantly correlated with the pro-inflammatory 
adipokines of leptin, and CRP but negatively correlated with the anti-
inflammatory adiponectin. This may be one mechanism through which obesity 
leads to increased inflammation and IR in pregnancy resulting in adverse 
metabolic complications. 
3.4.6 Summary 
My findings are summarised by the following diagrams:  
Error! Objects cannot be created from editing field codes. 
Figure 55 Visceral fat function in normal pregnancy 
As BMI increases in normal pregnancy so does visceral fat cell size, with resultant increase 
in maternal leptin, CRP, IL-6 and lower adiponectin levels. Leptin and CRP correlate with 
lipolytic function in visceral fat. The insulin sensitivity of visceral fat lipolysis is related to 
measures of maternal insulin resistance including HOMA, glucose and triglycerides.  
 
 
 
In subcutaneous fat there is no relationship with maternal BMI and fat cell size, although 
cell size does correlate with the insulin sensitivity of the fat depot. Maternal TNF alpha is 
closely related to lipolytic function in SAT in normal pregnancy. However lipolysis in SAT 
does not appear to influence maternal markers of insulin resistance and glucose 
metabolism.  
    
4 A Comparison of Adipocyte Lipolytic Function 
between Normal and Pre-eclamptic Pregnancies 
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4.1 Introduction 
Pre-eclampsia (PE) occurs in 2-4% of pregnancies and is a leading cause of 
maternal and neonatal morbidity and mortality in the developed world. It is a 
multi-system disorder resulting in the classic manifestations of hypertension due 
to vasoconstriction, proteinuria due to glomerular damage and oedema due to 
increased vascular permeability.84 As yet the underlying pathogenesis of the 
disorder had not been completely understood. The clinical signs of PE are 
relatively simple manifestations of a complex underlying pathological process 
with activation of the coagulation system, platelets and leukocytes and 
disturbances in metabolism which combine to provoke widespread endothelial 
damage and dysfunction. This in turn augments further activation of leukocytes 
and coagulation resulting in a vicious cycle of vascular injury. The disorder is 
likely to be a result of heterogeneous causes resulting from the interaction of 
placental and maternal factors.85 In the presence of a placental trigger the 
maternal response will depend on the maternal genotype and phenotype 
resulting in the clinical syndrome of PE.86 There are several reasons, as discussed 
in Chapter 1, why disordered lipid and adipocyte metabolism could contribute to 
the pathogenesis of this condition and include lipid accumulation at sites of 
endothelial damage, exaggerated dyslipidaemia and an early rise in FFA 
independent of maternal adiposity suggesting early exaggerated adipocyte 
lipolysis. There is preliminary evidence that the trigger for this increase in FFA 
and adipocyte lipolysis is present in serum of women with PE.107 These 
hypotheses are summarised in  Figure 56.  
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Figure 56 A summary of the potential role of a disturbance in lipid metabolism in the 
pathogenesis of pre-eclampsia.   
A factor(s) released from the placenta enhances peripheral lipolysis which is already 
stimulated in normal pregnancy by HPL.  This results in an increased flux of free fatty acids 
to the liver.  These are channelled predominantly into hepatic triglyceride synthesis so there 
is increased secretion (over and above normal pregnancy) of triglyceride-rich lipoproteins 
(VLDL1).  Accumulation of triglyceride occurs in the hepatocyte when this pathway is 
saturated.  Increased concentrations of VLDL1 in the circulation drives the production of an 
atherogenic lipoprotein profile by stimulating excessive synthesis of small, dense LDL 
(LDL-III) and by lowering HDL-cholesterol.  This lipid profile may contribute to endothelial 
dysfunction and therefore the expression of pre-eclampsia in the mother.  Finally, this 
pathway plays a part in the formation of lipid-laden macrophages (foam cells) in the spiral 
arteries of the decidua basalis, and as a result, may be involved in the enhanced placental 
production of pro-inflammatory mediators in PE. 
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4.2 Aims and Objectives 
4.2.1 Hypotheses 
1. That adipocyte release of fatty acids is exaggerated under either basal or 
stimulated conditions in women with PE, thereby implicating adipocyte 
function in its pathophysiology. 
2. That plasma from women with PE excessively stimulates adipocytes from 
healthy women as compared to plasma taken from healthy controls 
thereby suggesting the presence of an excessive lipolytic factor in PE 
plasma. 
4.2.2 Specific Research Questions 
1. Are there differences in basal or isoproterenol-stimulated lipolysis 
between adipocytes derived from women with pregnancies complicated 
by PE compared to healthy pregnant women matched for age, smoking 
and booking BMI?  
2. Is insulin-suppression of isoproterenol-stimulated lipolysis impaired in PE, 
and does the pattern of defects in PE reflect that in other insulin resistant 
conditions? 
3. Does plasma from women with PE stimulate adipocyte lipolysis excessively 
in comparison to plasma from healthy pregnant women matched for age, 
BMI, and smoking? 
4. Is the adipocyte defect dependent predominantly in one functional tissue 
depot - i.e. visceral vs subcutaneous? 
4.3 Results 
Fourteen cases each with two matched controls for age, BMI and smoking were 
recruited as described in methods 2.1. Processing of tissue and lipolysis assays 
were carried as detailed in methods sections 2.2 -2.7. Maternal biochemical 
markers were determined as detailed in methods section 2.12. 
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4.3.1 Subjects 
The characteristics of the subjects are described in Table 8. 
Characteristics Controls (n=28) PE (n=14) P value 
Age, y 30.8(5.1) 31.5(6.3) 0.72 
BMI, kg/m2 29.6(5.25) 31.1(8.0) 0.53 
Smokers (non,current)** 26,2 11,2 0.41 
DEPCAT* 5(4-6) 6(4-7) 0.14 
Gestation at delivery, days      272.5(9.1) 249.4(21.5) 0.002 
Parity (0,≥1)** 6,22 8,6 0.02 
Systolic pressure, mmHg 115.3(14.4) 127.1(13.1) 0.013 
Diastolic pressure, mmHg 69.6(8.6) 79.1(9.0) 0.003 
Birthweight, g 3525(533) 2330(926) 0.001 
Birthweight centile 60.3(28.1) 26.0(31.2) 0.003 
Table 8 Characteristics of cases and controls.  
Blood pressure refers to booking values. All values expressed as mean and standard 
deviation (*median and interquartile range). Comparisons made by paired t test except * 
Mann-whitney, and ** chi-squared test.  
 
Subjects were matched for age, BMI and smoking. Due to the most common 
indication for elective caesarean section being previous caesarean section it was 
difficult to obtain sufficient primiparous women in the control group to match 
for parity.  Women with PE had significantly higher systolic and diastolic BP at 
booking. They were more likely to deliver earlier than the control group and had 
babies with lower birthweight and birthweight centile (adjusting for gestational 
age).  
4.3.2 Maternal Lipids and Plasma Markers of Insulin Resistance 
Maternal triglycerides were significantly elevated in PE compared to controls. 
There was no difference in total cholesterol or HDL between the two groups. 
Maternal NEFA were also significantly elevated in PE compared to controls. 
Although maternal glucose, insulin and HOMA were all higher in PE compared to 
controls, these differences did not reach significance. These results are 
summarised in Table 9. 
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Plasma Markers Controls (n=28) PE (n=14) P value 
Total Cholesterol (mmol/L) 6.24 (0.97) 6.53 (1.48) 0.53 
Triglycerides (mmol/L)* 2.6 0.58) 3.9 (2.3) 0.02 
HDL (mmol/L) 1.86 (0.36) 1.7 (0.41) 0.24 
NEFA (mmol/L)* 0.4 (0.18) 0.55 (0.24) 0.02 
Glucose (mmol/L) 4.7 (0.41) 5.3 (1.2) 0.09 
Insulin (mU/L)* 10.9 (7.2) 16.6 (12.3) 0.20 
HOMA* 2.38 (1.8) 4.2 (0.98) 0.14 
Table 9 Comparison of maternal lipids and plasma markers of insulin rsistance. 
All values expressed as mean and standard deviation. Statistical analysis by paired t-test. 
*Data transformed to normal distribution but expressed as non-transformed values.  
 
4.3.3 Differences in Lipolysis 
4.3.3.1 Subcutaneous Adipose Tissue 
There is no difference in basal SAT lipolysis between control and PE when 
expressed either as release of NEFA (0.56[0.25] vs 0.68[0.29] sqrt NEFA 
mmol/L/ugDNA, p=0.23) (Figure 57) or glycerol release (9.88[4.25] vs 12.1[6.1] 
sqrt glycerol umol/L/ugDNA, p=0.24). 
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Figure 57 Basal Lipolysis in SAT between controls and PE. 
There is no significant difference in basal lipolysis when expressed as NEFA release 
between controls and PE (p=0.226) (PE:n=14, controls:n=28). NEFA SBA = SAT basal 
release of NEFA. Comparisons made using student t-test and results displayed as mean and 
SEM. 
 
There is no difference in rates of lipolysis in the presence of isoproterenol in SAT 
when expressed as either release of NEFA (0.77[0.42] vs 1.0[0.72] 
mmol/L/ugDNA, p=0.27) (Figure 58) or release of glycerol(267[108] vs 344[214] 
umol/L/ugDNA, p=0.22). Similarly there is no difference in rates of lipolysis 
between controls and PE in the presence of insulin or insulin and isoproterenol 
when expressed as either release of NEFA or release of glycerol. (Figure 59) 
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Figure 58 Lipolysis in presence of isoproterenol in controls and PE. 
There is no significant difference in NEFA release in the presence of isoproterenol  between 
controls and PE (p=0.27) (PE:n=14, controls:n=28).  Comparisons using student t-test and 
results displayed as mean and SEM. NEFA SISO = SAT in the presence of isoproterenol. 
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Figure 59 Lipolysis in presence of insulin in controls and PE. 
There is no significant difference in NEFA release between controls and PE in the presence 
of insulin (p=0.133) or in the presence of insulin and isoproterenol (p=0.14) (PE:n=14, 
controls:n=28). Comparisons using student t-test and results displayed as mean and SEM. 
SINS= SAT in presence of insulin; SINS+SIO=SAT in the presence of insulin and 
isoproterenol.  
 
There is no difference in percentage stimulation by isoproterenol in SAT 
between controls and PE (168[132] vs 130[142] %, p=0.42)(Figure 60) when 
related to lipolysis expressed as NEFA release. The same holds true for lipolysis 
expressed as glycereol release (252[217]% vs 235[313]%,p=0.85). 
122 
 
Shahzya S Huda, 2010  Chapter 4 122 
0
20
40
60
80
100
120
140
160
180
200
CONTROL PE
Pe
rc
en
ta
ge
 
St
im
u
la
tio
n
 
by
 
Is
o
pr
o
te
re
n
o
l (%
)
 
Figure 60 Percentage stimulation by isoproterenol in controls and PE. 
There is no difference in percentage stimulation by isoproterenol between controls and PE 
(p=0.42) (PE:n=14, controls:n=28). Comparisons using student t-test and results displayed 
as mean and SEM. 
 
 
There is no difference in percentage suppression by insulin of lipolysis between 
controls and PE (28[25.9] vs 22.8[29.6]%, p=0.59)(Figure 61) when expressed as 
NEFA release. The same holds true for glycerol release (-15.5[56.4] vs -36[107]%, 
p=0.51) 
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Figure 61 Percentage suppression of lipolysis by insulin in controls and PE. 
There is no difference in percentage suppression of lipolysis by insulin between controls 
and PE when expressed as NEFA release (p=0.59) (PE:n=14, controls:n=28). Comparisons 
using student t-test and results displayed as mean and SEM. 
 
 
4.3.3.2 Visceral Fat 
In VAT there is no difference in basal lipolysis between controls and PE when 
expressed as release of NEFA (-0.8[0.41] vs -0.77[0.35] log NEFA mmol/L/ugDNA, 
p=0.81) (Figure 62) or glycerol (7.9[3.6] vs 9.54[3.6] sqrt glycerol 
umol/L/ugDNA, p=0.18).  
There is no difference in lipolysis in presence of isoproterenol between controls 
and PE when expressed as release of NEFA (-0.3[0.34] vs -0.47[0.35] log NEFA 
mmol/L/ugDNA, p=0.16) or glycerol (13.6[3.7] vs 13.2[4.2] sqrt glycerol 
umol/L/ugDNA, p=0.8). Similarly there is no difference in lipolysis in presence of 
insulin (-0.87[0.4] vs -0.84[0.33] log NEFA mmol/L/ugDNA, p=0.8) or insulin and 
isoproterenol (-0.4[0.38] vs -0.48[0.33] log NEFA umol/L/ugDNA, p=0.46) 
between controls and PE when expressed as NEFA release (Figure 63). This is 
also the case when expressed as glycerol release (1.74[0.37] vs 1.9[0.34] log 
glycerol umol/L/ugDNA, p=0.11 and 2.17[0.29] vs 2.3[0.24] log glycerol 
umol/L/ugDNA, p=0.3 respectively). 
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Figure 62 Basal lipolysis in visceral fat in controls and PE 
There is no difference in basal lipolysis when expressed as release of NEFA between 
controls and PE in VAT (p=0.81) (PE:n=14, controls:n=28). Values displayed as mean and 
SEM of non-transformed data. Comparison made on log transformed values by student t-
test. 
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Figure 63 Lipolysis in visceral fat in controls and PE in the presence of isoproterenol, 
insulin and isoproterenol and insulin. 
There is no difference in lipolysis between controls and PE in the presence of isoproterenol 
(p=0.16), insulin (p=0.8) or isoproterenol and insulin (p=0.46), when expressed as release of 
NEFA (PE:n=14, controls:n=28). Values displayed as mean and SEM on non-transformed 
data, but comparisons made by transformed data using student t-test. VISO= VAT in 
presence of isoproterenol, VINS= VAT in presence of insulin, VISO+INS= VAT in presence of 
isoproterenol and insulin.  
 
There is no statistical difference in percentage stimulation by isoproterenol 
between controls and PE when expressed as NEFA release (265[176] vs 
152[177]%, p=0.06) or glycerol release (385[498] vs 369[1087]%, p=0.96).  
Furthermore there is no statistical difference in percentage inhibition by insulin 
between controls and PE when expressed as NEFA release (4.5[44.1] vs 
11.6[20.5]%, p=0.48) or glycerol release (-44[179] vs -25.9[89.7]%, p=0.67) 
4.3.4 Fat Cell Insulin Sensitivity Index 
A direct measure of insulin sensitivity of the fat cell was calculated from the 
percentage inhibition of catecholamine stimulated lipolysis by insulin measured 
from the release of NEFA. This was derived from the following calculation 
(Figure 27): 
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Figure 64  The fat cell insulin sensitivity index 
Fat cell insulin sensitivity index is calculated from the percentage inhibition of 
catecholamine stimulated lipolysis by insulin ie (SISO-SISO+INS)/(SISO-SBA)*100. SBA= 
SAT basal lipolysis, SISO= SAT in presence of isoproterenol, SISO +INS=SAT in presence of 
isoproterenol and insulin.   
 
This was called the fat cell insulin sensitivity index (FCISI). 
Using this index we found that SAT in controls was more insulin sensitive than in 
PE (65.7[18] vs 15.8[13], p=0.032) (Figure 65). 
Furthermore, VAT also appears to be more insulin sensitive in controls compared 
to PE although this did not quite reach significance ( 35.2[14] vs -3.0[14], 
p=0.06)(Figure 66) 
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Figure 65 The fat cell insulin sensitivity index of SAT in controls and PE. 
The FCISI of SAT is greater in controls than in PE, p=0.032 (PE:n=14, controls:n=28). 
Comparisons using student t-test and results displayed as mean and SEM. 
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Figure 66 The fat cell insulin sensitivity index of VAT in controls and PE. 
The FCISI (fat cell insulin sensitivity index) of VAT appears greater in controls than in PE 
(p=0.06) (PE:n=14, controls:n=28). Comparisons using student t-test and results displayed 
as mean and SEM. 
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4.3.5 Regional differences in adipocyte cell size and adipocyte 
function between controls and PE. 
4.3.5.1 Relationship of adipose fat cell size and BMI 
SAT cell size is closely correlated with BMI in PE (r=0.69, R2=47.1%, 
p=0.007)(Figure 67) as is VAT cell size (r=0.83, R2=69.5%, p<0.0001)(Figure 68). 
This is in contrast to that seen in the normal population as described in Chapter 
3 where only VAT cell size correlates with BMI. Indeed when we looked at the 28 
matched controls (a sub population of the “normal population”) the same lack of 
association between SAT cell size and BMI is seen (p=0.82)(Figure 69), but is 
present in VAT (r=0.39, R2=15.2%, p=0.04). 
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Figure 67 The relationship between maternal BMI and SAT cell size in PE. 
There is a positive correlation between maternal BMI and SAT cell size in PE (p=0.007) 
(n=14). 
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Figure 68 The relationship between maternal BMI and VAT cell size in PE. 
There is a positive correlation between maternal BMI and VAT cell size in PE (p<0.0001) 
(n=14). 
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Figure 69 The relationship between BMI and SAT cell size in controls. 
There is no correlation between maternal BMI and SAT cell size in controls (p=0.82) (n=28). 
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4.3.5.2 Relationship of adipocyte cell size and lipolytic function 
Also interestingly we have demonstrated that SAT cell size is closely correlated 
with SAT lipolytic function in PE including basal lipolysis(r=0.67, 
R2=45.1%,p=0.009)(Figure 70), lipolysis in presence of isoproterenol (r=0.6, 
R2=35.8%,p=0.024) and in presence of isoproterenol and insulin (r=0.66, 
R2=43.3%, p=0.01) which becomes more robust after adjustment for BMI and 
parity( p=0.007, p=0.004 and p=0.004 respectively). Conversely these 
associations are lacking in normal controls. However VAT cell size in controls 
strongly correlates with VAT cell function including basal lipolysis 
(r=0.67,R2=45.5%, p=0.001 adjusted for BMI and parity)(Figure 71), lipolysis in 
presence of isoproterenol (r=0.56, R2=31.1%,p=0.015 adjusted for BMI and 
parity), lipolysis in presence of insulin( r=0.64, R2=41.2%,p=0.003 adjusted for 
BMI and parity), and lipolysis in presence of isoproterenol and insulin (r=0.54, 
R2=28.6%, p=0.036 adjusted for BMI and parity) suggesting that in normal 
pregnancy VAT cell size is an important determinant of visceral fat cell function.  
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Figure 70 Relationship between SAT cell size and basal lipolysis. 
SAT cell size is positively correlated with SAT basal lipolysis in PE (p=0.009) (n=14).  NEFA 
SBA= SAT basal release of NEFA 
131 
 
Shahzya S Huda, 2010  Chapter 4 131 
 
 
 
12011010090807060
0.0
-0.2
-0.4
-0.6
-0.8
-1.0
-1.2
-1.4
-1.6
Cell size VAT (um)
lo
g
 N
E
FA
 V
B
A
 (
m
m
o
l/
L
/
u
g
D
N
A
)
r=0.67
 
Figure 71 Relationship between VAT cell size and basal lipolysis 
VAT cell size is positively correlated with VAT basal lipolysis in controls (p=0.015) (n=28). 
NEFA VBA = VAT basal release of NEFA. 
4.4 The Effect of Maternal Serum on Adipocyte Lipolysis: 
Pre-eclamptic vs Controls. 
I wanted to determine whether serum from women with PE stimulates adipocyte 
lipolysis excessively in comparison to serum from healthy pregnant women 
matched for smoking, BMI, age.  
4.4.1 Methods 
Healthy women from singleton pregnancies undergoing elective caesarean 
section at term were recruited as outlined in methods section 2.1. Lipolysis 
experiments were carried out as outlined in methods section 2.3 and 2.4. Only 
subcutaneous fat biopsies were obtained. As SAT from the same subject was 
used for all conditions in each experiment correction for fat cell number was not 
required.  
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All assays were carried out in duplicate. The reagents were prepared as outlined 
in methods section 1.5.  All reagents were added to the relevant tubes and the 
timing of the assay was commenced. The tubes were placed in a 37°C shaking 
water bath at 91 cycles per minute and incubated for 120 minutes. Control and 
pre-eclamptic serum was obtained from previously stored serum samples frozen 
at -80°C and defrosted at room temperature. An aliquot from tubes containing 
either control or PE serum was taken at time=0 to correct for NEFA and glycerol 
already present in the serum. Comparisons between the groups was perfomed 
using the paired t-test.  
 
4.4.2 The effect of control serum on lipolysis in adipose tissue 
explants. 
I attempted to determine whether maternal serum per se has any effect on rates 
of lipolysis in SAT in vitro. The condition of each tube used in this experiment is 
outlined in Table 10 Conditions of assay The number of subjects in this 
experiment was n=4.  
Condition Control 
900ul Buffer 
100ul adipocyte cells 
Serum 
800ul Buffer 
100ul adipocyte cells 
100ul control serum 
Basal No reagent No reagent 
Isoproterenol 
200nM 
Isoproterenol  Isoproterenol  
Insulin  
10nM 
Insulin Insulin 
Table 10 Conditions of assay 
4.4.2.1 Results 
There was no difference in basal lipolysis rates when expressed as NEFA release 
(1.12[0.02] vs 1.1[0.01] mmol/L, p=0.39) or glycerol release (20.6[10.7] vs 
27.3[17.3] µmol/L, p=0.39) in the presence of or absence of control serum. 
(Figure 72 and Figure 73)  Similarly, there was no difference between lipolysis 
rates in the presence of insulin when expressed as NEFA release (0.1[0.0] vs 
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0.09[0.02] mmol/L, p=0.61) or glycerol release (23.4[8.1] vs 29.6[19.6] µmol/L, 
p=0.64). However lipolysis rates in the presence of isoproterenol were increased 
in the control serum group when expressed as NEFA release (0.32[0.12] vs 
0.56[0.14] mmol/L, p=0.004)(Figure 74) or glycerol release (81.8[41] vs 
156[51.5] µmol/L, p=0.04). This was also true of percentage stimulation of 
lipolysis by isoproterenol when calculated from NEFA release (157%[97.9]vs 
379%[96.6], p=0.002) and glycerol release (375%[291] vs 809%[269], 
p=0.08)(Figure 75).  
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Figure 72 The effect of control serum on basal lipolysis and in the presence of insulin 
(NEFA). 
There was no difference in basal lipolysis (p=0.39) or insulin suppressed lipolysis (p=0.61) 
with the addition of maternal serum when expressed as NEFA release (n=4). 
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Figure 73 The effect of control serum on basal lipolysis and in the presence of insulin 
(glycerol). 
There was no difference in basal lipolysis (p=0.39) or insulin suppressed lipolysis (p=0.64) 
with the addition of maternal serum when expressed as glycerol release, n=4. 
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Figure 74 The effect of control serum on lipolysis in the presence of isoproterenol. 
Lipoloysis was increased in SAT exposed to isoproterenol and maternal serum compared to 
isoproterenol alone (p=0.004) (n=4). **p=≤0.01 
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Figure 75  The effect of control serum on the percentage stimulation of lipolysis 
The percentage stimulation of lipolysis was increased in SAT exposed to maternal serum in 
addition to isoproterenol when calculated from NEFA release (p=0.002) (n=4). **p=≤0.01. 
 
4.4.3 Does PE serum excessively stimulate lipolysis in AT 
compared to serum from healthy controls 
A preliminary experiment was performed to determine whether the effect of PE 
serum on lipolysis rates in SAT explants was different to that of serum from 
control women. The conditions of each tube are outlined in Table 11. All tubes 
contained 800ul warm wash buffer and 100ul adipocyte cells, giving a 
concentration of 10% volume/volume of maternal serum. All conditions were 
carried out in duplicate. Only NEFA concentration at time=120 minutes was 
determined. The number of subjects in this experiment was n=6. 
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Conditions Control 
800ul Buffer 
100ul adipocyte cells 
PE 
800ul Buffer 
100ul adipocyte cells 
Basal 100ul control serum 100ul PE serum 
Isoproterenol  100ul control serum 
+ isoproterenol 200nM 
100ul PE serum+ 
Isoproterenol 200nM 
Table 11 Conditions of each assay. 
 
4.4.3.1 Results 
There was no difference between the release of NEFA from adipocytes exposed 
to control serum compared to PE serum with a concentration odf 10% 
volume/volume (0.17[0.04] vs 0.14[0.04] mmol/L, p=0.44) with . There was no 
difference between isoproterenol stimulated NEFA release in adipocytes exposed 
to control serum compared to PE serum (0.66[0.05] vs 0.6[0.05] mmol/L, p=0.3). 
Furthermore there was no difference in percentage stimulation of NEFA release 
by isoproterenol in the two groups (383%[156] vs 390%[94], p=0.97) 
4.4.4 A comparison of pooled PE serum and pooled control 
serum on adipocyte lipolysis. 
Aliquots (500ul) of serum from 20 PE and 20 controls matched for BMI were 
thawed and pooled. This pooled serum was aliquoted (500ul) and refrozen at -
80ºC. The experiment was carried out as outlined in the methods above. The 
conditions of each tube is outlined in Table 12. The number of subjects in this 
experiment is n=4. 
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Condition (% volume/volume) Serum Wash Buffer Adipocytes 
Basal Nil 900ul 100ul 
10% 100ul control  800ul 100ul 
20% 200ul control 700ul 100ul 
30% 300ul control 600ul 100ul 
10% + isoproterenol (200nM) 100ul control 800ul 100ul 
10% 100ul PE 800ul 100ul 
20% 200ul PE 700ul 100ul 
30% 300ul PE 600ul 100ul 
10% + isoproterenol (200nM) 100ul PE 800ul 100ul 
Table 12 The condition of each assay.  
The total volume in each falcon tube was 1 ml. All conditions were carried out in duplicate 
 
 
4.4.4.1 Results  
There was no statistical difference in release of NEFA from adipocytes incubated 
in increasing concentrations of control and PE serum (10% volume/volume 
0.14[0.06] vs 0.06[0.09]mmol/L, p=0.3; 20% volume/volume 0.11[0.1] vs 
0.1[0.09]mmol/L, p=0.85; 30% volume/volume dilution 0.2[0.09] vs 0.015[0.05] 
mmol/L p=0.16 control vs PE), when these concentrations are used.(Figure 76)  
In addition there was no dose response effect in the ranges of concentrations 
used for either control serum(10% volume/volume vs 30% volume/volume, 
p=0.24) or PE serum (10% volume/volume vs 30% volume/volume, p=0.38) 
(Figure 76). Furthermore no difference was seen in lipolysis rates after 
stimulation with isoproterenol in the presence of serum (0.5[0.13] vs. 0.39[0.13] 
mmol/L, p=0.46) nor percentage stimulation (968[302] vs 1268[713]%, p=0.54). 
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Figure 76 Effect on increasing concentrations of control and PE serum on basal lipolysis. 
There is no difference in lipolysis rates of adipocytes exposed to control or PE serum in 
increasing concentrations (10%, 20%, 30% volume/volume, p=0.3, p=0.85 and p= 0.16 
respectively).Comparisons made using paired t-test and results displayed as mean and 
SEM.  
 
 
 
 
139 
 
Shahzya S Huda, 2010  Chapter 4 139 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
N
EF
A
 
(m
m
o
l/L
)
Control
PE
 
Figure 77 A comparison of the effect of control and PE serum on lipolysis in the presence of 
isoproterenol. 
There is no difference in lipolysis rates when expressed as release of NEFA between 
adipocytes incubated with isoproterenol (200 nM) together with either control or PE serum 
in a concentration of 10% of total volume (p=0.46). Comparison made using paired-t-test and 
results displayed as mean and SEM.  
 
4.5 Discussion 
4.5.1 Metabolic Phenotype 
The pre-eclamptic women in our cohort conform to the described metabolic 
phenotype86. They have a higher booking blood pressure, with an exaggerated 
hyperlipidaemia of pregnancy consisting of higher maternal serum TG and FFA. 
There is also a suggestion of increased insulin resistance with higher maternal 
glucose, insulin and HOMA compared to controls, despite an earlier gestational 
age at sampling. As expected our cases tend to deliver earlier and have babies of 
lower birth-weight centile than the controls. 
4.5.2 Lipolytic function of SAT and VAT 
Our data suggests that SAT and VAT in vitro does not differ in basal lipolysis, nor 
have an exaggerated response to catecholamine stimulation in women with PE 
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compared to controls. In addition there was no difference in either AT depot in 
the absolute response to insulin inhibition. However, we have demonstrated by 
using our FCISI that SAT in women with PE is less insulin sensitive than that in 
control women and a similar tendency is seen in VAT. Our FCISI reflects 
responsiveness to insulin once the tissue is stimulated by the catecholamine 
isoproterenol – a non-selective β-adrenergic agonist which acts to promote 
lipolysis through elevating cellular cAMP production and activation of protein 
kinase A (PKA) and HSL. Insulin inhibits lipolysis by its ability to lower cAMP 
levels via activation of phosphodiesterase 3B (PDE 3B) and therefore reduce PKA 
activity. FCISI may be more relevant in vivo than simple stimulation or 
suppression of adipocyte lipolysis as it represents a functional test of AT 
lipolysis. There may be a dysregulated response in SAT in women with PE 
whereby stimulated fat cells are less sensitive to effects of insulin resulting in 
excessive release of FFA. The mechanisms through which this occurs may be 
secondary to several factors including autocrine and paracrine effects of other 
“lipases” including the inflammatory adipokines such as TNF alpha which can 
attenuate the anti-lipolytic effect of insulin by suppressing PDE 3B activity and 
expression214. Metformin, a drug which is an insulin sensitizing agent and lowers 
circulating FFA inhibits isoproterenol stimulated lipolysis by reducing cellular 
cAMP production and PKA activity and attenuates the phosphorylation of 
perilipiin during isoproterenol-stimulated lipolysis in primary rat adipocytes 
illustrating potential interactions between insulin sensitivity and catecholamine 
stimulated lipolysis.215 In addition the rise of FFA in PE occurs in early pregnancy 
well in advance of manifestations of the disease. Sivan et al demonstrated that 
FFA in early pregnancy induces insulin resistance to levels similar to that seen in 
late pregnancy106. This may therefore result in a “vicious” cycle of reduced 
insulin sensitivity of the tissue resulting in increased release of FFA in early 
pregnancy with further exacerbation of insulin resistance in PE.   
4.5.3 Fat Cell Size  
Interestingly we see a discordant relationship between BMI and adipocyte size in 
controls and PE. As we have previously demonstrated, BMI is not as closely 
related to adipocyte cell size in SAT compared to VAT in normal controls. This 
may be explained by this depot adapting to increased fat mass and accumulation 
of lipid by both hyperplasia and hypertrophy of the cells, whereas increased VAT 
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is primarily due to hypertrophy, a phenomenon seen in non-pregnant women114. 
However in PE, SAT cell size is intimately related to BMI. This is possibly due to 
differences in the behaviour of this tissue in these metabolically challenged 
women to accumulate excess lipid by cell hypertrophy. This process is 
metabolically detrimental.  Individuals with type 2 diabetes and dyslipidaemia 
have larger adipocytes. Furthermore increasing adipocyte size is associated in a 
shift toward dominance of proinflammatory adipokines including TNF alpha and 
IL-6.120 Adipocyte hypertrophy is also thought to result in endoplasmic reticulum 
(ER) stress which results in activation of metabolic factors that trigger insulin 
resistance, with release of inflammatory cytokines and increased macrophage 
recruitment.121 Thus the propensity for SAT to accumulate fat mass by 
hypertrophy as opposed to hypertrophy and hyperplasia would potentially 
predispose them to metabolic complications of pregnancy such as PE. We also 
have shown that SAT cell size in PE is closely related to lipolytic function of the 
tissue independent of BMI, a relationship lacking in normal controls. Conversely 
VAT cell size is an important determinant of VAT function in normal controls but 
not in PE. This highlights potential disparate functional metabolic roles of each 
tissue depot in each group of women. 
4.5.4 The Effect of Maternal Serum 
Although we have show in vitro that AT does not have increased basal lipolysis or 
responsiveness to catecholamines per se, we hypothesised that there may be a 
factor originating from the placenta present in the maternal serum of PE which 
excessively stimulates lipolysis over and above that seen in normal pregnant 
women. We based this on a study by Endresen et al who showed that incubation 
of endothelial cells with sera from women with PE resulted in increased uptake 
of TG, with increased lipolytic activity of PE sera of 3-4 fold as measured by 
release of FFA 107.  Serum from control women did not appear to have an effect 
on basal lipolysis in SAT explants nor lipolysis in presence of insulin. Preliminary 
results indicated an exaggerated response to isoproterenol in the presence of 
control serum at 10% (volume/volume) but this was not reproduced in 
subsequent experiments. When using 10% serum (volume/volume) from PE and 
controls we found no difference in either basal or stimulated lipolysis. In 
addition there was no effect from increasing concentrations of serum between 
PE and controls on basal or stimulated lipolysis. There was an apparent 
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statistical difference in basal lipolysis in the presence PE serum at concentration 
of 30% but this was probably secondary to correcting for FFA already present in 
the serum. As FFA concentration is higher in PE serum and due to the margin of 
error of the NEFA assay its likely that this resulted in an “over-correction”. 
Overall we failed to demonstrate an effect of serum on lipolysis on SAT explants 
in vitro nor any differences between PE and controls, suggesting either an 
absence of a factor influencing lipolysis in serum of PE women or a lack of effect 
in vitro as compared to in vivo. Alternatively the processing of the blood sample 
and incubation with AT in buffer may have altered or inactivated such a factor.   
4.5.5 Limitations 
One limitation of our study is the disparity in gestational age of the cases and 
controls as there are some important metabolic changes in late pregnancy 
including the switch to a state of catabolism with a marked increase in lipolysis 
rates and increased insulin resistance. Unfortunately it was very difficult to 
obtain “pre-term” samples from healthy women being delivered for reasons 
other than IUGR or PE in a non-urgent manner to allow recruitment to a study. 
However, the mean gestational age of our cases was 35 weeks which is well into 
the third trimester by which time the majority of changes in carbohydrate and 
lipid metabolism have occurred. 27 28 80 Also in normal pregnancy IR increases as 
pregnancy advances. Therefore the effect of increased IR in adipose tissue PE is 
likely to be even more apparent if matched for gestational age.   
In summary, we have found some important differences in adipocyte cell 
function between controls and PE which could contribute to the metabolic 
challenges and pathophysiology of this disease.  This is summarised in Figure 78 
and Figure 79. 
. 
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Figure 78 Comparison of SAT and VAT cell size and lipolytic function in controls and PE 
In PE, SAT cell size is closely correlated with BMI, an effect not seen in controls. This 
maybe due to the adaptation of this fat depot to an increase in fat mass by adipocyte 
hypertrophy which could result in increased ER stress and release of pro-inflammatory 
adipokines. Although VAT cell size is closely related to BMI in PE, it is not related to 
lipolytic function in this depot unlike in controls.  
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Figure 79 SAT and VAT in PE is less insulin sensitive than controls. 
Decreased insulin sensitivity of SAT and VAT could potentially lead to exaggerated lipolysis 
with increase release of circulating FFA. FFA can further contribute to insulin resistance, 
endothelial dysfunction and dyslipidaemia, all features of the syndrome of PE. 
    
5 Adipose Tissue, Inflammation and Pre-
eclampsia 
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5.1 Introduction 
Endothelial dysfunction as part of an overall more general inflammatory reaction 
is a hallmark of pre-eclampsia and involves placental and systemic circulations216 
217.  Healthy pregnancy is a state of systemic inflammation and therefore pre-
eclampsia may represent an extreme end of maternal systemic inflammatory 
responses engendered by the pregnancy itself216.  Notably all the inflammatory 
changes of normal pregnancy are exaggerated in pre-eclampsia and features of 
the disease are derived not only from endothelial dysfunction but a wider stress 
response including the acute phase response and effects on metabolism.217 The 
corollary is that any maternal or fetal factor, which would enhance this 
inflammatory response, would predispose to endothelial dysfunction and pre-
eclampsia.  For example maternal diabetes and maternal obesity are associated 
with an increased risk of endothelial dysfunction with a concomitant increase in 
the risk of pre-eclampsia71 218.Many similarities between the metabolic syndrome 
and pre-eclampsia can be found including insulin resistance, dyslipidaemia, 
inflammation and endothelial dysfunction. The link between adiposity, 
inflammation and insulin resistance has been increasingly defined since 
Hotamisligil first demonstrated this relationship in 1993219. White adipose tissue 
(WAT) secretes a number of pro-inflammatory mediators which contributes 
significantly to the chronic inflammatory state and metabolic complications of 
obesity113. Therefore it is plausible that similar disturbances in adipocyte 
function could contribute to the development of the clinical syndrome of PE.  
5.1.1 Adipokines 
WAT secretes a diverse range of cytokines, proteins and signals which have both 
paracrine and endocrine actions and a wide-ranging influence on the metabolic 
and physiological function of other organs122. It releases a host of pro-
inflammatory cytokines (e.g. TNF alpha, IL-1,IL-6,IL-8, IL-10), chemokines (e.g. 
MCP1, MIP-1 alpha) and acute phase proteins (e.g. serum amyloid A, C-reactive 
protein, haptoglobin, PAI-1). In addition there are AT specific adipokines such as 
leptin which acts not only in the control of appetite and energy balance, but 
contributes to inflammation through modulation of T-cell and monocyte 
functions220, and the anti-inflammatory and potent insulin-sensitising agent 
adiponectin. The function of important adipokines and their potential roles in 
normal and complicated pregnancy have been detailed previously. 
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5.1.2 Adipose Tissue Macrophages 
WAT is a heterogeneous tissue composed of several cell types including mature 
adipocytes, pre-adipocytes, fibroblasts,endothelial cells, histiocytes, and 
adipose tissue macrophages (ATM).The non-adipocyte cells are termed the 
‘stroma vascular fraction’ (SVF). Many of the pro-inflammatory factors are 
secreted by the non-adipocyte cells, and this is of particular relevance in the 
pathological condition of obesity 221. Similar to the Th1/Th2 concept of T-cell 
activation, a concept of M1/M2 polarization has been described for 
macrophages. Macrophages are classically stimulated by IFNγ alone or in 
combination with LPS and produce inflammatory cytokines, reactive oxygen 
species such as NO and are capable of inducing Th1-polarized T-cell responses. 
These pro-inflammatory “classical” macrophages are named M1.222 In contrast 
M2 or “alternatively activated” macrophages are induced by IL-4 and IL-13 and 
have an anti-inflammatory phenotype.223 They down-regulate inflammatory 
processes that are initiated by M1 by production of IL-10, TGFβ, and the IL-1 
receptor antagonist.222. In obesity, there is increased macrophage recruitment 
and retention with a shift toward the more pro-inflammatory M1 phenotype. The 
driving force behind this is thought to be secondary to adipocyte hypertrophy, 
cell death and local hypoxia within expanding WAT.224-226 The alteration in the 
cellularity of WAT contributes to adipose inflammation, altered production of 
adipokines and promotion of insulin resistance through dysregulation of glucose 
and lipid metabolism227.  Monocyte chemotactic protein-1, acting through its 
receptor CCR2 is strongly implicated in ATM recruitment and remodelling228. It is 
over-expressed in obese rodents and obese diabetic humans, and is implicated in 
insulin resistance 229 230. In addition macrophage accumulation is also required 
for angiogenesis at sites of inflammation and ischaemia in AT. The action of 
these inflammatory cells may represent one of the key links between adiposity 
and its metabolic complications including those occurring in pregnancy.  
5.1.3 Toll-like receptors and innate immunity 
In addition to adipokine receptors, adipocytes and the SVF express all toll-like 
receptors (TLR) except 5 and 7231. TLRs are part of the innate immune system 
that classically alert the immune system to the presence of pathogens. TLR4 is 
an LPS receptor which is also activated by long-chain fatty acids that transduce 
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cytokine expression 232. Activation of TLR4 in adipocytes alters key mediators of 
insulin signalling and glucose uptake including NFKB target genes and via an 
MyD88 independent pathway 233. TLR4 deficient mice were protected from diet 
induced obesity and IR 234. Previous groups have reported that experimental 
human endotoxinemia promotes adipose inflammation and alters adipokine 
function coincident with systemic IR 235.  
5.1.4 Macrophage Markers 
Cfms is a type III receptor tyrosine kinase that is selectively expressed on 
macrophages and their progenitor cells and serves as the exclusive receptor for 
colony-stimulating factor (CSF-1), a cytokine which controls the production, 
differentiation and function of macrophages236.Upon binding to CSF-1, cfms 
undergoes autophosphorylation and dimerization, and ultimately induces the 
phosphorylation of downstream signalling proteins, thereby driving the 
differentiation and activation of these cells237. Thus, ligation of cfms by CSF-1 
results in activation and proliferation of macrophages and their subsequent 
release of inflammatory mediators. Therefore the identification of cfms+ 
macrophages would represent activated ATM. All tissue macrophages highly 
express CD68, a transmembrane glycoprotein of unknown function, and anti-
CD68 is commonly used as a macrophage marker in ICC.  
5.2 Aims and Objectives 
5.2.1 Hypotheses 
1. That adipocyte release of adipokines is exaggerated under either basal or 
stressed conditions in women with PE, thereby implicating adipocyte function 
in its pathophysiology. 
2. That macrophage infiltration of adipose tissue, a marker of tissue 
inflammation, is increased in women with PE compared to controls. 
 
5.2.2 Specific Research Questions 
1. Is the release of the adipokines IL-6, TNF-alpha, IL-10, CRP, leptin, 
adiponectin and PAI-1 altered in adipocytes from women with PE under basal 
conditions or when stimulated by LPS? 
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2. Is the basal release of MCP-1 altered in adipocytes in women with PE or when 
stimulated by LPS? 
3. Is the adipocyte defect dependent predominantly on one functional tissue 
depot - i.e. visceral vs subcutaneous? 
4. If differences in adipokine release are found, is this reflected by differences 
in the gene expression in adipose tissue? 
5. Does either basal or stimulated adipokine release relate to maternal markers 
of insulin resistance and adipocyte lipolysis? 
6. Does either basal or stimulated adipokine release relate to adipocyte cell 
size? 
7. Is there a higher percentage of macrophages (CD68+) and activated 
macrophages (cfms+) in the adipose tissue of women with PE?  
 
5.3 Methods 
Fourteen PE and matched controls for age, BMI, smoking and parity were 
recruited as outlined in Methods section 2.1. Adipose tissue was processed as 
outlined in methods section 2.3-2.5. At time=120min paired 120ul aliquots of the 
buffer layer below the adipocyte layer was frozen at -80°C for later analysis of  
adipokines by Bio-Plex (BIO-RAD®) system a suspension array technology as 
outlined in section 2.8. Adipokines were corrected for cell number by dividing by 
the quantity of DNA in a known volume of adipocytes as outlined in methods 
section 2.7. The values are therefore expressed as pg/ml/ugDNA. RNA was 
isolated from adipose tissue using methods described in 2.9. Reverse transcribed 
RNA to cDNA was synthesised and cDNA was quantitated using TaqMan 
technology as outlined in section 2.10.  
Immunocytochemistry and quantification of macrophage cell density was 
performed as outlined in methods section 2.11 and 2.12 . 
Statistical analysis was performed as per methods section 2.14. 
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5.4 Results 
5.4.1 Subjects 
The characteristics of the subjects are described in Table 13. Subjects were 
matched for age, BMI and smoking.  
Characteristics Controls (n=14) PE (n=14) P value 
Age, y 30.0(5.8) 31.5(6.3) 0.51 
BMI, kg/m2 29.7(6.6) 31.1(8.0) 0.62 
Smokers (non,current)** 12,2 11,2 0.82 
DEPCAT* 4(4-5.75) 6(4-7) 0.06 
Gestation at delivery, days      270.3(11.2) 249.4(21.5) 0.004 
Systolic pressure, mmHg 114.7(12.3) 127.1(13.1) 0.013 
Diastolic pressure, mmHg 69.9(9.0) 79.1(9.0) 0.009 
Birthweight, g 3304(633) 2330(926) 0.004 
Birthweight centile 50.7(31.7) 26(31.2) 0.046 
Table 13 Characteristics of cases and controls. Blood pressure refers to booking values. All 
values expressed as mean and standard deviation (*median and interquartile range). 
Comparisons made by paired t test except * Mann-whitney, and ** chi-squared test.  
5.4.2 Adipokines 
5.4.2.1 TNF-alpha 
There was no difference in subcutaneous adipose tissue (SAT) of basal release of 
TNF-alpha (p=0.10) or LPS stimulated release (p=0.97) between controls and PE. 
Similiarly there was no difference in visceral adipose tissue (VAT) of basal 
release (p=0.64) or LPS stimulated release (p=0.39) between controls and PE. In 
addition there was no significant difference in basal release of TNF-alpha 
between SAT and VAT in controls (p=0.23) or PE (0.88). 
TNF-alpha secretion was significantly increased in VAT after stimulation by LPS 
in PE (64.1[20.6] vs 89.1[26.0] pg/ml/ugDNA, p=0.018), but not in controls 
(45.4[9.2] vs 55.5[11.8] pg/ml.ugDNA, p=0.16)(Figure 80). 
   
Shahzya Huda, 2010  Chapter 5  151
0
20
40
60
80
100
120
Control PE
TN
Fa
lp
ha
 
pg
/m
l/u
gD
N
A
Basal
LPS
*
 
Figure 80 Comparison of basal release and stimulated release of TNF-alpha in visceral 
adipose tissue.  
TNF-alpha secretion was significantly increased in PE (p=0.018)(n=14) but not in controls 
(n=14). Raw data shown but analysis performed on transformed data by paired t-test, and 
expressed as mean and SEM. *=p≤0.05. 
Conversely, TNF- alpha secretion was significantly increased in SAT after 
stimulation by LPS in controls (34.0[7.7] vs 57.7[13.6] pg/ml/ugDNA, p=0.02) but 
not in PE (62.1[14.6] vs 49.0[11.0] pg/ml/ugDNA, p=0.26) (Figure 81). Basal 
release of TNF-alpha from SAT in PE is almost double that of controls although 
not significantly so (62.1[14.6] vs 34.0[7.7] pg/ml/ugDNA, p=0.097).  
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Figure 81 Comparison of basal release and LPS stimulated release of TNF-alpha in 
subcutaneous adipose tissue.  
TNF-alpha secretion was significantly increased in controls (p=0.02) (n=14) but not in PE 
(n=14). Analysis performed on transformed data by paired t-test, but raw data shown and 
expressed as mean and SEM. *=p≤0.05. 
In controls, TNF-alpha basal secretion from SAT is positively correlated with BMI 
(r=0.63, R2=39.4%, p=0.009) as is TNF-alpha secretion after stimulation by LPS 
(r=0.59, R2=34.9, p=0.016)(Figure 82 and Figure 83). This relationship is not 
affected when adjusted for cell size (p=0.014 and p=0.018 respectively).There is 
no correlation with BMI and VAT basal or stimulated TNF-alpha secretion.  
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Figure 82 Relationship between maternal BMI and basal release of TNF-alpha in SAT of 
controls.  
There is a positive correlation between BMI and basal release of TNF-alpha from SAT in 
controls (p=0.009). SQRT TNF-alpha= square root TNF-alpha. 
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Figure 83 Relationship between maternal BMI and LPS stimulated release of TNF-alpha from 
SAT of controls.  
There is a positive relationship between TNF-alpha and BMI (p=0.016). SQRT TNF-alpha= 
square root TNF-alpha. 
There is no correlation with SAT or VAT TNF-alpha secretion (either basal or 
stimulated) and maternal triglycerides, maternal NEFA, maternal glucose, insulin 
or HOMA. SAT or VAT TNF-alpha secretion (basal or stimulated) is not correlated 
with maternal plasma TNF-alpha, leptin or adiponectin or CRP. In addition there 
appears to be no apparent relationship between SAT or VAT TNF-alpha secretion 
(basal or stimulated) and direct measures of adipocyte lipolysis and adipose 
tissue insulin sensitivity. However VAT TNF-alpha secretion, both basal and 
stimulated, correlates with maternal IL-6 plasma levels (r=0.55, R2=30.0%, 
p=0.042 and r=0.54, R2=29.3%, p=0.045 respectively). 
Conversely, unlike in controls, in PE there is no apparent correlation between 
SAT TNF-alpha release (basal or stimulated) and maternal BMI (p=0.40 and 
p=0.88 respectively). In addition, VAT TNF-alpha release does not correlate with 
maternal BMI in PE.  
Similar to data from controls, there is no correlation in PE between TNF-alpha 
release (basal or stimulated) and maternal TG, maternal NEFA, glucose, insulin 
or HOMA. Furthermore no relationship was found with maternal serum leptin, 
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adiponectin, maternal TNF-alpha, IL-6 and maternal CRP. However SAT basal and 
stimulated release of TNF alpha was positively correlated with NEFA release in 
the presence of isoproterenol (r=0.63, p=0.017 and r=0.62, p=0.017 respectively) 
and NEFA release in the presence of isoproterenol and insulin (r=0.58, p=0.03 
and r=0.55, p=0.04 respectively).  
In PE, VAT basal release of TNF-alpha is negatively correlated with FCISI (fat cell 
insulin sensitivity) of VAT(r=-0.60, R2=41.5%, p=0.018 adjusted for BMI), as is 
stimulated release of TNF-alpha(r=-0.53, R2=34.3%, p=0.037 adjusted for BMI) 
(Figure 84 & Figure 85). The FCISI is a direct measure of insulin sensitivity of 
adipose tissue and is calculated from the percentage inhibition of catecholamine 
stimulated lipolysis by insulin measured from the release of NEFA (see section 
3.3.6). This relationship is not seen in SAT in PE, nor SAT and VAT in controls.  
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Figure 84 Relationship between basal release of VAT TNF-alpha and FCISI. 
Basal release of VAT TNF-alpha is negatively correlated with FCISI of VAT in PE (p=0.018 
adjusted for BMI) (n=14). SQRT TNF-alpha = square root TNF-alpha, FCISI=fat cell insulin 
sensitivity index. 
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Figure 85 Relationship between stimulated release of VAT TNF-alpha and FCISI. 
Stimulated release of VAT TNF-alpha by LPS is negatively correlated with FCISI of VAT in 
PE (p=0.037 adjusted for BMI) (n=14). SQRT TNF-alpha = square root TNF-alpha, FCISI=fat 
cell insulin sensitivity index 
5.4.2.2 IL-6 
Statistical analysis was performed on log transformed data to ensure normal 
distribution. Values are expressed as mean and SEM of untransformed data 
unless otherwise stated. There was no significant difference between basal 
release of IL-6 in SAT between controls and PE (169.1[61.3] vs 107.8[27.0] 
pg/ml/ugDNA, p=0.74), nor after stimulation with LPS (173.5[40.6] vs 76.8[16.9] 
pg/ml/ugDNA, p=0.12). In VAT, there was no difference between basal release 
of IL-6 (454[93.8] vs 584[180] pg/ml/ugDNA, p=0.90) or after stimulation with 
LPS (581[117] vs 912[242] pg/ml/ugDNA, p=0.65) between controls and PE. 
IL-6 secretion was significantly increased in VAT after stimulation by LPS in PE 
(584[180] vs 912[242] pg/ml/ugDNA, p=0.007), but not in controls (454[9308] vs 
581[117] pg/ml/ugDNA, p=0.09) (Figure 86).  There was no significant difference 
in IL-6 secretion in SAT after stimulation by LPS in controls and PE.  
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Figure 86 Comparison of the basal release of IL-6 and LPS stimulated release in visceral 
adipose tissue. 
IL-6 release was significantly increased in PE (n=14) but not in controls (n=14) (p=0.007). 
Data normalized by log transformation prior to analysis by paired t-test but displayed as 
untransformed data as mean and SEM. **=p≤0.01. 
Basal and LPS stimulated release of IL-6 in SAT positively correlated with BMI in 
controls(r=0.60, R2=35.9%, p=0.014 and r=0.65, R2=41.7%, p=0.007 
respectively)(Figure 87). 
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Figure 87 Correlation between BMI and LPS stimulated release of IL-6 in controls. 
LPS stimulated release of IL-6 in SAT positively correlated with BMI in controls (p=0.007). 
There was no correlation between SAT and VAT basal and stimulated release of 
IL-6 and maternal total cholesterol and TG, maternal NEFA, and maternal serum 
markers of insulin resistance including glucose, insulin and HOMA. There was no 
relationship between SAT and VAT basal and stimulated release of IL-6 and 
maternal serum IL-6, TNF alpha, CRP, leptin or adiponectin. Furthermore there 
was no correlation between IL-6 release in SAT and VAT and direct markers of 
adipocyte lipolysis or FCISI. There was no correlation between SAT and VAT cell 
size and IL-6 release. Basal and stimulated release of IL-6 from SAT was 
negatively correlated with maternal HDL (r=-0.59,R2=34.8%, p=0.016 and r=-0.52, 
R2=26.8%, p=0.04 respectively) an effect which is attenuated when adjusted for 
BMI (p=0.053 and p=0.13 respectively). 
Basal release of IL-6 is higher in VAT than SAT in controls (169.1[61.3] vs 
454.7[93.8] pg/ml/ugDNA, p=0.009), as is IL-6 release after stimulation by LPS 
(173.5[40.6] vs 581[117] pg/ml/ugDNA, p=0.003)(Figure 88). 
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Figure 88 Comparison of basal and LPS stimulated release of IL-6 from SAT and VAT. 
Basal and stimulated release of IL-6 is higher in VAT than in SAT (p=0.009 and p=0.003 
respectivey) (n=14). Data displayed as mean and SEM. **=p≤0.01. 
In PET, there is no correlation between basal and stimulated IL-6 release and 
BMI in SAT and VAT. There was no correlation between IL-6 release in SAT and 
VAT and maternal lipids, NEFA or maternal markers of insulin resistance. There 
was no correlation between SAT and VAT basal and stimulated IL-6 release and 
maternal plasma IL-6, TNF-alpha, CRP, leptin or adiponectin. There was no 
association between SAT and VAT basal and stimulated IL-6 release and direct 
measures of adipocyte lipolysis and insulin sensitivity.  
Basal and LPS stimulated release of TNF-alpha and IL-6 are closely related in SAT 
and VAT in controls (Table 14) and PE (Table 15). 
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CONTROLS SAT TNF-alpha 
Basal 
SAT TNF-alpha 
LPS stimulated 
VAT TNF alpha  
Basal 
VAT TNF alpha 
LPS stimulated 
SAT IL-6  
Basal 
r=0.71 
R2=50.4%   
p=0.002 
   
SAT IL-6 
LPS 
stimulated 
 r=0.87 
R2= 74.9% 
p<0.001 
  
VAT IL-6 
Basal 
  r=0.79 
R2=61.6%   
p=0.001 
 
VAT IL-6 
LPS 
stimulated 
   r=0.79 
R2=63.0%   
p=0.001 
Table 14 Correlations between basal and stimulated TNF-alpha and IL-6 release from SAT 
and VAT in controls (n=14) 
PRE-
ECLAMPTICS 
SAT TNF-
alpha 
Basal 
SAT TNF-alpha 
LPS stimulated 
VAT TNF 
alpha  
Basal 
VAT TNF alpha 
LPS stimulated 
SAT IL-6  
Basal 
r=0.79 
R2= 63.2%  
p=0.001 
   
SAT IL-6 
LPS stimulated 
 r=0.74 
R2= 55.0% 
p=0.002 
  
VAT IL-6 
Basal 
  r=0.72 
R2= 52.2% 
p=0.004 
 
VAT IL-6 
LPS stimulated 
   r=0.86 
R2= 73.5% 
p<0.001 
Table 15 Correlations between basal and stimulated TNF-alpha and IL-6 release from SAT 
and VAT in controls (n=14) 
5.4.2.3 Adiponectin 
Basal and LPS stimulated release of adiponectin from VAT in controls is 
positively correlated with measures of visceral lipolytic function (see Figure 89 
and Table 16). No apparent relationship in PE is found.  
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Figure 89 Relationship of basal release of adiponectin and VAT stimulated lipolysis.   
Basal release of adiponectin is positively correlated with NEFA release in the presence of 
isoproternol (p=0.008). Data normalised by log transformation prior to statistical analysis. 
VISO = VAT in the presence of isoproterenol.  
Controls (VAT) VISO VINS VISO+ VINS 
Basal release of adiponectin r=0.67, 
p=0.008 
r=0.59, 
p=0.027 
r=0.71, 
p=0.004 
Stimulated release of 
adiponectin 
r=0.65, 
p=0.011 
r=0.57, 
p=0.034 
r=0.72, 
p=0.004 
Table 16 Correlations between basal and stimulated release of adiponectin and measures of 
lipolytic function in VAT.  
VISO= NEFA release from VAT in presence of isoproternol. VINS = NEFA release from VAT 
in presence of insulin. VISO + VINS = NEFA release from VAT in presence of isoproterenol 
and insulin. 
 
No other significant differences between controls or PE were found, nor were 
there any other significant correlations (data not shown).  
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5.4.2.4 PAI-1 
In controls, there was a greater amount of PAI-1 released from VAT than SAT 
both basally (median 26.1 vs 110.0 pg/ml/ugDNA, p=0.01, Mann-Whitney) and 
after stimulation with LPS (median 32.2 vs 81.8 pg/ml/ugDNA, p=0.02, Mann-
Whitney)(Figure 90).  Similarly in PE there is a greater amount of PAI-1 released 
from VAT than SAT both basally(median 35.2 vs 123.8 pg/ml/ugDNA, p=0.03) and 
after stimulation(median 34.0 vs 144.6 pg/ml/ugDNA, p=0.01 Mann-
Whitney)(Figure 91). 
VAT stimulatedSAT stimulatedVAT basalSAT basal
400
300
200
100
0
P
A
I-
1
 (
p
g
/
m
l/
u
g
D
N
A
)
* *
 
Figure 90 Difference in PAI-1 release between VAT and SAT in controls. 
There is a greater amount of PAI-1 released from VAT compared to SAT both basally 
(p=0.01) and after stimulation with LPS (p=0.02) in controls (n=14). Data displayed as median 
and interquartile range. Analysis by Mann-Whitney. *=p≤0.05. 
 
   
Shahzya Huda, 2010  Chapter 5  163
VAT stimulatedSAT stimulatedVAT basalSAT basal
1800
1600
1400
1200
1000
800
600
400
200
0
P
A
I-
1
 p
g
/
m
l/
u
g
D
N
A
* *
 
Figure 91 Difference in PAI-1 release between VAT and SAT in PE. 
There is a greater amount of PAI-1 released from VAT compared to SAT both basally 
(p=0.03) and after stimulation with LPS (p=0.01) in PE (n=14). Data displayed as median and 
interquartile range. Analysis by Mann-Whitney. *=p≤0.05. 
Basal PAI-1 release from SAT is positively correlated with BMI in controls (r=0.64, 
R2=41.3%, p=0.007) and PE(r=0.63, R2=40.2%, p=0.015). HDL is negatively 
correlated with PAI-1 release from SAT in PE only (r=0.60, R2= 35.6%, p=0.024) 
which is attenuated but not obliterated when adjusted for BMI (p=0.036). 
No other significant differences between controls and PE were found, nor were 
there any other significant correlations (data not shown).  
5.4.2.5 Leptin 
In controls, basal release of leptin from SAT is higher than VAT (1033[191] vs 268 
[72] pg/ml/ugDNA, p=0.002), as is release after LPS stimulation (973[165] vs 
261.1[72.1] pg/ml/ugDNA, p=0.005)(Figure 92).  
This effect is similar in PE (1334[191] vs 220.4[55.3] pg/ml/ugDNA, p=0.001 and 
1269[399] vs 182.2[47.2] pg/ml/ugDNA, p<0.001)(Figure 93).   
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Figure 92 Comparison of release of leptin from SAT and VAT in controls.  
Release of leptin from SAT compared to VAT is greater both basally (p=0.002) and after 
stimulation with LPS (p=0.005)(n=14). Comparison made using unpaired t-test. **=p≤0.01. 
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Figure 93 Comparison of release of leptin from SAT and VAT in PE.  
Release of leptin from SAT compared to VAT is greater both basally (p=0.001) and after 
stimulation with LPS (p<0.001) (n=14). Comparisons made using un-paired t-test. 
***=p≤0.001. 
BMI does not correlate with leptin release from SAT or VAT in PE or controls.  
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In PE, basal and stimulated release of leptin from SAT is negatively correlated 
with maternal serum adiponectin (r=-0.78, R2= 61.2%, p=0.001 and r=-0.76, 
R2=57.0%, p=0.001 respectively)(Figure 94). This is independent of BMI (p=0.007 
and 0.009). This relationship is not apparent in controls (p=0.82 and p=0.73).  
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Figure 94 Relationship of basal release of leptin from SAT and maternal plasma levels of 
adiponectin in PE.  
There is a negative correlation between basal release of leptin from SAT and maternal 
plasma adiponectin independent of BMI (p=0.007) (n=14). 
In PE, both basal and stimulated release of leptin from SAT positively correlates 
with direct measures of adipocyte lipolytic function in this adipose depot (Figure 
95 and Table 17).  
PE (SAT) SBA  SISO SINS SISO+INS 
Leptin basal  r=0.85, 
p<0.001 
r=0.60, 
p=0.024 
r=0.73, 
p=0.003 
r=0.74, 
p=0.002 
Leptin 
stimulated 
r=0.79, 
p=0.001 
r=0.55, 
p=0.042 
r=0.71, 
p=0.004 
r=0.69, 
p=0.006 
Table 17 Table of correlations between basal and LPS stimulated release of leptin and 
measures of lipolytic function (release of NEFA ug/ml/udDNA) in SAT in PE.  
SBA= basal lipolysis, SISO=lipolysis in presence of isoproterenol, SINS= lipolysis in 
presence of insulin, SISO+SINS= lipolysis in presence of isoproterenol and insulin.  
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Figure 95 Relationship between basal release of leptin and basal lipolysis in SAT in PE.  
There is a positive relationship between the basal release of leptin and basal lipolysis in 
SAT (p<0.001) (n=14).  
Release of leptin from VAT is also correlated with direct measures of adipocyte 
lipolytic function in this adipose depot (Table 18).  
PE (VAT) VBA VISO VINS VISO+INS 
Leptin basal r=0.57, 
p=0.05 
r=0.70, p=0.01 NS r=0.66, p=0.02 
Leptin 
stimulated 
r=0.62, 
p=0.03 
r=0.65, p=0.02 r=0.62, p=0.03 r=0.62, p=0.03 
Table 18 Table of correlations between basal and LPS stimulated release of leptin and 
measures of lipolytic fuction (release of NEFA ug/ml/ugDNA) in VAT in PE.  
VBA= basal lipolysis, VISO=lipolysis in presence of isoproterenol, VINS= lipolysis in 
presence of insulin, VISO+INS= lipolysis in presence of isoproterenol and insulin.  
In contrast, in controls, SAT release of leptin is not a significant correlate of 
lipolytic function (data not shown). However VAT release of leptin does relate to 
measures of lipolysis (Table 19). 
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Controls (VAT VBA VISO VINS VISO+INS 
Leptin basal NS r=0.89, p<0.001 r=0.68, p=0.02 r=0.80, p=0.002 
Leptin stimulated NS r=0.79, p=0.002 r=0.59, p=0.04 r=0.72, p=0.009 
Table 19 Table of correlations between basal and LPS stimulated release of leptin and 
measures of lipolytic fuction (release of NEFA ug/ml/ugDNA) in VAT in controls.  
VBA= basal lipolysis, VISO=lipolysis in presence of isoproterenol, VINS= lipolysis in 
presence of insulin, VISO+INS= lipolysis in presence of isoproterenol and insulin.  
No other significant differences in PE and controls were found, nor were there 
any other significant correlations. 
5.4.2.6 IL-10 
In PE, basal and stimulated release of IL-10 from SAT is closely correlated with 
BMI (r=0.81, R2= 65.6%, p<0.001 and r=0.73, R2=53.1%, p=0.003), a relationship 
which is not seen in controls.  
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Figure 96 Correlation between BMI and basal release of IL-10 from SAT in PE.  
There is a positive correlation between BMI and basal release of IL-10 from SAT in PE 
(p<0.001) (n=14). 
Indeed in PE, IL-10 release from SAT correlates with SAT cell size (p=0.008) but 
this is not independent of BMI (p=0.33).IL-10 release from SAT negatively 
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correlates with the insulin sensitivity of the tissue as calculated by FCISI (r=-
0.58, p=0.03), but again not independent of BMI (p=0.36).  
No other significant differences between controls and PE, nor any other 
significant correlations were found (data not shown).  
5.4.2.7 CRP 
Release of CRP from SAT is a significant determinant of maternal plasma CRP in 
both controls (r=0.66, R2=43.0%, p=0.006) and PE (r=0.89, R2=78.9%, p<0.001) 
independent of BMI (p=0.015 and p<0.001 respectively)(Figure 97). 
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Figure 97 Correlation between basal release of CRP and maternal plasma CRP from SAT in 
controls and PE.  
There is a positive correlation between basal release of CRP from SAT and maternal plasma 
levels of CRP in controls (p=0.006) (n=14) and PET (p<0.001)(n=14) . 
Both basal and stimulated release of CRP from VAT is correlated with measures 
of VAT lipolysis in controls. This effect is not seen in PE (data not shown).  
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Controls (VAT) VBA VISO VINS VISO+INS 
CRP basal r=0.60, 
p=0.02 
r=0.66, p=0.01 r=0.65, p=0.01 r=0.75, 
p=0.002 
CRP stimulated r=0.61, 
p=0.02 
r=0.63, p=0.02 r=0.63, p=0.02 r=0.76, 
p=0.001 
Table 20 Table of correlations between basal and LPS stimulated release of CRP and 
measures of lipolytic function (release of NEFA ug/ml/ugDNA) in VAT in controls.  
VBA= basal lipolysis, VISO=lipolysis in presence of isoproterenol, VINS= lipolysis in 
presence of insulin, VISO+INS= lipolysis in presence of isoproterenol and insulin.  
No other significant differences between controls and PE, nor any further 
significant correlations were found (data not shown).  
5.4.2.8 MCP-1 
Stimulated release of MCP-1 was higher in VAT than SAT in PE (44.3[11.8] vs 
248.5[73.8] pg/ml/ugDNA, p=0.004). There was also a trend for basal release of 
MCP to be greater in VAT than SAT but did not reach significance (68.6[15.9] VS 
195.2[57.0] pg/ml/ugDNA, p=0.07)(Figure 98). There was no significant 
difference in basal or stimulated MCP-1 release between SAT and VAT in controls 
(Figure 99).  
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Figure 98 Comparison of SAT and VAT basal and stimulated release of MCP-1 in PE.  
   
Shahzya Huda, 2010  Chapter 5  170
Stimulated release of MCP-1 is greater from VAT than SAT (p=0.004) (n=14). Comparisons 
made using student t-test and data displayed as mean and SEM. **=p≤0.01. 
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Figure 99 Comparison of SAT and VAT basal and stimulated release of MCP-1 in controls.  
There is no significant difference between SAT and VAT (p=0.18 and p=0.15) (n=14). 
Comparisons made using student t-test and data displayed as mean and SEM. 
In controls, there was a positive correlation between release of MCP-1 in SAT 
and BMI (r=0.68, R2=46.2%, p=0.004). No such association was apparent in PE. 
No other significant differences between PE or controls, nor any other significant 
correlations were found (data not shown).  
5.4.3 Relationship of adipocyte cell size and release of adipokines 
5.4.3.1 Subcutaneous Adipose Tissue 
In controls, no correlation with SAT cell size and release of adipokines was found 
(data not shown). However in PE several associations were apparent. CRP basal 
release was positively correlated with SAT cell size (r=0.60, R2=36.4%, p=0.02) 
although not independent of BMI (p=0.10). Leptin basal release was also 
positively correlated with SAT cell size (r=0.53, R2=28.1%, p=0.05) again not 
independent of BMI (p=0.28). PAI-1 basal release was also positively correlated 
with SAT cell size (r=0.53, R2=27.7%, p=0.05) not independent of BMI (p=0.59). 
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Furthermore the release of IL-10 was also positively correlated with cell size in 
this depot in PE only (r=0.68, R2=46.2%, p=0.008) not independent of BMI 
(p=0.34). No other associations were found.  
5.4.3.2 Visceral adipose tissue 
No significant correlations with VAT cell size and release of adipokines were 
apparent (data not shown). VAT cell size negatively correlated with the release 
of adiponectin in PE (r=-0.56, R2=30.9%, p=0.04) independent of BMI (p=0.045). 
5.4.4 Messenger RNA expression 
5.4.4.1 TNF-alpha 
All comparisons were made using Mann-Whitney test for non-parametric data. 
Median TNF-alpha mRNA expression in VAT was higher in PE relative to controls 
(2.2 vs 0.9 TNF-alpha to PPIA ratio, p=0.039)(Figure 100). There was no 
difference in TNF-alpha mRNA expression in SAT between PE and controls 
(p=0.94).  
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Figure 100 TNF-alpha gene expression in VAT in controls and PE.  
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Median TNF- alpha gene to PPIA ratio is greater in PE relative to controls (p=0.039) (n=14). 
Data expressed as median and interquartile range and analysis by Mann-Whitney.*=p≤0.05 
5.4.4.2 IL-6 
Median IL-6 mRNA expression in VAT appeared higher in PE relative to controls 
but did not reach significance (11.8 vs 4.0 target gene to PPIA ratio, 
p=0.11)(Figure 101). There was no difference in IL-6 mRNA expression in SAT 
between PE and controls (p=0.72). 
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Figure 101 IL-6 gene expression in VAT in controls and PE.  
Median Il-6 to PPIA ratio appears greater in PE (n=14) relative to controls (p=0.11) (n=14). 
Data expressed as median and interquartile range and analysis by Mann-Whitney. 
5.4.4.3 MCP-1 
Comparisons made on log transformed data by unpaired t-test (control vs PE) 
and paired t-test (SAT vs VAT). Data expressed as absolute values. There was no 
statistical difference between MCP-1 mRNA expression relative to PPIA in VAT 
(40.5 vs 67.4 MCP1to PPIA ratio, p=0.15) or SAT (55.8 vs 52.2 MCP1 to PPIA ratio, 
p=0.42) between controls and PE. However MCP1 mRNA expression appeared 
higher in VAT compared to SAT in PE (67.4 vs 52.2 MCP1 to PPIA ratio, p=0.049) 
but not in controls (40.5 vs 55.8 MCP1 to PPIA ratio, p=0.55), although caution 
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needs to used when comparing gene expression between the different adipose 
depots.  
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Figure 102 Expression of MCP1 in SAT and VAT.  
There is a greater expression of MCP1 from VAT relative to SAT in PE (p=0.049) (n=14) but 
not in controls (p=0.55) (n=14). Comparisons made using paired t-test and data displayed as 
mean and SEM. *=p≤0.05. 
5.4.5 Adipose Tissue Macrophage Infiltration 
5.4.5.1 Messenger RNA expression 
The mean cfms mRNA expression in VAT was higher in PE relative to controls 
matched for BMI (28.1[3.9] vs 57.2[10.1], p=0.033)(Figure 103). No other 
differences between CD68 expression in VAT or SAT or cfms expression in SAT 
was seen (Table 21). All data is expressed and displayed as absolute values but 
analysis was performed using unpaired t-test on log transformed data.  
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Figure 103 VAT cfms gene expression in controls and PE.  
The cfms to PPIA ratio was greater in PE (n=14) than in controls (p=0.033)(n=14)in VAT. 
Comparisons made using student t test and expressed as mean and SEM. *=p≤0.05. 
 Control 
(n=14) 
PE 
(n=14) 
P 
VAT CD68/PPIA mRNA ratio 57.6(9.2) 67.9(5.2) 0.342 
SAT CD68/PPIA mRNA ratio 73.4(11.2) 76.8(11.8) 0.494 
VAT cfms/PPIA mRNA ratio 28.1(3.9) 57.2(10.1) 0.033 
SAT cfms/PPIA mRNA ratio 70.0(25.2) 57.4(12.1) 0.855 
 n=9 n=9  
VAT CD68+/adipocyte(%) 19.6(1.7) 23.1(4.5) 0.491 
SAT CD68+/adipocyte(%) 22.3(3.2) 18.8(6.1) 0.379 
VAT cfms+/adipocyte(%) 8.2(1.5) 16.4(3.0) 0.032 
SAT cfms+/adipocyte (%) 8.2(1.3) 18.2(5.5) 0.118 
Table 21 Table summarising differences between VAT and SAT mRNA expression and cell 
density of cfms and CD68 between PE and controls matched for BMI. 
5.4.5.2 Adipose tissue macrophage density 
Adipose tissue macrophage densities were quantified as outlined in methods 
section 2.11, and expressed as mean cell count per adipocyte. PE (n=9) were 
matched with controls for BMI (p=0.66). 
The mean percentage of cfms+/adipocyte in VAT was higher in PE relative to 
controls (8.2[1.5] vs 16.4[3.0] %, p=0.032). No other differences between cfms 
counts in SAT or CD68 in SAT or VAT were found.  
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Figure 104 Mean cfms+/adipocyte counts in VAT in PE and controls.  
There is a higher percentage of cfms+/adipocyte in PE (n=14)  than in controls 
(p=0.032)(n=14). Comparisons made using student t test and expressed as mean and SEM. 
*=p≤0.05. 
 
There was no correlation between basal or stimulated MCP1 release and 
macrophage counts in VAT or SAT in controls or PE. 
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Figure 105 CD68 staining of adipose tissue (at x 400). 
A-SAT of control, B- SAT of PE, C- VAT of control, D- VAT of PE. Arrow highlights CD68 positive staining of macrophage. Tissue macrophage densities were 
expressed as cell count per adipocyte. 
A B 
C D 
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Figure 106 Cfms staining of adipose tissue (at x400).  
A-SAT of control, B- SAT of PE, C- VAT of control, D- VAT of PE. Arrow highlights cfms positive staining of cell (activated macrophage). Tissue macrophage 
densities were expressed as cell count per adipocyte. 
A B 
C D 
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5.5 Discussion 
We have demonstrated clear differences in adipose tissue function between PE 
and controls including important regional differences.  
There is an increased tendency to secrete the inflammatory adipokines of TNF 
alpha and IL-6 from visceral fat in PE, with increased gene expression in this fat 
depot. TNF alpha is an important determinant of insulin sensitivity in pregnancy 
and can lead directly to insulin resistance by inhibiting insulin signaling through 
several mechanisms including inducing serine phosphorylation of the insulin 
receptor IRS1.155 Correspondingly, we have also shown that TNF-alpha release 
from VAT is negatively correlated with the fat-cell insulin sensitivity of this 
depot in PE providing evidence of a potentially more pathogenic role of VAT in 
PE. IL-6, a stimulator of whole body lipolysis with anti-insulin effects,162 163 has 
been related to pregnancy-associated insulin resistance, although we did not 
determine a relationship between IL-6 and direct measures of insulin sensitivity 
in adipose tissue in our cohort. 167 Important regional difference in the release of 
these inflammatory adipokines are also apparent between controls and PE. In 
healthy pregnancy, BMI is an important determinant of both TNF alpha and IL-6 
release from SAT, a relationship not seen in PE pregnancies, implicating 
disordered release from this depot. In PE, TNF alpha release from SAT, although 
not determined by BMI, does relate to lipolytic function of this adipose depot. 
TNF alpha itself is a potent stimulator of lipolysis through down regulation of 
perilipin and suppression of the anti-lipolytic GTP-binding membrane proteins 
GAi.
238 It may therefore be a more important determinant of lipolysis in SAT in 
PE compared to controls. TNF alpha release and IL-6 release are closely 
correlated in both PE and controls in both SAT and VAT. TNF alpha has been 
found to  induce other pro-inflammatory adipokines including IL-6, and both are 
produced by activated macrophages present in adipose tissue which may explain 
their close association.239 
The source of excess release of TNF-alpha and IL-6 form VAT is still to be 
determined as both adipocytes and macrophages produce these cytokines. We 
have demonstrated both an increase in the mRNA expression of cfms relative to 
control gene and an increased density of cfms+ macrophages/adipocyte in the 
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visceral fat of PE women implicating adipose tissue macrophages as the potential 
source of increased release of pro-inflammatory adipokines. Moreover, MCP-1 
release from VAT is higher relative to SAT in PE only with a similar pattern of 
gene expression of MCP-1 in VAT. Our data suggests that PE women have more 
pro-inflammatory/activated macrophages in VAT than controls potentially 
implicating this group of cells as the source of excess TNF alpha and IL-6 
production from this depot. Higher maternal concentrations of TNF-alpha and IL-
6 have been demonstrated in PE 240 241. In addition to potential paracrine and 
autocrine effects on lipid and glucose metabolism, TNF-alpha in particular is 
implicated in endothelial dysfunction, leukocyte activation, and alterations in 
coagulation – all characteristic of PE. 156 157 242 Furthermore, the chronic infusion 
of TNF-alpha or Il-6 into normal pregnant rodents significantly increases arterial 
pressure and impairs renal haemodynamics.243  Although TNF alpha and IL-6 may 
be overproduced by the placenta secondary to hypoxia, their expression has not 
consistently been seen to by higher in the placentae of women with PE thereby 
implicating another source for the elevated concentrations found  in peripheral 
blood.160 244  
PAI-1 is a regulatory serine-protease inhibitor that decreases fibrinolysis and 
correlates well with visceral adiposity, hyperinsulinaemia and the expression of 
which is increased in the SAT of obese individuals.174 175 In keeping with this we 
found a positive correlation with basal PAI-release from SAT and BMI in both PE 
and controls, with increased release from VAT than SAT. Interestingly PAI-1 is 
known to be an independent risk factor for the metabolic syndrome and 
correlates closely with features such as waist circumferences, plasma fasting 
glucose, TG and negatively with HDL.245  In women with PE we determined 
further parallels with the metabolic syndrome, namely increasing PAI-1 release 
from SAT is negatively correlated with HDL. Low levels of HDL are an 
independent risk factor for atherosclerosis. HDL particles are believed to be 
anti-atherogenic secondary to their capacity to drive reverse cholesterol 
transport and antagonize pathways of inflammation, thrombosis, and oxidation 
246. HDL increases in normal pregnancy which may impart a protective role on 
the endothelium and this rise is attenuated in pre-eclampsia. We have shown a 
negative correlation with IL-6 release from SAT and maternal plasma HDL in 
controls, which could represent an appropriate anti-inflammatory effect of HDL 
on SAT.   
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Leptin correlates with VAT lipolytic function not only in healthy pregnant women 
as shown in Chapter 3 but also is an important determinant of VAT lipolysis in 
women with PE. We found no influence of leptin of SAT lipolytic function in 
healthy controls in spite of its release being higher from this depot than VAT. 
However leptin release does correlate closely with lipolytic function in SAT in 
PE, particularly basal lipolysis. This is perhaps surprising as previous studies have 
shown that despite hyperleptinaemia in pregnancies complicated by PE, there 
was no increased expression of leptin in SAT.134 However the function or 
expression of leptin receptors in adipose tissue has not been studied in normal or 
complicated human pregnancy. Human adipocytes express the long form of the 
leptin receptor (OB-R) and two of the short forms (OB-R 219.1 and 219.3).247 
Leptin is thought to have autocrine/paracrine actions on adipose tissue. In 
rodents leptin has been demonstrated to have lipolytic actions248 but this has not 
been reproduced in human primary adipocyte culture.249 Our data is suggestive 
of an autocrine/paracrine action of leptin on basal lipolysis in SAT in PE but 
further studies are required to determine this and potential underlying 
mechanisms.  
We hypothesised in Chapter 4 that a tendency for SAT in PE to adapt to 
increasing fat mass by adipocyte hypertrophy rather than hyperplasia and 
hypertrophy may in part contribute to disordered metabolism of this adipose 
depot. Our data does show some relationships between fat cell size and 
adipokine release which is more apparent in PE. We have demonstrated that 
leptin release in SAT in PE is correlated with cell size but not in controls. Basal 
release of leptin from VAT also appears to be positively related to fat cell size, 
although not independent of BMI. In addition other pro-inflammatory adipokines 
including PAI-1 and CRP release from SAT are closely related to cell size in PE 
and not controls, again not independent of BMI. There appears to be no 
correlation between TNF alpha and IL-6 release and fat cell size in SAT in either 
controls of PE. The anti-inflammatory IL-10 release is related to increasing fat 
cell-size in SAT in PE, not independent of BMI, and this paradoxical increase may 
represent a compensatory mechanism in this tissue.  
In summary, we have identified a more pathogenic role of VAT in PE with 
increased infiltration of activated macrophages and corresponding increased 
release of inflammatory adipokines which could contribute to the disturbances in 
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lipid and glucose metabolism and vascular dysfunction apparent in this maternal 
syndrome.  
    
6 Adverse Pregnancy Outcomes and Maternal 
Cardiovascular Risk: A pilot study of carotid 
ultrasound assessment in women with a history 
of pre-eclampsia. 
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6.1 Introduction 
6.1.1 Coronary heart disease in women: the extent of the problem 
Coronary heart disease (CHD) is the commonest single cause of death among 
women in Britain, with 41,796 British women dying of CHD in 2006.250 There is 
growing evidence of some unique sex-specific features of CHD.251 Women with 
CHD more often present atypically with a greater frequency of non-exertional 
chest pain, and this preponderance of atypical presentation may have 
scontributed to findings of poorer uptake of primary and secondary prevention 
initiatives among women compared to men.252-254 Furthermore women with 
established CVD are twice as likely to have associated metabolic syndrome than 
men, and when present the risk of death is over 10-fold compared to two to 
threefold in men.255 Thus more proactive approaches to identifying those at high 
risk at an early stage in their life course are particularly important for women. 
The US Institute of Medicine report Exploring the Biological contributions to 
Human Health: Does Sex Matter? called for increased research into the aetiology, 
diagnosis and management of CHD in women.256  
6.1.2 Pregnancy, Preeclampsia and cardiovascular disease 
There is increasing epidemiological evidence to suggest that adverse pregnancy 
outcomes such as pre-eclampsia (PE), preterm delivery and low birth weight are 
associated with increased risk in later life of cardiovascular disease (CVD) in the 
mother. 183-186 Jonsdottier et al, in a population based study investigated the 
association between hypertensive complications in pregnancy and death rates 
from ischemic heart disease (IHD). They found that the relative risk (RR) of dying 
from IHD was significantly higher among eclamptic women (RR=2.61; 1.11-6.123) 
and those with pre-eclampsia (RR=1.90; 1.02-3.52) than those with hypertension 
alone.184 In a retrospective cohort study in Scotland using discharge data of 
almost 130,000 women, PE was associated with a two-fold increased risk of 
subsequent IHD (RR2.0;1.5-2.5).185 More alarmingly if a woman had a 
combination of PE, preterm delivery and a baby of low birth weight she had a 
risk of IHD admission or death seven times that of controls (95% CI 3.3-14.5). A 
recent meta-analysis combining eight studies (2 346 997 women) with a mean 
follow up of 11.7 years demonstrated a relative risk of 2.16 (1.86-2.52) of IHD in 
women with PE substantiating previous evidence.187 This doubling of risk remains 
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robust even after adjusting for pre-pregnancy hypertension, diabetes mellitus, 
obesity, dyslipidaemia, the metabolic syndrome and smoking.186 Gestation of 
onset also appears to influence the risk - if PE occurred prior to 37 weeks’ 
gestation the risk of IHD was almost eight-fold (7.71,4.4-13.5).187 Indeed parity 
itself is associated with increased risk of CVD with prospective studies finding a 
positive association.188 189  A study by Lawlor and colleagues found a “J” shaped 
association between number of children and CHD, with the lowest prevalence 
among those with two children and a linear increase with subsequent children.190  
Although the association was attenuated by adjustment for obesity and 
metabolic risk factors it was not completely obliterated. The authors suggest 
that normal pregnancy is a state of insulin resistance and dyslipidaemia and 
repeated pregnancies may have adverse long-term effects. Hypertensive 
disorders of pregnancy have also been shown to predispose to diabetes in later 
life.257 A genetic predisposition to hypertensive disorders of pregnancy is also 
suggested by family-linkage studies with Inheritance followed both through sons 
and daughters, potentially through a single gene.258-260Greer and Sattar proposed 
a model whereby pregnancy with its concomitant digression into a metabolic 
syndrome is a “stress test” of maternal metabolic response.191 Women who 
develop adverse pregnancy outcomes such as PE make greater excursions into 
metabolic disturbances during pregnancy and are predisposed to metabolic and 
vascular disease in later life.  
Furthermore there is evidence of impaired vascular function in women with a 
history of PE potentially predisposing to an increased risk of CVD. Laser Doppler 
imaging in vivo has confirmed impaired microvascular function in women with 
PE90 and these differences are maintained 15-25 years after pregnancies 
complicated by PE261. In addition, there is evidence of impaired vascular 
dilatation in women several years after a pre-eclamptic pregnancy.262 
6.1.3 Carotid ultrasound: a predictor of cardiovascular disease 
Epidemiological evidence for the increase risk of CVD in women with pregnancies 
complicated by PE is not able to adjust for all potential confounders and there is 
very little direct evidence for this increased risk. Furthermore there is minimal 
data on the underlying mechanisms for this apparent increase in risk of CVD. 
Carotid intima media thickness (IMT) is a validated non-invasive surrogate 
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marker for the presence and progression of atherosclerosis. Carotid IMT 
correlates well with traditional cardiovascular risk factors and is relatively easy 
to perform. A recent meta-analysis showed that the age and sex adjusted 
relative risk for myocardial infarction increases by 1.15% (95% CI 1.16-1.21) for 
every 0.10 mm increase in carotid IMT.263 The adjusted relative risk for stroke 
increases by 1.18 (95% CI 1.16 to 1.21). The detection of carotid plaques by 
ultrasound is also extremely informative.264 Plaque score has been show to be 
associated with risk of myocardial infarction 265 266 and stroke267. In the 
Rotterdam study, the hazard ratio for myocardial infarction for a plaque score of 
three or more compared with one of zero was 1.83 (95% CI 1.27-2.62), and 
relative risk for stroke was 1.61 (95% CI 1.16 to 2.23) when comparing the 
highest tertile of plaque score to the lowest tertile.265 267 
6.2 Objectives 
6.2.1 Primary Objective 
 To determine whether carotid IMT and plaque counts, as accepted surrogate 
markers for atherosclerosis, are increased in women with a history of PE 
compared to age-matched women with history of normal pregnancies.  As such 
our work would help corroborate data from epidemiological and observations 
studies, which although consistent, can on occasions be misleading.  
6.2.2 Secondary Objectives 
To determine which risk factors best correlate with carotid IMT and plaque 
counts in cases and controls and in particular whether any established or novel 
risk factors can account for any observed difference in carotid IMT or plaque 
counts. 
6.3 Materials and Methods 
6.3.1 Study Population  
We initially recruited primigravid women who delivered between 1975 and 1985 
with PE and matched controls for time of index pregnancy, age and smoking. 
The diagnosis of PE was in line with International Society for the Study of 
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Hypertension in Pregnancy (ISSHP) criteria. These women had previously been 
identified and recruited for a study by our group.  The relevant data was 
originally taken from the maternity records which were recorded at the time of 
the index pregnancy available from 1975. Thus all women with PE were 
primigravid, had a diastolic blood pressure ≥90 mmHg on 2 occasions more than 
4 hours apart (but normal blood pressure at booking) and had ≥ 2+ proteinuria on 
dipstick in the absence of renal disease or infection. Due to lack of initial 
response to recruit these women we also extended recruitment to include 
women from the GOAL 268 database which prospectively examined the impact of 
the Factor V Leiden mutation on the vascular complication of pregnancy. 4250 
unselected subjects who consecutively attended for routine antenatal care at 
the Glasgow Royal Maternity Hospital between May 1997 and May1999 were 
recruited to the study. Case records were examined 6 weeks after delivery to 
determine outcomes of the index pregnancy and 70 subjects with a diagnosis of 
PE were identified using the criteria outlined above. Controls were matched as 
above for time of index pregnancy, age and smoking.  
6.3.2 Study Protocol 
The women were approached initially by letter requesting if they would 
participate in the study. One visit was required which lasted between 30 -45 
minutes. Standardised measures of height, weight, waist circumference and 
blood pressure were taken. Subjects then completed a brief questionnaire 
regarding history of cardiovascular disease, lifestyle and family history.  
 Venous blood was taken for analysis of lipids and lipoproteins, glucose, and CRP. 
These samples were non-fasting as patients were required to attend in the 
afternoon due to limitations of use of the equipment. This was justifiable as 
non-fasting measurements do not alter cholesterol, HDL-C, CRP or glycosylated 
haemoglobin and both non-fasting triglyceride269 and non-fasting insulin270 
predict CHD in large studies in the non-pregnant populations, with magnitudes of 
effect that are similar to those found for associations with fasting levels. 
The Carstairs Indicator is a measure of deprivation, produced decennially using 
data collected by the UK Censuses on the basis of four components: car 
ownership, low social class, male unemployment and overcrowding. The 1991 
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and 2001 Carstairs Indicators, calculated from the 1991 and 2001 Censuses were 
both included in this analysis, in categorical form, ranging from most affluent 
(DepCat 1) to most deprived (DepCat 7). 271 
All ultrasound scans were performed on a Siemens Acuson Sequoia 512 scanner 
with an L7 5-12MHz linear array broadband transducer (Siemens Medical 
Solutions, Erlangen, Germany). The scans were performed by myself (SSH) in the 
unit following a protocol developed by colleagues in Amsterdam. Before the 
study commenced scanning reproducibility was assessed by repeat scanning of 
staff volunteers. The sonographer (SSH) mean absolute difference  per subject 
for mean common carotid artery IMT was 0.036mm based on the quality control 
scans which is less than the minimum standard of <0.15mm required. 
The scanning protocol involved initially measuring the Doppler velocity in the 
internal carotid artery in order to exclude significant internal carotid artery 
stenosis. Thereafter, still B-mode images and video clips were recorded of the 
distal 1cm of the common carotid artery, the carotid bulb and the proximal 
internal carotid artery. The same series of images and clips was recorded on 
both right and left sides. All images were saved in Digital Imaging and 
Communications in Medicine (DICOM) format for later off-line analysis. 
Scans were read using the eTrack software provided by the Department of 
Physiology, Academic Medical Centre, Amsterdam. All scans were read by the 
same independent reader (KD), who was blinded to the identities of the 
participants. 
6.3.3 Outcome measures 
The pre-specified primary outcome was mean common carotid intima-media 
thickness and plaque counts. Intima-media thickness was measured on the far 
wall of each arterial segment, averaged along a 1cm length of the segment, or 
as much of this as was able to be read265. Number of plaques per subject was 
counted, with plaque being defined as a focal structure encroaching into the 
arterial lumen of at least 0.5 mm or 50% of the surrounding IMT value, or 
demonstrating a thickness >1.5 mm as measured from the media-adventitia 
interface to the intima-lumen interface264. In order to adjust for images which 
could not be read, the total plaque count for each subject was divided by the 
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number of readable images present and multiplied by 6 (the maximum possible 
number of images per subject) giving a plaque score265.  
 
6.3.4 Biochemical analysis 
All blood samples were centrifuged, separated and frozen at -80oC within 1 hour 
of venepuncture. Cholesterol and triglyceride were determined by enzymatic 
colorimetric assays on a Roche 917 analyser (Roche Diagnostics Ltd., Burgess 
Hill, United Kingdom). LDL and HDL were measured after ultracentrifugation at 
105,000g at 4 oC for 16 hours, followed by precipitation of the LDL fraction using 
a solution of heparin and manganous chloride. Glucose was measured by 
hexokinase/glucose-6-phosphate dehydrogenase assay on an Abbott c8000 
analyser (Abbott Diagnostics, Maidenhead, United Kingdom). High sensitivity C-
reactive protein (CRP) was measured by an immunoturbidimetric assay (Roche 
Diagnostics Ltd., Burgess Hill, United Kingdom).  
6.3.5 Statistical Power 
At the time of commencement of the study there were no prior published data 
on IMT and plaque counts in women with a history of PE.  Hence, we 
extrapolated from carotid IMT data on women of similar age with PCOS272 273 (a 
group with perhaps slightly lower CHD risk [HR ~ 1.5 based on the best 
epidemiological findings274]), and we anticipated a minimum difference in 
carotid IMT of 0.05mm between PE and normal women.  Therefore, we would 
require 25 subjects in each group to provide greater than 90% power to detect 
this difference with α=0.05. Despite using data from pathology with lower CHD 
risk, given the potential for overestimation of any difference in IMT between 
cases and controls, we selected to recruit 40 women from each group in order to 
be confident that the study was of sufficient size to detect meaningful 
difference in carotid IMT. 
The data in two groups was compared by unpaired t-test using where necessary 
normalised data, Mann-Whitney or Chi-squared test where appropriate.  
Adjustment for potential explanatory factors or confounders was made using 
general linear model. Values were expressed as mean and SEM unless otherwise 
stated. 
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6.4 Results 
6.4.1 Subjects 
A total of 60 subjects who delivered between 1975 and 1998 with PE (n=31) and 
matched controls (n=29). The characteristics of the two groups are shown in 
Table 22. There was no difference in risk factors for CVD including age, BMI, 
smoking, deprivation scores, systolic or diastolic blood pressure. The gestational 
age at index pregnancy was significantly different with PE delivering around 4 
weeks earlier.  
Characteristics PE  
(n=31) 
Control  
(n=29) 
p 
Index Pregnancy data    
Age, y 25.4(1.10) 27.3(0.89) 0.17 
BMI, kg/m2 23.4(0.81) 22.3(0.55) 0.18 
Smokers (non,current)* 22,9 22,7 0.67 
DEPCAT** 4(3-6) 4(2-5) 0.30 
Gestation at delivery, wk       35.1(0.74) 39.4(0.35) P<0.0001 
Time since index pregnancy 23.4(1.50) 22.6(1.60) 0.70 
Data at recall    
Age, y 48.6(1.12) 49.6(1.24) 0.44 
BMI, kg/m2 28.8(1.24) 27.7(1.01) 0.81 
Waist circumference, cm 91.5(2.61) 90.1(2.55) 0.69 
Parity (1,2, ≥2)* 7,13,10 9,11,6 0.57 
Systolic pressure, mmHg 127.0(2.81) 125.1(2.23) 0.55 
Diastolic pressure, mmHg 79.5(2.05) 75.7(1.88) 0.17 
Smokers (non,current) 6,25 5,24 0.83 
Antihypertensive Rx (no,yes)* 19,12 23,6 0.13 
Lipid lowering Rx (no,yes)* 24,7 26,3 0.20 
Hormone replacement therapy 0 0 NS 
Table 22 Characteristics of PE and controls.  
All values expressed as mean and SEM except DEPCAT expressed as median and 
interquartile range. Comparisons made using unpaired t test except * Chi-squared test and 
** Mann-Whitney. 
6.4.2 Biochemical Analysis 
There was no significant difference in traditional biochemical risk factors for 
cardiovascular disease including cholesterol, triglycerides, HDL and glucose and 
CRP (Table 23).  
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Plasma markers (non-fasting) PE  
(n=31) 
Control  
(n=29) 
p 
Cholesterol 5.00 (0.18) 5.32 (0.21) 0.25 
Triglycerides 1.57 (0.15) 1.31(0.11) 0.71 
HDL 1.40(0.06) 1.55(0.09) 0.20 
Glucose* 5.50(5.10-5.80) 5.70(5.20-6.25) 0.30 
CRP 3.89(0.80) 2.78(0.60) 0.46 
Table 23 Biochemical plasma markers in PE and controls.  
All values expressed as mean and SEM and statistical analysis using paired t-test except 
*glucose which is expressed as median and interquartile range and analysis by Mann-
Whitney.  
6.4.3 Carotid Ultrasound 
Although the carotid IMT was greater in PE than controls (0.66[0.02] vs 
0.63[0.02]), there was no statistical difference (p=0.17). 
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Figure 107 Difference in carotid IMT between controls and PE. 
Carotid IMT is not significantly greater in PE compared to controls (p=0.17). 
Of those women in whom plaque counts could be assessed, 50% of women with a 
history of PE (14 out of 28) had one or more plaques compared to only 25% of 
normal controls (6 out of 24) ( p=0.065, chi squared test).(Figure 108) 
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Figure 108 Dotplot of the presence of plaques in controls and PE. 
Dotplot of the presence of plaques in controls (6 out of 24) and PE (14 out of 28), p=0.065, 
chi-squared test. 
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The mean number of plaques per subject (plaque score) was greater in PE than 
in controls (0.81[0.19] vs 0.34[0.13], p=0.043 unpaired t-test). 
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Figure 109 A comparison of plaque scores between controls and PE. 
The plaque score (mean number of plaques per subject) was higher in PE than in controls 
(p=0.043). 
When adjusted for classical risk factors including age, triglycerides, cholesterol, 
HDL cholesterol, systolic blood pressure, diastolic blood pressure, smoking and 
history of hypertension there was no attenuation of this effect (p=0.042)(Table 
24). However the addition of BMI to classical risk factors (p=0.076) did partially 
attenuate the difference between PE and controls.   
Model P value 
Unadjusted 0.043 
Model 1 (classic) 0.042 
Model 2 (classic + BMI) 0.076 
Table 24 Multivariate analysis by general linear model for difference in plaque score 
between PE and controls.  
Model 1 (classic): adjusted for age, triglycerides, cholesterol, HDL,systolic BP, diastolic BP, 
smoking and history of hypertension.: Model 2 = Model 1 +BMI.  
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In the group as a whole age (r=0.37, R2=13.4%, p=0.004), systolic BP (r=0.43, 
R2=18.9%, p=0.001), cholesterol(r=0.25,R2=6.38%, p=0.051), triglycerides 
(r=0.38,R2=14.7%, p=0.003), CRP (r=0.34,R2=13.5%, p=0.012) and family history 
of CVD (r=0.40, R2=15.93%, p=0.002) were predictive of carotid IMT whereas 
smoking (r=0.33,R2=11.1%, p=0.016), HDL (r=-0.31,R2=9.7%, p=0.025), 
triglycerides (r=0.30, R2=8.4%, p=0.037) and glucose (r=0.29, R2=8.1%, p=0.040)  
were predictive of total plaque numbers.  
6.5 Discussion 
CHD is an important cause of morbidity and mortality among women. Due to the 
atypical presentation of CHD in women and the perception that CHD is 
predominantly a male disease rates of primary and secondary prevention in 
women is lower compared to men. Identifying additional risk factors such as PE 
which is an independent risk factor for coronary artery disease may help target 
and improve primary prevention strategies.275  It is important to corroborate 
epidemiological evidence of this increased associated risk.  
Our study has demonstrated direct evidence that atherosclerosis is increased in 
women with a history of PE compared to women with healthy pregnancies. We 
have shown that the mean plaque score is higher in women with a history of PE 
compared to controls. Although carotid IMT was higher in PE, this was not 
statistically significant.  
Plaque counts appear to be a better discriminator and predictor of CVD than 
carotid IMT in women with a history of PE. This may be due to several factors. 
The median age of the women undergoing carotid artery ultrasound in our study 
was around 50.  Carotid IMT is age related, with an estimated increase in 
thickness of around 6.5–10.1 µm/year.276 In healthy individuals the average IMT 
is 0.4mm at birth and 0.8mm by age 80 if no risk factors are present. Women 
have thinner IMT compared to men (and atherosclerosis tends to develop about 
10 years later in women) and it may not be until later in life that we would see a 
significant divergence of IMT in these two groups.  
The pathological processes resulting in increased intima media thickening in the 
common carotid and plaque formation may differ significantly and reflect 
distinct aspects of atherogenesis and therefore clinical manifestations of 
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disease. Carotid plaque presence is more strongly predictive of future 
cardiovascular events and in particular acute myocardial infarction277 and is 
more biologically and mechanistically similar to the development of 
atherosclerosis.278  Similar to previous data we have shown that different risk 
factors are predictive of either carotid IMT or plaque counts. 
Previous studies have suggested that plaque scores may be a better 
discriminator of future CVD than carotid IMT in women compared to men, and at 
an earlier age. A recent study by Deans et al which compared the prevalence of 
carotid atherosclerosis in participants at extremes of the socioeconomic gradient 
in Glasgow (the incidence of CVD is higher in areas of socioeconomic 
deprivation) demonstrated that differences in plaque scores appeared at an 
earlier age than a difference in carotid IMT.279 In this study, the population was 
subdivided into three age groups – 35-44years, 45-54 years, and 55-64years. 
Furthermore differences in IMT between the study groups did not reach 
statistical significance in women at any age tertile, and only in the highest age 
tertile in men. In contrast differences in plaque scores were highly statistically 
significant in the two highest age tertiles in men and the highest age tertile in 
women. Another population based study of 6226 men and women aged 25 to 84 
demonstrated that carotid plaque was a stronger predictor of first ever MI than 
was carotid IMT, and this was more striking in women than in men, with a 
relative risk for MI of 2.92(95% CI 2.04-4.17) in men and 7.8(95% CI 4.46-13.34) in 
women when comparing the top tertile of plaque area to those without 
plaques.266 
In a similar cohort, our group have previously shown a long term differences in 
inflammatory markers including significantly higher IL-6/IL-10 ratio, an index of 
proinflammatory cytokine (IL-6) status to anti-inflammatory cytokine (IL-10) 
status, in PE women compared with matched controls (PE 3.96 [6.07] versus 
control 2.12 [1.89]; P=0.034), independent of smoking, current BMI, and 
menopause status (P=0.03)240, with higher concentrations of vascular cell 
adhesion molecule-1 and intercellular adhesion molecule-1 (ICAM-1), by 14% 
(P=0.038) and 44% (P=0.002), respectively. The differences in ICAM-1 
concentration persisted (P=0.010) after adjustment for potential confounders, 
including hormonal use/menopausal status, antihypertensive or lipid-lowering 
therapy, and social class.280 Interestingly there were no significant differences in 
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fasting lipoprotein concentrations (P>0.20). The cases also demonstrated a 
tendency toward higher fasting insulin (P=0.08) concentrations and had higher 
glycosylated hemoglobin levels (P=0.004). Leptin concentrations were not 
significantly elevated. These data are suggestive that classic risk factors alone 
cannot fully explain the elevated CHD risk in women with a history of PE, with 
long –term changes in inflammation, endothelial dysfunction and subtle features 
of insulin resistance perhaps underpinning this apparent relationship. Our data 
are in-keeping with this, as adjustment for classical risk factors did not 
obliterate the difference in plaque scores between PE and controls. Disturbance 
in inflammation are important contributors to the pathogenesis of both PE and 
atherosclerosis and may provide one of the key links between these two 
conditions216 281. Although CRP, an inflammatory biomarker is an important 
predictor of CVD, the contribution of other emerging novel inflammatory factors 
including TNF-alpha and IL-6 have not been explored in this study. In addition, 
further investigation of markers of insulin resistance (which potentially links PE, 
obesity and CVD) and vascular dysfunction and their relationship to plaque 
counts would be valuable. Although increasing obesity is risk factor for both PE 
and CVD, adjusting for BMI only partially attenuated the effect on plaque 
numbers and therefore only partly explains the discrepancy in risk.  
A limitation of our study was that despite endeavouring to recruit 80 individuals 
we only recruited 60.  It is therefore possible that the study is underpowered to 
show a difference in carotid IMT between the groups, one of our primary 
outcomes measures. A post hoc power calculation estimated that a sample size 
of 64 in each group would have been required to detect a difference in IMT of 
0.05 with a power of 80%.  However as we have previously described this lack of 
significant difference may also be due to the mean age of the cohort, and 
therefore studying older women may also have been of benefit.  In addition due 
to limitations on the use of the equipment, plasma samples were non-fasting 
which may explain the lack of difference seen in plasma lipids and glucose.  
There are several particular strengths of the study. The methodology of CIMT 
and plaque assessment is robust with close following of established protocols 
with excellent reproducibility. In addition, both the sonographer and the 
independent reader of scans were blinded to the category of the subjects. In 
addition the identification of subjects in the control and cases groups was 
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rigorous as data was either collected prospectively or medical records 
retrospectively checked to confirm the diagnosis of PE.  
In summary we have shown direct evidence that a prior history of PE is 
associated with increased atherosclerosis, which cannot be fully explained by 
classic cardiovascular risk factors. Further analysis is required to help determine 
the mechanisms for this difference. Future studies on women with adverse 
pregnancy complications with even higher risk of CVD (PE, preterm delivery and 
small for gestational age) is warranted. Carotid ultrasound may provide a 
valuable screening tool in this high risk group of women in addition to more 
traditional risk assessment.  
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7.1 Discussion 
Maternal metabolism undergoes dramatic changes in pregnancy in order to 
sustain and nourish the developing fetus. During healthy pregnancy the mother 
goes from an anabolic state in early pregnancy to a state of catabolism in late 
pregnancy with increased lipolysis together with a significant reduction in insulin 
sensitivity. The mother accumulates fat in the first and second trimester of 
pregnancy in preparation for the increased energy demands of the fetus in the 
third trimester and for lactation.  Increased FFA use in the mother increases the 
availability of glucose and other substrates for the fetus. Pregnancy is 
characterised by hyperlipidaemia with a pronounced rise in TG and lesser rise in 
cholesterol and LDL-cholesterol. However this is combined with an increase in 
HDL-cholesterol which may have a protective role on the endothelium. 
Adipose tissue has increasingly been recognised as an important endocrine 
organ. It releases a wide array of cytokines and proteins with corresponding 
autocrine, paracrine and endocrine functions. Metabolism in pregnancy has been 
extensively studied but much of the work has focused on carbohydrate 
metabolism with lesser knowledge regarding lipid metabolism and in particular 
adipose tissue function in both normal and complicated human pregnancy. I have 
therefore endeavoured in this thesis to acquire a better understanding of 
adipocyte lipid metabolism and function in normal pregnancy as a basis for 
further understanding metabolic complications of pregnancy and in particular 
PE. 
In this thesis I have focussed on the hypothesis that PE is “metabolic syndrome” 
that develops in pregnancy. PE shares many risk factors with CVD and similarities 
between the metabolic syndrome – namely dyslipidaemia, insulin resistance, 
inflammation and endothelial dysfunction – are striking. Important predisposing 
factors for PE include obesity and dyslipidaemia. The pathogenesis of PE is still 
not fully understood and it is likely the disorder is multifactorial with several 
underlying contributing mechanisms manifesting as this maternal syndrome. I 
have concentrated on the “lipid-centric” view that the development of PE is in 
part related to alterations in lipid and adipocyte metabolism. These 
perturbances in lipid and glucose metabolism not only may predispose these 
women to PE but also to CVD in later life.  
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In chapter 1 I examined lipolytic function of adipocytes in normal pregnancy. 
The most surprising finding is the lack of association between maternal booking 
BMI and lipolytic function of adipocytes. This may be accounted for by several 
factors. Firstly booking BMI, although a reflection of pre-gravid status, may not 
accurately reflect BMI in late pregnancy. Sattar et al has shown that waist 
circumference may be a better indicator of risk of development of hypertensive 
disorders of pregnancy than BMI and indeed it may be the distribution of fat 
rather than total fat mass which is relevant.51 Visceral adiposity is linked to 
adverse metabolic outcomes both in the non-pregnant and pregnant including 
gestational diabetes mellitus, gestational hypertension and pre-eclampsia.49-51 
Visceral adiposity in early pregnancy appears to correlate better than 
subcutaneous fat or body mass index (BMI) with metabolic risk factors such as 
blood pressure, insulin resistance and lipids.52Furthermore it may be the total 
amount of fat mass gained during pregnancy that critically determines the 
lipolytic function in pregnancy which would not be reflected by a booking BMI. 
I have shown that adipose tissue in pregnancy is very metabolically flexible, 
particularly that stored in the subcutaneous compartment. This is of particular 
benefit to the fetus in that those mothers with lower basal lipolysis respond 
quickly to times of ‘stress’ facilitating increased utilisation of FFA in the mother, 
and thereby increasing the availability of glucose and amino acids for the fetus. 
The subcutaneous compartment is the largest maternal store of adipose tissue. 
In addition, the rate of whole body lipolysis is still insulin sensitive in fasting 
conditions in normal pregnancy. This might be a reflection of the distribution of 
fat mass accumulation in women with normal pregnancy, with a greater 
propensity to store fat in the lower body, which is much more insulin 
sensitive.282 Lower body fat is independently associated with a lower risk of lipid 
and carbohydrate metabolic dysregulation283 and larger depots of lower body 
adipose tissue are associated with a more efficient storage of dietary fat. All 
women accrue fat mass during pregnancy of similar amounts, whether lean or 
obese, and location of fat storage may be one mechanism through which 
“metabolically healthy” women can adapt efficiently to pregnancy. 
Furthermore I have demonstrated some important regional differences in 
lipolytic function in normal pregnancy with potential relevance to metabolic 
complications of pregnancy. Similar to previous literature I have shown that 
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visceral adiposity is more closely related to measures of maternal insulin 
resistance. In visceral fat there is a higher turnover of lipids due to its greater 
sensitivity to catecholamine-induced lipolysis and decreased sensitivity to 
insulin, both demonstrated by the data presented here. Visceral fat is in direct 
contact with the liver via the portal venous system. The liver is therefore 
exposed to chronic elevation of NEFA (non-esterified fatty acids) which can 
produce alteration in liver metabolism and promotes hepatic IR – the basis for 
the ‘portal paradigm’. This is illustrated by the inverse correlation seen between 
visceral fat insulin sensitivity and maternal TG in this cohort. In later stages of 
pregnancy there is an increase in both the thickness of pre-peritoneal fat 
(visceral) and the ratio  of  pre-peritoneal to subcutaneous fat as measured by 
ultrasound.47 This may be relevant to increasing insulin resistance and lipid 
changes that occur as pregnancy progresses. Indeed accumulation of hepatic fat 
has been shown to be an important mediator of insulin resistance during 
pregnancy in the rat model.48 I have also shown that increasing BMI is associated 
with an increase in visceral fat cell size, with increased lipolysis and an increase 
in plasma levels of the pro-inflammatory adipokines leptin, IL-6 and CRP and a 
reduction in the anti-inflammatory adiponectin. This may be one potential 
mechanism through which increasing obesity predisposes to metabolic 
complications of pregnancy through increased inflammation and insulin 
resistance.  
In contrast, the subcutaneous depot appears to work independently to visceral 
fat.  Fat cell size is not a closely related to BMI and this may reflect the 
propensity of this fat depot to increase by both adipose cell hyperplasia and 
hypertrophy, a metabolically advantageous response. Fat cell size in SAT does 
however correlate with the insulin sensitivity of the cell. It appears that 
maternal TNF-alpha is a significant correlate of adipocyte lipolytic function in 
this depot and in particular basal lipolysis. TNF alpha has been shown to 
stimulate lipolysis through several mechanisms including inhibition of insulin 
receptor signalling, interaction with adenosine, and direct stimulation of basal 
lipolysis through phosphorylation and decreased expression of perilipin. Although 
we failed to demonstrate any relationship between TNF-alpha and maternal 
markers of insulin resistance in our cohort, Kirwan et al demonstrated that TNF-
alpha was the most significant independent predictor of insulin sensitivity in 
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human pregnancy.159 TNF-alpha not only exerts its effects on the adipocyte but 
also influences insulin signalling in skeletal muscle and the liver.  
Pre-eclampsia is a multi-system disorder with complex underlying mechanisms. 
We know that both the rise in maternal TG and FFA is exaggerated in PE and 
occurs well in advance manifestation of the disease suggesting disordered 
adipocyte metabolism. In chapter 4 I attempted to explore this hypothesis and 
to determine if there were any significant underlying differences in adipocyte 
lipolytic function between PE and control women. Interestingly we found that 
there was no inherent difference in the effect of catecholamines or insulin in 
either adipose depot in vitro. However the insulin sensitivity as calculated by 
the FCISI (or responsiveness to insulin once the tissue is stimulated by 
isoproterenol) of SAT and probably VAT was lower in women with PE than 
controls. This is likely to be more relevant in vivo as this is a functional test of 
adipose tissue function. Almost 60% of circulating NEFA is from upper body fat ie 
abdominal subcutaneous and visceral fat.282 I have shown that both these depots 
are insulin resistant and this potentially would make a significant impact on total 
circulating FFA. The rise of FFA in PE occurs early in pregnancy and contributes 
significantly to IR in pregnancy.106 Therefore the IR of adipose tissue could lead 
to a vicious cycle of increased lipolysis and release of FFA with further 
exacerbation of IR. 
In addition to increasing IR of adipose tissue we have shown a difference in SAT 
response to increasing BMI. I have previously highlighted that SAT cell size does 
not closely correlate with BMI in controls and theorised that this is potentially a 
healthy adaptive response by increasing fat mass by both hypertrophy and 
hyperplasia. However in PE, SAT cell size is intimately related to BMI suggesting 
that they increase fat mass predominantly by adipocyte hypertrophy. This is a 
maladaptive response and can result in increased ER stress, increased IR, 
increased release of inflammatory cytokines and increased macrophage 
recruitment. SAT cell size is closely related to lipolytic function of the tissue in 
PE but not in controls. 
I also hypothesised that in addition to an inherent defect in adipocyte function, 
there was an additional factor present in maternal serum of women with PE 
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released from the placenta which excessively stimulates lipolysis. I failed to 
demonstrate any effect of serum on adipocyte lipolysis in either controls or PE.  
An alternative mechanism through which adipose tissue could affect maternal 
metabolism resulting in PE would be through dysregulated release of adipokines 
and increased tissue inflammation similar to process of chronic inflammation in 
obesity. In Chapter 5 I examined differences in adipokine release from SAT and 
VAT between controls and PE. I found that there was an increased tendency for 
the pro-inflammatory adipokines TNF-alpha and IL-6 to be released after 
stimulation of VAT, with increased gene expression in this fat depot. TNF-alpha 
release also correlated negatively with the fat cell insulin sensitivity of VAT 
implicating a paracrine effect in this tissue potentially due to its known effect 
on insulin signalling. TNF-alpha also appears to influence SAT lipolytic function 
in PE. Both TNF alpha and IL-6 are released from adipocytes and macrophages 
and the actual source of excess release is still to be identified. However I have 
demonstrated increased release of MCP-1 from VAT relative to SAT in PE only. 
Furthermore there is both an increase in gene expression of cfms and increased 
density of cfms+ macrophages/adipocytes in the VAT of PE women implicating 
activated adipose tissue macrophages as a potential source of increased release 
of these pro-inflammatory adipokines. TNF-alpha and IL-6 have been shown to 
be elevated in women with PE and their effects of metabolism, endothelial 
dysfunction and inflammation may provide one of the mechanisms through which 
the maternal syndrome develops.  
Following on from data in Chapter 4 which showed that SAT cell size was closely 
related to BMI in PE but not in controls, I have shown that SAT cell size does 
relate to adipokine release in PE. The basal release of leptin, PAI-1 and CRP are 
closely related to SAT cell size in PE but not in controls. In addition the anti-
inflammatory IL-10 release paradoxically increases with increasing SAT cell size 
in PE only suggesting a possible compensatory mechanism.  
Leptin also appears to have disparate roles on lipid metabolism in PE and healthy 
pregnancy. Leptin, secreted from adipose tissue, decreases lipid accumulation in 
the liver by promoting FA oxidation and in adipose tissue via a direct autocrine 
effect 284 285.  I previously identified that leptin is an important correlate of VAT 
and not SAT lipolytic function in normal pregnancy. However in PE women it is 
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closely related to basal lipolysis in SAT. Although previous studies have shown no 
increased expression of leptin in SAT complicated by PE, the expression or 
function of leptin receptors in adipose tissue in normal or complicated 
pregnancy has yet to be determined. My data is suggestive of an 
autocrine/paracrine effect of leptin not only in VAT in PE but also in SAT, but 
further studies are required define the role of leptin in pregnancy adipocyte 
function.  
There is increasing epidemiological evidence that PE is associated with an 
increase risk of CVD in later life. Greer and Sattar proposed a model whereby 
pregnancy with its concomitant digression into a metabolic syndrome is a “stress 
test” of maternal metabolic response.191 Women who develop adverse pregnancy 
outcomes such as PE make greater excursions into metabolic disturbances during 
pregnancy and are predisposed to metabolic and vascular disease in later life. 
There are some unique sex-specific characteristics of CVD. Women with 
established CVD are twice as likely to have associated metabolic syndrome than 
men, and when this cluster of features is present the risk of death is over 10-fold 
compared to two to threefold in men.255 The purpose of Chapter 6 was to 
corroborate the increasing epidemiological evidence and to determine which risk 
factors could account for any observed differences. Two surrogate markers of 
atherosclerosis in the carotid artery were assessed- namely carotid IMT and 
plaque scores.  Both were found to be increased in women with a history of PE, 
with plaque scores significantly so, corroborating evidence of increased 
atherosclerotic burden in these women. Classic risk factors such as age, lipids, 
BP and smoking did not attenuate this effect. Interestingly BMI only marginally 
attenuated this relationship, therefore only partially explaining this increased 
risk. Women who develop early onset pre-eclampsia with associated IUGR and 
preterm delivery are epidemiologically at much higher risk of CVD than those 
with late onset disease  suggestive of differing underlying pathological 
processes. It is possible that long-term changes in inflammation, endothelial and 
vascular dysfunction and features of insulin resistance which have previously 
been identified in women with a history of PE underlie the increased risk of CVD 
in later life. 
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7.2 Future Research 
This thesis has determined some important aspects of adipocyte and lipid 
metabolism in normal pregnancy and PE, and established direct evidence for an 
increased risk of CVD in women with a history of PE. However the data from this 
thesis has clearly stimulated further avenues for future research. 
Maternal obesity has far reaching consequences for both mother and offspring 
and predisposes to metabolic complications of pregnancy including GDM and 
PE.286 Independent of maternal pregnancy BMI, gestational weight gain (GWG) 
has also been associated with adverse outcomes. However the evidence for the 
association of GWG with adverse pregnancy outcome is somewhat weaker than 
the evidence for pre-pregnancy BMI.287 In addition, although obese women have 
and exaggerated metabolic response in pregnancy, lean and obese women put on 
similar fat mass, although obese women tend to accumulate fat more centrally 
than lean women, which may reflect their more insulin-resistant state. 70 71 288  
Clearly there is a gap in our knowledge to explain these apparently contradictory 
facts.  
Human fat can be subdivided into lower body subcutaneous fat, upper body 
subcutaneous fat and intra-abdominal/visceral fat as previously detailed. In 
general visceral fat is thought to be more pathogenic and associated with an 
abnormal metabolic and adipokine profile with is supported by data in this 
thesis. However upper body subcutaneous fat, as studied here, and visceral fat 
stores are often not differentiated and both are relatively resistant to insulin 
suppression of lipolysis282. Conversely lower body fat subcutaneous fat (eg 
gluteal-femoral fat) is much more insulin sensitive and is independently 
associated with a reduced risk of lipid and carbohydrate metabolic 
dysregulation.283 289 Thus the compartment in which fat is stored during 
pregnancy may impact on the metabolic response to pregnancy.  
Important avenues for further research therefore would include determining the 
relationships between the pattern and mass of adipose tissue as it accumulates 
in pregnancy in both lean and obese women and determine the relationships 
between maternal energy metabolism and markers of “lipotoxicity” or disorderd 
lipid metabolism. Similar studies on comparing adipocyte function of 
subcutaneous abdominal AT and visceral AT with biopsies of femoral fat would 
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be of particular value. Other areas of interest would be to further examine the 
relationships between fat cell size and maternal metabolism. In particular 
further examination of the differences in adipose tissue adaptation to the 
normal increase in fat mass in pregnancy in lean and obese women would be of 
value. Furthermore, it is not known whether the nature of AT in obese pregnant 
women, which was mostly pre-existing before pregnancy, is different to AT in 
lean pregnant women which has been accumulated in the gestational period.  
Adipose tissue from lean women not only may be deposited in different 
subcutaneous compartments than obese women, but the composition of the AT 
may also differ significantly. One component of the insulin resistant state 
apparent in obesity is disordered fatty acid (FA) metabolism whereby fewer FA 
are diverted down the elongation and desaturation pathways to form LC-PUFA 
(long chain polyunsaturated fatty acids). Desaturases are key enzymes in the 
remodelling of FA by introducing a double-bond in the FA chain. Therefore it 
would be of important to determine the fatty acid composition and desaturase 
activity of AT in lean and obese women, and women with metabolic 
complications of pregnancy and relate them to measures of adipocyte lipolysis 
and insulin sensitivity. 
I have also identified that leptin appears to play an important regulatory role in 
VAT lipolysis in normal pregnancy and both SAT and VAT lipolysis in PE. The 
mechanism through which this occurs is still to be determined. There is evidence 
in humans that adipose tissue leptin and leptin receptor mRNA expression is 
related to changes in insulin sensitivity in a physiologically dynamic situation – 
exercise. Barwell et al have shown that daughters of women with type 2 
diabetes have a significantly greater improvement in insulin sensitivity in 
response to an exercise training programme than controls and that this is 
accompanied by a significant decrease in plasma leptin, whereas leptin was 
unchanged in controls.290 Adipose tissue leptin expression was not different 
between controls and offspring of type 2 diabetics but the offspring had 
increased levels of both long and short forms of the leptin receptor291. In a 
multivariate analysis leptin and leptin receptor mRNA expression contributed 
significantly to insulin sensitivity index at baseline and change in insulin 
sensitivity index in response to exercise. Parallels with the dynamic situation of 
pregnancy may occur with adipocyte first trimester accumulation of fat and 
third trimester depletion of fat being regulated by leptin in an 
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autocrine/paracrine manner. It would therefore be valuable to measure leptin 
and leptin receptor mRNA levels in subcutaneous and visceral fat in normal (lean 
and obese) pregnancy and PE and relate this to adipocyte lipolysis and maternal 
insulin resistance.  
Furthermore although I have determined that SAT and probably VAT is less 
insulin sensitive in PE than controls perhaps contributing to the early 
exaggerated rise in FFA, further investigation to determine the mechanism for 
this would be of great importance. This would help establish whether this 
“defect” would be amenable to interventions such as pharmacological or 
lifestyle.  
Lastly, using carotid ultrasound assessment, and in particular plaque counts in 
other groups of women with a history of adverse pregnancy outcome would be of 
interest. It would also be useful to distinguish between early (with its 
particularly high risk of CVD) and late onset PE to determine which risk factors 
(traditional or novel) best account for any observed difference to help 
corroborate increasing support that these two conditions are distinct 
pathological processes.   
In conclusion the data in this thesis provides further evidence that PE is 
“metabolic syndrome of pregnancy” with disordered adipocyte function and 
metabolism. Further studies on adipose accumulation, function, and composition 
in normal and complicated human pregnancy are warranted.  
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